<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults - Kohli, M - 2021 | Cochrane Library</title> <meta content="Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults - Kohli, M - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012768.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults - Kohli, M - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012768.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012768.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults" name="citation_title"/> <meta content="Mikashmi Kohli" name="citation_author"/> <meta content="McGill University" name="citation_author_institution"/> <meta content="Ian Schiller" name="citation_author"/> <meta content="McGill University Health Centre - Research Institute" name="citation_author_institution"/> <meta content="Nandini Dendukuri" name="citation_author"/> <meta content="McGill University Health Centre - Research Institute" name="citation_author_institution"/> <meta content="Mandy Yao" name="citation_author"/> <meta content="McGill University Health Centre - Research Institute" name="citation_author_institution"/> <meta content="Keertan Dheda" name="citation_author"/> <meta content="Claudia M Denkinger" name="citation_author"/> <meta content="Samuel G Schumacher" name="citation_author"/> <meta content="FIND" name="citation_author_institution"/> <meta content="Karen R Steingart" name="citation_author"/> <meta content="Department of Clinical Sciences, Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="karen.steingart@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012768.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/01/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012768.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012768.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012768.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibiotics, Antitubercular [*therapeutic use]; Bias; *Drug Resistance, Bacterial; False Negative Reactions; False Positive Reactions; Mycobacterium tuberculosis [*drug effects, isolation &amp; purification]; *Nucleic Acid Amplification Techniques [methods, statistics &amp; numerical data]; Reagent Kits, Diagnostic; Rifampin [*therapeutic use]; Sensitivity and Specificity; Tuberculosis [cerebrospinal fluid, *diagnosis, drug therapy]; Tuberculosis, Lymph Node [cerebrospinal fluid, diagnosis, drug therapy]; Tuberculosis, Meningeal [cerebrospinal fluid, diagnosis, drug therapy]; Tuberculosis, Multidrug-Resistant [cerebrospinal fluid, diagnosis, drug therapy]; Tuberculosis, Pleural [cerebrospinal fluid, diagnosis, drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012768.pub3&amp;doi=10.1002/14651858.CD012768.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012768\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012768\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","hr","fa","fr","ms"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012768.pub3",title:"Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults",firstPublishedDate:"Jan 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012768.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012768.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012768.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012768.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012768.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012768.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012768.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012768.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012768.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012768.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9194 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012768.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0193"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-sec-0172"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-sec-0198"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/table_n/CD012768StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/table_n/CD012768StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0004">Mikashmi Kohli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0005">Ian Schiller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0006">Nandini Dendukuri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0007">Mandy Yao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0008">Keertan Dheda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0009">Claudia M Denkinger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0010">Samuel G Schumacher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Karen R Steingart</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information/en#CD012768-sec-0262">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 January 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012768.pub3">https://doi.org/10.1002/14651858.CD012768.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012768-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012768-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012768-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012768-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012768-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012768-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012768-abs-0001" lang="en"> <section id="CD012768-sec-0001"> <h3 class="title" id="CD012768-sec-0001">Background</h3> <p>Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely used for simultaneous detection of <i>Mycobacterium tuberculosis</i> complex and rifampicin resistance in sputum. To extend our previous review on extrapulmonary tuberculosis (Kohli 2018), we performed this update to inform updated WHO policy (WHO Consolidated Guidelines (Module 3) 2020). </p> </section> <section id="CD012768-sec-0002"> <h3 class="title" id="CD012768-sec-0002">Objectives</h3> <p>To estimate diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin resistance in adults with presumptive extrapulmonary tuberculosis. </p> </section> <section id="CD012768-sec-0003"> <h3 class="title" id="CD012768-sec-0003">Search methods</h3> <p>Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, 2 August 2019 and 28 January 2020 (Xpert Ultra studies), without language restriction. </p> </section> <section id="CD012768-sec-0004"> <h3 class="title" id="CD012768-sec-0004">Selection criteria</h3> <p>Cross‐sectional and cohort studies using non‐respiratory specimens. Forms of extrapulmonary tuberculosis: tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, disseminated tuberculosis. Reference standards were culture and a study‐defined composite reference standard (tuberculosis detection); phenotypic drug susceptibility testing and line probe assays (rifampicin resistance detection). </p> </section> <section id="CD012768-sec-0005"> <h3 class="title" id="CD012768-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias and applicability using QUADAS‐2. For tuberculosis detection, we performed separate analyses by specimen type and reference standard using the bivariate model to estimate pooled sensitivity and specificity with 95% credible intervals (CrIs). We applied a latent class meta‐analysis model to three forms of extrapulmonary tuberculosis. We assessed certainty of evidence using GRADE. </p> </section> <section id="CD012768-sec-0006"> <h3 class="title" id="CD012768-sec-0006">Main results</h3> <p>69 studies: 67 evaluated Xpert MTB/RIF and 11 evaluated Xpert Ultra, of which nine evaluated both tests. Most studies were conducted in China, India, South Africa, and Uganda. Overall, risk of bias was low for patient selection, index test, and flow and timing domains, and low (49%) or unclear (43%) for the reference standard domain. Applicability for the patient selection domain was unclear for most studies because we were unsure of the clinical settings. </p> <p><b>Cerebrospinal fluid</b> </p> <p><i>Xpert Ultra (6 studies)</i> </p> <p>Xpert Ultra pooled sensitivity and specificity (95% CrI) against culture were 89.4% (79.1 to 95.6) (89 participants; low‐certainty evidence) and 91.2% (83.2 to 95.7) (386 participants; moderate‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 168 would be Xpert Ultra‐positive: of these, 79 (47%) would not have tuberculosis (false‐positives) and 832 would be Xpert Ultra‐negative: of these, 11 (1%) would have tuberculosis (false‐negatives). </p> <p><i>Xpert MTB/RIF (30 studies)</i> </p> <p>Xpert MTB/RIF pooled sensitivity and specificity against culture were 71.1% (62.8 to 79.1) (571 participants; moderate‐certainty evidence) and 96.9% (95.4 to 98.0) (2824 participants; high‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 99 would be Xpert MTB/RIF‐positive: of these, 28 (28%) would not have tuberculosis; and 901 would be Xpert MTB/RIF‐negative: of these, 29 (3%) would have tuberculosis. </p> <p><b>Pleural fluid</b> </p> <p><i>Xpert Ultra (4 studies)</i> </p> <p>Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) (158 participants; very low‐certainty evidence) and 87.0% (63.1 to 97.9) (240 participants; very low‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 192 would be Xpert Ultra‐positive: of these, 117 (61%) would not have tuberculosis; and 808 would be Xpert Ultra‐negative: of these, 25 (3%) would have tuberculosis. </p> <p><i>Xpert MTB/RIF (25 studies)</i> </p> <p>Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) (644 participants; low‐certainty evidence) and 98.9% (97.6 to 99.7) (2421 participants; high‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 60 would be Xpert MTB/RIF‐positive: of these, 10 (17%) would not have tuberculosis; and 940 would be Xpert MTB/RIF‐negative: of these, 50 (5%) would have tuberculosis. </p> <p><b>Lymph node aspirate</b> </p> <p><i>Xpert Ultra (1 study)</i> </p> <p>Xpert Ultra sensitivity and specificity (95% confidence interval) against composite reference standard were 70% (51 to 85) (30 participants; very low‐certainty evidence) and 100% (92 to 100) (43 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 70 would be Xpert Ultra‐positive and 0 (0%) would not have tuberculosis; 930 would be Xpert Ultra‐negative and 30 (3%) would have tuberculosis. </p> <p><i>Xpert MTB/RIF (4 studies)</i> </p> <p>Xpert MTB/RIF pooled sensitivity and specificity against composite reference standard were 81.6% (61.9 to 93.3) (377 participants; low‐certainty evidence) and 96.4% (91.3 to 98.6) (302 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 118 would be Xpert MTB/RIF‐positive and 37 (31%) would not have tuberculosis; 882 would be Xpert MTB/RIF‐negative and 19 (2%) would have tuberculosis. </p> <p>In lymph node aspirate, Xpert MTB/RIF pooled specificity against culture was 86.2% (78.0 to 92.3), lower than that against a composite reference standard. Using the latent class model, Xpert MTB/RIF pooled specificity was 99.5% (99.1 to 99.7), similar to that observed with a composite reference standard. </p> <p><b>Rifampicin resistance</b> </p> <p><i>Xpert Ultra (4 studies)</i> </p> <p>Xpert Ultra pooled sensitivity and specificity were 100.0% (95.1 to 100.0), (24 participants; low‐certainty evidence) and 100.0% (99.0 to 100.0) (105 participants; moderate‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 100 would be Xpert Ultra‐positive (resistant): of these, zero (0%) would not have rifampicin resistance; and 900 would be Xpert Ultra‐negative (susceptible): of these, zero (0%) would have rifampicin resistance. </p> <p><i>Xpert MTB/RIF (19 studies)</i> </p> <p>Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9 to 98.8) (148 participants; high‐certainty evidence) and 99.1% (98.0 to 99.7) (822 participants; high‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 105 would be Xpert MTB/RIF‐positive (resistant): of these, 8 (8%) would not have rifampicin resistance; and 895 would be Xpert MTB/RIF‐negative (susceptible): of these, 3 (0.3%) would have rifampicin resistance. </p> </section> <section id="CD012768-sec-0007"> <h3 class="title" id="CD012768-sec-0007">Authors' conclusions</h3> <p>Xpert Ultra and Xpert MTB/RIF may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across different extrapulmonary specimens: while for most specimens specificity is high, the tests rarely yield a positive result for people without tuberculosis. For tuberculous meningitis, Xpert Ultra had higher sensitivity and lower specificity than Xpert MTB/RIF against culture. Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance. Future research should acknowledge the concern associated with culture as a reference standard in paucibacillary specimens and consider ways to address this limitation. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012768-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012768-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012768-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012768-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012768-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012768-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012768-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012768-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012768-abs-0002" lang="en"> <h3>How accurate are tests (Xpert Ultra and Xpert MTB/RIF) for diagnosing tuberculosis outside the lungs (extrapulmonary tuberculosis) and rifampicin resistance? </h3> <p><b>Why is using Xpert tests for extrapulmonary tuberculosis important?</b> </p> <p>Tuberculosis is one of the top 10 causes of death worldwide. Tuberculosis mainly affects the lungs (pulmonary) but may occur in other parts of the body (extrapulmonary). When people receive proper and timely treatment, tuberculosis is usually curable. One problem involved in managing tuberculosis is that the bacteria become resistant to antibiotics. Not recognizing tuberculosis early may result in delayed diagnosis and treatment and increased illness and death. An incorrect tuberculosis diagnosis may result in increased anxiety and unnecessary treatment. </p> <p><b>What is the aim of this review?</b> </p> <p>To update the evidence on accuracy of Xpert tests for diagnosing extrapulmonary tuberculosis and rifampicin resistance in adults. Rifampicin is an important tuberculosis drug. We included tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, and disseminated tuberculosis. </p> <p><b>What was studied in this review?</b> </p> <p>Xpert Ultra and Xpert MTB/RIF are rapid tests for simultaneously diagnosing tuberculosis and rifampicin resistance. We combined study results to determine:<br/>‐ sensitivity: people with tuberculosis (rifampicin resistance) correctly diagnosed as having the condition.<br/>‐ specificity: people without tuberculosis (rifampicin resistance) correctly identified as not having the condition.<br/>The closer sensitivity and specificity are to 100%, the better the test. We measured Xpert results against culture and a composite reference standard (neither is a perfect reference standard because extrapulmonary tuberculosis is paucibacillary (few bacteria)). </p> <p><b>What are the main results in this review?</b> </p> <p>69 studies tested lymph node, pleural, and cerebrospinal fluid, and other specimens from people with presumptive extrapulmonary tuberculosis. Studies were conducted in 28 different countries. </p> <p>For every 1000 people tested, if 100 had tuberculosis according to the reference standards:</p> <p><b>cerebrospinal fluid</b> </p> <p>‐<i>Xpert Ultra (6 studies)</i>: </p> <p>· 89% sensitivity: 168 people would test positive, including 79 without tuberculosis</p> <p>· 91% specificity: 832 people would test negative, including 11 with tuberculosis</p> <p>‐ <i>Xpert MTB/RIF (30 studies)</i>: </p> <p>· 71% sensitivity: 99 people would test positive, including 28 without tuberculosis</p> <p>· 97% specificity: 901 people would test negative, including 29 with tuberculosis</p> <p><b>pleural fluid</b> </p> <p>‐ <i>Xpert Ultra (4 studies)</i>: </p> <p>· 75% sensitivity: 192 people would test positive, including 117 without tuberculosis</p> <p>· 87% specificity: 808 people would test negative, including 25 with tuberculosis</p> <p>‐ <i>Xpert MTB/RIF (25 studies)</i>: </p> <p>· 50% sensitivity: 60 people would test positive, including 10 without tuberculosis</p> <p>· 99% specificity: 940 would test negative, including 50 with tuberculosis</p> <p><b>lymph node fluid</b> </p> <p>‐ <i>Xpert Ultra (1 study)</i>: </p> <p>· 70% sensitivity: 70 people would test positive (all have tuberculosis)</p> <p>· 100% specificity: 930 people would test negative, including 30 with tuberculosis</p> <p>‐<i>Xpert MTB/RIF (4 studies):</i> </p> <p>· 82% sensitivity:118 people would test positive, including 37 without tuberculosis</p> <p>· 96% specificity: 882 people would test negative, including 19 with tuberculosis</p> <p><b>rifampicin resistance</b> </p> <p>‐<i>Xpert Ultra (4 studies)</i>: </p> <p>· 100% sensitivity: 100 people would test positive (all have rifampicin resistance)</p> <p>· 100% specificity: 900 people would test negative (none have rifampicin resistance)</p> <p>‐ <i>MTB/RIF test (19 studies)</i>: </p> <p>· 97% sensitivity: 105 people would test positive, including eight without rifampicin resistance </p> <p>· 99% specificity: 895 people would test negative, including three with rifampicin resistance </p> <p><b>Who do the results of this review apply to?</b> </p> <p>People thought to have extrapulmonary tuberculosis.</p> <p><b>How confident are we in our results?</b> </p> <p>Fairly confident for Xpert MTB/RIF in cerebrospinal fluid and less so in lymph node fluid. Less confident for Xpert Ultra, as there were few studies and few people tested. Both reference standards are imperfect, which may affect accuracy estimates. </p> <p><b>What are the implications of this review?</b> </p> <p>The Xpert tests may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across different extrapulmonary specimens, while for most specimens, specificity is high, the test rarely yielding a positive result for people without tuberculosis (verified by culture). For tuberculous meningitis, Xpert Ultra had higher sensitivity than Xpert MTB/RIF and lower specificity than Xpert MTB/RIF. The tests had similar accuracy for diagnosing rifampicin resistance. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>28 January 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012768-sec-0193" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012768-sec-0193"></div> <h3 class="title" id="CD012768-sec-0194">Implications for practice</h3> <section id="CD012768-sec-0194"> <p>In people presumed to have extrapulmonary tuberculosis, Xpert Ultra and Xpert MTB/RIF may be helpful in confirming the diagnosis. Sensitivity varies across different extrapulmonary specimens, while for most specimens specificity is high, the test rarely yielding a positive result for people without tuberculosis. For tuberculous meningitis, Xpert Ultra had higher pooled sensitivity and lower pooled specificity than Xpert MTB/RIF against culture. Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance. </p> </section> <h3 class="title" id="CD012768-sec-0195">Implications for research</h3> <section id="CD012768-sec-0195"> <p>Future studies should perform comparisons of different tests, including Xpert Ultra, as this approach will reveal which tests (or strategies) yield superior diagnostic accuracy. For these studies, the preferred study design is one in which all participants receive all available diagnostic tests or are randomly assigned to receive one or another of the tests. Studies should include children and people living with HIV. Future research should acknowledge the concern associated with culture as a reference standard in paucibacillary specimens, and should consider ways to address this limitation. </p> <p>Rapid point‐of‐care diagnostic tests for extrapulmonary tuberculosis are critically needed. Research groups should focus on developing diagnostic tests and strategies that use readily‐available clinical specimens, such as urine, rather than specimens that require invasive procedures for collection. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012768-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012768-sec-0008"></div> <div class="table" id="CD012768-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in cerebrospinal fluid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have tuberculous meningitis </p> <p><b>Prior testing:</b> people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and possibly received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> solid or liquid culture </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> participants were evaluated exclusively as inpatients at a tertiary care centre, or, if the clinical setting was not reported, Xpert was performed at a reference laboratory rather than at primary care facilities and local hospitals </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 89.4% (79.1 to 95.6); pooled specificity (95% CrI): 91.2% (83.2 to 95.7)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 71.1% (62.8 to 79.1); pooled specificity (95% CrI): 96.9% (95.4 to 98.0)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert</b> Ultra<b>(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (participants with TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(20 to 24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(79 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> <p>(158 to 191)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>89 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (participants incorrectly classified as not having TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>(1 to 5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(4 to 21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(9 to 42)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (participants without TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>889</p> <p>(811 to 933)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>821</p> <p>(749 to 861)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> <p>(666 to 766)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>386 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (participants incorrectly classified as having TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> <p>(42 to 164)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(39 to 151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(34 to 134)</p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert</b> <b>MTB/RIF (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (participants with TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> <p>(16 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> <p>(63 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(126 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>571 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (participants incorrectly classified as not having TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> <p>(5 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>(21 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(42 to 74)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (participants without TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>945</p> <p>(930 to 956)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872</p> <p>(859 to 882)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>775</p> <p>(763 to 784)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2824 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (participants incorrectly classified as having TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(19 to 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> <p>(18 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(16 to 37)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was 35.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 15.2%. </p> <p>Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><sup>a</sup>There were few participants in this analysis. The very wide 95% CrI around true‐positives and false‐negatives may lead to different decisions, depending on which credible limits are assumed. We downgraded two levels for imprecision.<br/><sup>b</sup>The wide 95% CrI around true‐negatives and false‐positives would likely lead to different decisions, depending on which credible limits are assumed. We downgraded one level for imprecision.<br/><sup>c</sup>The wide 95% CrI around true‐positives and false‐negatives may lead to different decisions, depending on which credible limits are assumed. We downgraded one level for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012768-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in pleural fluid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have pleural tuberculosis </p> <p><b>Prior testing:</b> people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice, which may include more invasive tests, such as pleural biopsy </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> solid or liquid culture </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laboratory </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 75.0% (58.0 to 86.4); pooled specificity (95% CrI): 87.0% (63.1 to 97.9)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 49.5% (39.8 to 59.9); pooled specificity (95% CrI): 98.9% (97.6 to 99.7)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert Ultra (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (patients with pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(14 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> <p>(58 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> <p>(116 to 173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (patients incorrectly classified as not having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> <p>(3 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(14 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(27 to 84)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (patients without pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848</p> <p>(615 to 955)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>783</p> <p>(568 to 881)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>696</p> <p>(505 to 783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (patients incorrectly classified as having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> <p>(20 to 360)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> <p>(19 to 332)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> <p>(17 to 295)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert MTB/RIF (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (patients with pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(10 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(40 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> <p>(80 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>644 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g,h</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (patients incorrectly classified as not having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(10 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(40 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> <p>(80 to 120)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (patients without pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>964</p> <p>(952 to 972)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890</p> <p>(878 to 897)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>791</p> <p>(781 to 798)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2421 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (patients incorrectly classified as having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(3 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(3 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(2 to 19)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: CrI: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was 46.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 19.8%. </p> <p><sup>a</sup>We were interested in how Xpert Ultra performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness.<br/><sup>b</sup>For individual studies, sensitivity estimates ranged from 48% to 84%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>c</sup>There was a low number of participants contributing to this analysis for the observed sensitivity. As we had already downgraded for inconsistency, we downgraded one level for imprecision.<br/><sup>d</sup>For individual studies, specificity estimates ranged from 65% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>e</sup>We thought the wide 95% CrI around false‐positives and true‐negatives would likely lead to different decisions depending on which confidence limits are assumed. As we had already downgraded for inconsistency, we downgraded one level for imprecision.<br/><sup>f</sup>We were interested in how Xpert MTB/RIF performed in participants presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness.<br/><sup>g</sup>For individual studies, sensitivity estimates ranged from 10% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>h</sup>As we had already downgraded for inconsistency, we did not downgrade further for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012768-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in lymph node aspirate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have lymph node tuberculosis </p> <p><b>Prior testing:</b> people who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice, which may include more invasive tests, such as biopsy of affected organs </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> composite reference standard </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laboratory performed at a reference laboratory </p> <p><b>Xpert Ultra sensitivity (95% CI): 70% (51 to 85); specificity: 100% (92 to 100)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 81.6% (61.9 to 93.3); pooled specificity: 96.4% (91.3 to 98.6)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert Ultra</b> <br/><b>(95% Cl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients with lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (13 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (51 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 (102 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as not having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (4 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (15 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (30 to 98)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients without lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>975 (897 to 975)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 (828 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800 (736 to 800)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 64)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert MTB/RIF (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients with lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (16 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81 (62 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 (124 to 184)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as not having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (8 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (16 to 76)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients without lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>935 (878 to 958)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863 (811 to 885)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>767 (721 to 786)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (17 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (15 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (14 to 79)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the prevalence of tuberculosis in the included study was 41%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 55.5%. </p> <p><sup>a</sup>We identified only one study, which was conducted at a tertiary referral centre in South Africa, a high TB burden country. Most participants (84%) were seen as outpatients. With only one study, applicability to other settings comes with some uncertainty. We downgraded one level for indirectness.<br/><sup>b</sup>There were very few participants contributing to this analysis. The 95% CI was very wide. We downgraded two levels for imprecision.<br/><sup>c</sup>There were very few participants contributing to this analysis. The 95% CI was wide. We downgraded two levels for imprecision.<br/><sup>d</sup>The composite reference standard was defined by the primary study authors and therefore, was not uniform. We downgraded one level for risk of bias.<br/><sup>e</sup>For indirectness, regarding applicability, for the patient population, we considered most studies to have unclear concern. We were interested in how Xpert MTB/RIF performed in patients presumed to have extrapulmonary TB who were evaluated as they would be in routine practice. However, none of the studies reported this information. We downgraded one level for indirectness. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012768-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF for rifampicin resistance</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people with tuberculosis detected by Xpert Ultra or Xpert MTB/RIF </p> <p><b>Role:</b> initial test<b>,</b> replacement test for standard practice, which includes culture‐based drug susceptibility testing or line probe assay </p> <p><b>Settings:</b> primarily tertiary care centres, the index test was often run in central (reference laboratories), where drug susceptibility testing for the reference standard could be performed </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> culture‐based drug susceptibility testing using solid or liquid media or line probe assay </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 100.0% (95.1 to 100.0); pooled specificity (95% CrI): 100.0% (99.0 to 100.0)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 96.5% (91.9 to 98.8); pooled specificity (95% CrI): 99.1% (98.0 to 99.7)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for rifampicin resistance using Xpert Ultra (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 15%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients correctly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (19 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (95 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 (143 to 150)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients correctly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>980 (979 to 980)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 (899 to 900)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>850 (849 to 850)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>105 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for rifampicin resistance using Xpert MTB/RIF (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 15%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients correctly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (18 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (92 to 99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (138 to 148)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0 to 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2 to 12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients correctly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 (960 to 977)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>892 (882 to 897)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>842 (833 to 847)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>822 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (3 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (3 to 18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (3 to 17)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of rifampicin resistance in the included studies was 19.2%. For Xpert MTB/RIF, the median prevalence of rifampicin resistance in the included studies was 11.9%. </p> <p><sup>a</sup>All these studies were conducted in China (high TB‐burden country). Applicability to other settings comes with some uncertainty and therefore we downgraded one level for indirectness.<br/><sup>b</sup>There was a low number of participants contributing to this analysis for the observed sensitivity. We downgraded one level for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012768-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012768-sec-0009"></div> <p>Tuberculosis (TB) causes tremendous suffering worldwide and has surpassed HIV/AIDS as the world’s leading infectious cause of death. The World Health Organization (WHO) estimates that globally in 2019, 10.0 million (range, 8.9 to 11.0 million) people fell ill with tuberculosis. In 2019, around 1.2 million HIV‐negative people died from tuberculosis and 208,000 HIV‐positive people died from tuberculosis (<a href="./references#CD012768-bbs2-0365" title="World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.">WHO Global TB Report 2020</a>). When people receive proper treatment, tuberculosis is treatable and curable. The WHO estimates that from 2000 to 2019 more than 60 million lives were saved by diagnosing and treating tuberculosis. However, the COVID‐19 pandemic threatens the gains made over recent years. A modelling study by the WHO suggests that there could be between 200,000 and 400,000 additional tuberculosis deaths in 2020 if, over a period of three months, 25% to 50% fewer people were detected and treated with tuberculosis (<a href="./references#CD012768-bbs2-0365" title="World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.">WHO Global TB Report 2020</a>). </p> <p>Of the 7.1 million new cases of tuberculosis notified to the WHO in 2019, 16% were cases of extrapulmonary tuberculosis, (range, 8% in the WHO Western Pacific Region to 24% in the WHO Eastern Mediterranean Region) (<a href="./references#CD012768-bbs2-0365" title="World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.">WHO Global TB Report 2020</a>). Among countries in the European Union, extrapulmonary tuberculosis was responsible for 19% of all notified cases (range, 6% to 44%) (<a href="./references#CD012768-bbs2-0327" title="SandgrenA , HolloV , Van der WerfMJ . Extrapulmonary tuberculosis in the European Union and European economic area, 2002 to 2011. Euro Surveillance2013;18(12):pii: 20431.">Sandgren 2013</a>). A large retrospective analysis from China found that of 19,279 hospitalised tuberculosis patients, around 33% had extrapulmonary tuberculosis (<a href="./references#CD012768-bbs2-0318" title="PangY , AnJ , ShuW , HuoF , ChuN , GaoM , et al. Epidemiology of extrapulmonary tuberculosis among inpatients, China, 2008-2017. Emerging Infectious Diseases2019;25:457-64.">Pang 2019</a>). The number of people affected by extrapulmonary tuberculosis is likely to be higher, given that, according to the WHO, extrapulmonary tuberculosis is notified as pulmonary tuberculosis when the two forms exist together, and diagnosing extrapulmonary tuberculosis is challenging, as described below. Additionally, extrapulmonary tuberculosis accounts for an increasing proportion of tuberculosis cases in some countries, in part because of host and genetic considerations, and the association of extrapulmonary tuberculosis and HIV (<a href="./references#CD012768-bbs2-0287" title="GoldenMP , VikramHR . Extrapulmonary tuberculosis: an overview. American Family Physician2005;72(9):1761-8.">Golden 2005</a>; <a href="./references#CD012768-bbs2-0317" title="PaiM , BehrM , DowdyD , DhedaK , DivangahiM , BoehmeCC , et al. Tuberculosis. Nature Reviews. Disease Primers2016;2:16076. [DOI: 10.1038/nrdp.2016.76]">Pai 2016</a>; <a href="./references#CD012768-bbs2-0320" title="PerkinsMD , CunninghamJ . Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. Journal of Infectious Diseases2007;196 Suppl 1:S15–27.">Perkins 2007</a>; <a href="./references#CD012768-bbs2-0353" title="WebsterAS , ShanderaWX . The extrapulmonary dissemination of tuberculosis: a meta-analysis. International Journal of Mycobacteriology2014;3:9-16.">Webster 2014</a>). Based on surveillance and epidemiological data, extrapulmonary tuberculosis affects a greater proportion of children than adults (<a href="./references#CD012768-bbs2-0314" title="NelsonLJ , WellsCD . Global epidemiology of childhood tuberculosis. International Journal of Tuberculosis and Lung Disease2004;8(5):636-47.">Nelson 2004</a>). </p> <p>Drug‐resistant tuberculosis is a serious threat to global health. For the purpose of surveillance and treatment, drug‐resistant tuberculosis is classified as rifampicin‐resistant tuberculosis, multidrug‐resistant tuberculosis (MDR‐TB), and extensively drug‐resistant tuberculosis. MDR‐TB is defined as resistance to at least isoniazid and rifampicin, the two most important first‐line anti‐tuberculosis drugs. Extensively drug‐resistant tuberculosis is defined as MDR‐TB plus resistance to at least one drug in the following two classes of medicines used in treatment of MDR‐TB: fluoroquinolones and second‐line injectable agents. In 2019, there were approximately half a million new cases of rifampicin‐resistant tuberculosis (of which 78% had MDR‐TB), with India (27%), China (14%) and the Russian Federation (9%) accounting for the largest burden (<a href="./references#CD012768-bbs2-0365" title="World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.">WHO Global TB Report 2020</a>). In 2019, 12,350 cases of extensively drug‐resistant tuberculosis were reported (<a href="./references#CD012768-bbs2-0365" title="World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.">WHO Global TB Report 2020</a>). </p> <p>In 2014, the World Health Assembly unanimously approved the WHO End TB Strategy, a 20‐year strategy devised to end the global tuberculosis epidemic (<a href="./references#CD012768-bbs2-0364" title="World Health Organization. The END TB strategy. www.who.int/tb/strategy/end-tb/en/ 2014 (accessed 1 April 2020).">WHO END TB 2014</a>). Early diagnosis of tuberculosis, including universal drug susceptibility testing (DST) and systematic screening of contacts and high‐risk groups, is a part of pillar one of the strategy. </p> <section id="CD012768-sec-0010"> <h3 class="title" id="CD012768-sec-0010">Target condition being diagnosed</h3> <section id="CD012768-sec-0011"> <h4 class="title">Extrapulmonary TB</h4> <p>Tuberculosis is caused by infection with <i>Mycobacterium tuberculosis</i> (<i>M tuberculosis</i>) bacteria. Tuberculosis predominantly affects the lungs (pulmonary tuberculosis). Extrapulmonary tuberculosis refers to tuberculosis in parts of the body other than the lungs. Extrapulmonary tuberculosis is known to affect virtually every part of the body, with lymph nodes and the pleura being the most common sites (<a href="./references#CD012768-bbs2-0338" title="SharmaSK , MohanA . Extrapulmonary tuberculosis. Indian Journal of Medical Research2004;120(4):316-53.">Sharma 2004</a>). Although active pulmonary tuberculosis is transmissible by droplets spread by coughing, extrapulmonary tuberculosis is thought to result from hematogenous spread (spread by way of the bloodstream) from an initial lung infection and is not infectious. Extrapulmonary tuberculosis can occur alone or together with pulmonary tuberculosis. </p> <p>The various forms of extrapulmonary tuberculosis cause signs and symptoms related to the structures affected. <a href="#CD012768-tbl-0005">Table 1</a> describes the forms of extrapulmonary tuberculosis included in this review, as well as the respective specimens that may be collected for diagnosis. </p> <div class="table" id="CD012768-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Forms of extrapulmonary TB</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of extrapulmonary TB</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diagnostic specimens and means of collection</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculous meningitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the meninges affects people of all ages but is most common among children and people with untreated HIV infection. In adults, tuberculous meningitis presents with gradual onset of headache, neck stiffness, malaise, and fever, and if untreated can progress to altered sensorium, focal neurological deficits, coma, and death. Young children may present with poor weight gain, low‐grade fever, and listlessness. Infants may present with fever, cough (related to the primary pulmonary infection that occurs before tuberculous meningitis develops), change of consciousness at presentation, bulging anterior fontanel, and seizures (<a href="./references#CD012768-bbs2-0348" title="ThwaitesGE , Van ToornR , SchoemanJ . Tuberculous meningitis: more questions, still too few answers. Lancet Neurology2013;12(10):999-1010.">Thwaites 2013</a>). Tuberculous meningitis is sometimes associated with a concurrent cerebral tuberculoma, or, more rarely, a tuberculous abscess </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrospinal fluid, acquired by lumbar puncture with or without radiological guidance; biopsy of tuberculoma, acquired surgically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural tuberculosis, also called TB pleurisy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TB infection of the pleura presents with gradual onset of pleuritic chest pain, shortness of breath, fever, night sweats, and weight loss. Chest X‐ray may demonstrate unilateral or occasionally bilateral pleural effusion. The severity of symptoms is highly variable, with many patients experiencing spontaneous resolution of symptoms, while others may develop severe pleural effusions requiring drainage. Pleuro‐pulmonary tuberculosis, in which parenchymal lung involvement is visible on a chest X‐ray, is associated with higher mortality than isolated pleural infection, which appears to be rarely fatal (<a href="./references#CD012768-bbs2-0341" title="ShuCC , WangJT , WangJY , LeeLN , YuCJ . In-hospital outcome of patients with culture-confirmed tuberculous pleurisy: clinical impact of pulmonary involvement. BMC Infectious Diseases2011;11:46. [DOI: 10.1186/1471-2334-11-46]">Shu 2011</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid; pleural biopsy, which may be performed via thoracoscopy or percutaneously with Abram's needle, with or without ultrasound guidance </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node tuberculosis, also called TB lymphadenitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the lymph nodes may affect one node or a group of nodes, or multiple groups within a chain. Lymph node tuberculosis is relatively more common among children than adults. The most common presentation is of a single, firm, non‐tender enlarged node in the neck, although any lymph node group can be affected. This may be accompanied by fever, weight loss, and night sweats, particularly in people with HIV. Patients with tuberculosis in deep lymph nodes, such as the mediastinal or mesenteric lymph nodes, may present with fever, night sweats, and weight loss, or, more rarely, with symptoms related to compression of adjacent structures. Over time lymph nodes become fluctuant and may discharge via a sinus to the skin or an adjacent viscus. It should be noted that lymphadenopathy may also be seen in other forms of tuberculosis as part of the immune response, but this is not usually caused by direct infection of the lymph nodes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fine‐needle aspiration of fluid from affected lymph node, with or without radiological guidance; surgical biopsy of superficial lymph nodes; endoscopic biopsy of deep lymph nodes with ultrasound guidance </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone or joint tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of bones or joints or both causes chronic pain, deformity, and disability, and tuberculosis of the cervical spine can be life‐threatening. The usual presenting symptom is pain. Fever and weight loss, with or without signs of spinal cord compression, may be present. Patients with advanced disease may have severe pain, spinal deformity, paraspinal muscle wasting, and neurological deficit. Children may have failure to thrive and difficulty walking </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspiration of joint fluid or periarticular abscesses; percutaneous computed tomography‐guided biopsy of lesions is preferred, but some patients may require open biopsy </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genitourinary tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the genitourinary tract includes renal tuberculosis and tuberculosis of the reproductive system. Renal tuberculosis presents with flank pain, haematuria, and dysuria. Female genital tuberculosis presents with infertility (and may be otherwise asymptomatic), pelvic pain, and vaginal bleeding. Testicular tuberculosis presents with a scrotal mass and infertility </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine; biopsy of affected organs, acquired under radiological guidance or surgically</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pericardial tuberculosis, also called TB pericarditis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the pericardium presents with fever, malaise, night sweats, and weight loss. Chest pain and shortness of breath are also commonly‐experienced symptoms. Pericardial tuberculosis may be associated with pericardial effusion, which can be severe and lead to life‐threatening tamponade. Some patients go on to develop pericardial constriction, which can lead to heart failure and death and may require surgical intervention even after mycobacterial cure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pericardial fluid acquired by pericardiocentesis; pericardial biopsy, acquired under radiological guidance or surgically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peritoneal tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the peritoneum usually presents with pain and abdominal swelling, which may be accompanied by fever, weight loss, and anorexia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ascitic fluid acquired by paracentesis; peritoneal biopsy (<a href="./references#CD012768-bbs2-0273" title="ChowKM , ChowVC , HungLC , WongSM , SzetoCC . Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clinical Infectious Diseases2002;35(4):409-13.">Chow 2002</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disseminated tuberculosis, also called miliary tuberculosis. It has been proposed that the designation ‘miliary TB' be restricted to disseminated TB with miliary shadows on chest radiograph (<a href="./references#CD012768-bbs2-0325" title="ReuterH , WoodR , SchaafHS , DonaldPR . Overview of extrapulmonary tuberculosis in adults and children. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:377-90.">Reuter 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disseminated tuberculosis involves two or more distinctly separate sites. Manifestations may be varied, ranging from acute fulminant disease to non‐specific symptoms of fever, weight loss, and weakness. HIV‐positive people are more likely to have disseminated tuberculosis than HIV‐negative people. In a systematic review of the prevalence of tuberculosis in post mortem evaluations of HIV‐positive people, among adults disseminated tuberculosis was found in 88% of tuberculosis cases and was considered the cause of death in 91% of TB cases (<a href="./references#CD012768-bbs2-0290" title="GuptaRK , LucasSB , FieldingKL , LawnSD . Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS2015;29(15):1987-2002.">Gupta 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood; specimens acquired from affected extrapulmonary sites</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: TB: tuberculosis.</p> <p>We adapted the table from <a href="./references#CD012768-bbs2-0339" title="SharmaSK , RyanH , KhapardeS , SachdevaKS , SinghAD , MohanA , et al. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian Journal of Medical Research2017;145(4):448-63.">Sharma 2017b</a>. </p> </div> </div> <p>Diagnosis of extrapulmonary tuberculosis is challenging for several reasons. Many forms of extrapulmonary tuberculosis require invasive diagnostic sampling; gathering adequate specimens can pose risk of harm to the patient and can be costly. Most forms of extrapulmonary tuberculosis are paucibacillary (tuberculosis disease caused by a small number of bacteria), making diagnosis by various tests less sensitive. Culture, for example, has reduced sensitivity in paucibacillary disease. In addition, culture takes several weeks for results and requires a highly‐equipped laboratory. Limitations are also associated with histology, which relies on highly‐trained operators, and characteristic morphology is shared with other diseases. As a result of these difficulties, diagnosis of extrapulmonary tuberculosis is often made on the grounds of clinical suspicion alone, and many people receive the wrong diagnosis, leading to unnecessary tuberculosis treatment or poor outcomes from untreated extrapulmonary tuberculosis. </p> <p>Tuberculosis treatment regimens must contain multiple drugs to which the organisms are sensitive to cure tuberculosis and avoid selection for drug resistance. WHO tuberculosis treatment guidelines recommend the same drug regimens for extrapulmonary and pulmonary disease, with notable mention of tuberculous meningitis and bone or joint tuberculosis, for which longer treatment regimens are recommended (<a href="./references#CD012768-bbs2-0355" title="World Health Organization. Guidelines for treatment of tuberculosis, fourth edition. who.int/tb/publications/2010/9789241547833/en/ 2010 (accessed 2 July 2020).">WHO 2010</a>; <a href="./references#CD012768-bbs2-0359" title="World Health Organization. Guidelines for the treatment of drug-susceptible tuberculosis and patient care (2017 update). www.who.int/tb/publications/2017/dstb_guidance_2017/en/ 2017 (accessed 1 April 2020).">WHO 2017</a>; <a href="./references#CD012768-bbs2-0361" title="World Health Organization. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition. www.who.int/tb/publications/Compendium_WHO_guidelines_TB_2017/en/ (accessed 2 July 2020).">WHO Compendium 2018</a>). For patients with tuberculous meningitis or tuberculous pericarditis, the use of adjuvant corticosteroid therapy is recommended in addition to appropriate tuberculosis treatment regimens (<a href="./references#CD012768-bbs2-0359" title="World Health Organization. Guidelines for the treatment of drug-susceptible tuberculosis and patient care (2017 update). www.who.int/tb/publications/2017/dstb_guidance_2017/en/ 2017 (accessed 1 April 2020).">WHO 2017</a>; <a href="./references#CD012768-bbs2-0361" title="World Health Organization. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition. www.who.int/tb/publications/Compendium_WHO_guidelines_TB_2017/en/ (accessed 2 July 2020).">WHO Compendium 2018</a>). Other tuberculosis treatment guidelines include <a href="./references#CD012768-bbs2-0339" title="SharmaSK , RyanH , KhapardeS , SachdevaKS , SinghAD , MohanA , et al. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian Journal of Medical Research2017;145(4):448-63.">Sharma 2017b</a> (India), and those issued by the American Thoracic Society, the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (<a href="./references#CD012768-bbs2-0312" title="NahidP , DormanSE , AlipanahN , BarryPM , BrozekJL , CattamanchiA , et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases2016;63(7):e147-95. [DOI: 10.1093/cid/ciw376]">Nahid 2016</a>). The drugs used to treat MDR‐TB are less potent and more toxic than the drugs used to treat drug‐susceptible tuberculosis, historically requiring two years or more of therapy. However, in December 2019, based on new evidence on the management of drug‐resistant tuberculosis, the WHO issued recommendations that all patients with MDR‐TB or rifampicin‐resistant tuberculosis, including those who are also resistant to fluoroquinolones, may benefit from effective all‐oral treatment regimens, either shorter or longer (<a href="./references#CD012768-bbs2-0363" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/9789240007048 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 4) 2020</a>). </p> </section> <section id="CD012768-sec-0012"> <h4 class="title">Rifampicin resistance</h4> <p>Rifampicin inhibits bacterial DNA‐dependent RNA polymerase, encoded by the RNA polymerase gene (<i>rpoB</i>) (<a href="./references#CD012768-bbs2-0295" title="HartmannG , HonikelKO , KnüselF , NüeschJ . The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochimica et Biophysica Acta1967;145(3):843–4.">Hartmann 1967</a>). Resistance to this drug has been associated mainly with mutations in a limited region of the <i>rpoB</i> gene (<a href="./references#CD012768-bbs2-0346" title="TelentiA , ImbodenP , MarchesiF , LowrieD , ColeS , ColstonMJ , et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis . Lancet1993;341(8846):647-50.">Telenti 1993</a>). Rifampicin resistance may occur alone or in association with resistance to isoniazid and other drugs. In settings with a high burden of MDR‐TB, the presence of rifampicin resistance alone may serve as a proxy for MDR‐TB (<a href="./references#CD012768-bbs2-0356" title="World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational ‘How-to’. Practical considerations. who.int/tb/publications/tb-amplificationtechnology-implementation/en/ 2011 (accessed 2 July 2020).">WHO 2011</a>). People with drug‐resistant tuberculosis can transmit the infection to others. </p> </section> </section> <section id="CD012768-sec-0013"> <h3 class="title" id="CD012768-sec-0013">Index test(s)</h3> <p>The index tests, Xpert MTB/RIF and Ultra Xpert MTB/RIF (Xpert Ultra, the newest version) (Cepheid Inc, Sunnyvale, USA), are nucleic acid amplification tests (NAATs) (i.e. molecular tests) used for diagnosing tuberculosis and rifampicin‐resistant tuberculosis. Xpert MTB/RIF and Xpert Ultra cartridges are used with the GeneXpert system (<a href="./references#CD012768-bbs2-0268" title="Cepheid. Brochure: Xpert® MTB/RIF Ultra. www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-RIF-Ultra (accessed 26 March 2020).">Cepheid 2018</a>; <a href="./references#CD012768-bbs2-0269" title="Cepheid. Xpert® MTB/RIF. Two-hour detection of MTB and rifampin resistance mutations. www.cepheid.com/Package%20Insert%20Files/Xpert-MTB-RIF-ENGLISH-Package-Insert-301-1404-Rev-F.pdf (accessed 29 March 2020).">Cepheid 2019</a>). Xpert MTB/RIF and Xpert Ultra are able to detect both <i>M tuberculosis</i> complex and rifampicin resistance within two hours after starting the test, with minimal hands‐on technical time. Unlike conventional NAATs, with Xpert MTB/RIF and Xpert Ultra, sample processing and polymerase chain reaction (PCR) amplification and detection are integrated into a single, self‐enclosed test unit, the GeneXpert cartridge. Following sample loading, all steps in the assay are completely automated and self‐contained. In addition, the assays' sample reagent, used to liquefy sputum, has potent tuberculocidal (the ability to kill tuberculosis bacteria) properties and so largely eliminates biosafety concerns during the test procedure (<a href="./references#CD012768-bbs2-0259" title="BanadaPP , SivasubramaniSK , BlakemoreR , BoehmeC , PerkinsMD , FennellyK , et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. Journal of Clinical Microbiology2010;48(10):3551-7.">Banada 2010</a>). Except as described below for Ultra trace call results, a single Xpert MTB/RIF or Xpert Ultra run will provide both detection of tuberculosis and detection of rifampicin resistance. One cannot deselect testing for rifampicin resistance and only run the assay for tuberculosis detection. </p> <p>The development of Xpert MTB/RIF was a major step toward improving detection of tuberculosis and rifampicin resistance globally (<a href="./references#CD012768-bbs2-0263" title="BoehmeCC , NabetaP , HillemannD , NicolMP , ShenaiS , KrappF , et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine2010;363(11):1005–15.">Boehme 2010</a>; <a href="./references#CD012768-bbs2-0342" title="SmallPM , PaiM . Tuberculosis diagnosis - time for a game change. New England Journal of Medicine2011;363(111):1070–1.">Small 2011</a>). Since Xpert MTB/RIF was released, there have been four generations (G1, G2, G3, and G4) of the test involving different software and cartridge combinations. Although in comparison with smear microscopy Xpert MTB/RIF has increased sensitivity for pulmonary tuberculosis (<a href="./references#CD012768-bbs2-0344" title="SteingartKR , SchillerI , HorneDJ , PaiM , BoehmeCC , DendukuriN . Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593.pub3]">Steingart 2014</a>), the test has suboptimal sensitivity in people with smear‐negative and HIV‐associated tuberculosis. A Cochrane Review on the diagnostic accuracy of Xpert MTB/RIF for pulmonary tuberculosis found pooled sensitivity and specificity (95% credible Interval (CrI)) of 85% (82% to 88%) and 98% (97% to 98%), (70 studies, 37,237 unselected participants; high‐certainty evidence) (<a href="./references#CD012768-bbs2-0297" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593]">Horne 2019</a>). However, Xpert MTB/RIF sensitivity was decreased in people with smear‐negative culture‐positive disease, pooled sensitivity of 67% (62% to 72%), and people living with HIV, pooled sensitivity of 81% (75% to 86%) (<a href="./references#CD012768-bbs2-0297" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593]">Horne 2019</a>). Xpert MTB/RIF versions have also had some limitations in detecting rifampicin resistance. </p> <p>In order to overcome limitations with Xpert MTB/RIF, Cepheid developed Xpert Ultra, a re‐engineered assay that uses a newly‐developed cartridge but may be run on the same device after a software upgrade. To improve sensitivity for tuberculosis detection, Xpert Ultra incorporates two different multi‐copy amplification targets and a larger DNA reaction chamber than Xpert MTB/RIF (<a href="./references#CD012768-bbs2-0369" title="World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. WHO/HTM/TB/2017.04. www.who.int/tb/publications/2017/XpertUltra/en/ 2017 (accessed 2 July 2020).">WHO Xpert Ultra 2017</a>). A laboratory study reported that the limit of detection (the lowest number of colony‐forming units (CFUs) per sample that can be reproducibly distinguished from negative samples with 95% confidence) using Xpert Ultra improved to 15.6 CFU/mL of sputum compared to 112.6 CFU/mL for Xpert MTB/RIF (<a href="./references#CD012768-bbs2-0270" title="ChakravortyS , SimmonsAM , RownekiM , ParmarH , CaoY , RyanJ , et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio2017;8(4):e00812-17. [DOI: 10.1128/mBio.00812-17]">Chakravorty 2017</a>). Xpert Ultra has added a new result category, ‘trace call', that corresponds to the lowest bacillary load for <i>M tuberculosis</i> detection (<a href="./references#CD012768-bbs2-0369" title="World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. WHO/HTM/TB/2017.04. www.who.int/tb/publications/2017/XpertUltra/en/ 2017 (accessed 2 July 2020).">WHO Xpert Ultra 2017</a>). This new category is reported as 'MTB trace DETECTED'. Interpreting a trace call result requires a reassessment of clinical symptoms and history of prior tuberculosis. No rifampicin resistance results are available (indeterminate) for people with trace results. As with Xpert MTB/RIF (<a href="./references#CD012768-bbs2-0309" title="MiottoP , BigoniS , MiglioriGB , MatteelliA , CirilloDM . Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. European Respiratory Journal2012;39(5):1269-71.">Miotto 2012</a>), Xpert Ultra detects both live and dead bacteria. </p> <p>To address limitations in rifampicin resistance detection, Xpert Ultra uses melting temperature‐based analysis, in lieu of real‐time PCR analysis with Xpert MTB/RIF. Melting temperature‐based analysis allows Xpert Ultra to better distinguish resistance‐conferring mutations from silent mutations with improved diagnostic accuracy for rifampicin resistance detection (<a href="./references#CD012768-bbs2-0285" title="Global Laboratory Initiative. Planning for country transition to Xpert® MTB/RIF Ultra cartridges. www.stoptb.org/wg/gli/assets/documents/gli_ultra.pdf (accessed 2 July 2020).">Global Laboratory Initiative 2017</a>). </p> <p>For sputum specimens, the test procedure may be used either directly on raw sputum specimens or sputum pellets created after decontaminating and concentrating the sputum (<a href="./references#CD012768-bbs2-0262" title="BlakemoreR , StoryE , HelbD , KopJ , BanadaP , OwensMR , et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of Clinical Microbiology2010;48(7):2495-501.">Blakemore 2010</a>). In both cases, the test material is combined with the assay sample reagent (sodium hydroxide and isopropanol), mixed by hand or vortex, and incubated at room temperature for 15 minutes. After the incubation step, 2 mL of the treated specimen are transferred to the cartridge and the run is initiated (<a href="./references#CD012768-bbs2-0296" title="HelbD , JonesM , StoryE , BoehmeC , WallaceE , HoK , et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology2010;48(1):229-37.">Helb 2010</a>). According to the manufacturer, as with Xpert MTB/RIF, Xpert Ultra may be used with fresh sputum specimens, which may be either unprocessed sputum or processed sputum sediments. The sample reagent:sample volume ratio is 2:1 for unprocessed sputum and 3:1 for sputum pellets. The manufacturer does not specifically mention the use of the index tests with frozen specimens (<a href="./references#CD012768-bbs2-0268" title="Cepheid. Brochure: Xpert® MTB/RIF Ultra. www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-RIF-Ultra (accessed 26 March 2020).">Cepheid 2018</a>; <a href="./references#CD012768-bbs2-0269" title="Cepheid. Xpert® MTB/RIF. Two-hour detection of MTB and rifampin resistance mutations. www.cepheid.com/Package%20Insert%20Files/Xpert-MTB-RIF-ENGLISH-Package-Insert-301-1404-Rev-F.pdf (accessed 29 March 2020).">Cepheid 2019</a>). As with Xpert MTB/RIF, Xpert Ultra using the GeneXpert sytem requires an uninterrupted and stable electrical power supply, temperature control, and yearly calibration of the cartridge modules (<a href="./references#CD012768-bbs2-0286" title="Global Laboratory Intiaitive. Practical guide to implementing a quality assurance system for Xpert MTB/RIF testing. www.stoptb.org/wg/gli/assets/documents/Xpert-QA-guide-2019.pdf (accessed 7 January 2020).">Global Laboratory Initiative 2019</a>). Like previous Xpert cartridge generations, Xpert Ultra can be performed by operators with minimal technical expertise (<a href="./references#CD012768-bbs2-0347" title="TheronG , ZijenahL , ChandaD , ClowesP , RachowA , LesoskyM , et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet2014;383(9915):424-35.">Theron 2014a</a>). The time to run the assay is shorter for Xpert Ultra (around 65 to 87 minutes) than for Xpert MTB/RIF (112 minutes) (<a href="./references#CD012768-bbs2-0285" title="Global Laboratory Initiative. Planning for country transition to Xpert® MTB/RIF Ultra cartridges. www.stoptb.org/wg/gli/assets/documents/gli_ultra.pdf (accessed 2 July 2020).">Global Laboratory Initiative 2017</a>). Currently, the manufacturer, Cepheid Incorporated (Sunnyvale, CA, USA), has made no claim for the use of Xpert Ultra and Xpert MTB/RIF in non‐sputum specimens (<a href="./references#CD012768-bbs2-0269" title="Cepheid. Xpert® MTB/RIF. Two-hour detection of MTB and rifampin resistance mutations. www.cepheid.com/Package%20Insert%20Files/Xpert-MTB-RIF-ENGLISH-Package-Insert-301-1404-Rev-F.pdf (accessed 29 March 2020).">Cepheid 2019</a>). However, there is a standard operating procedure provided by WHO for processing non‐sputum specimens (<a href="./references#CD012768-bbs2-0358" title="World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’ practical considerations. apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf 2014 (accessed 2 July 2020).">WHO 2014</a>). </p> </section> <section id="CD012768-sec-0014"> <h3 class="title" id="CD012768-sec-0014">Clinical pathway</h3> <p>Xpert Ultra and Xpert MTB/RIF are used for the diagnosis of extrapulmonary tuberculosis and rifampicin resistance. <a href="#CD012768-fig-0001">Figure 1</a> shows the clinical pathway and presents the context in which Xpert Ultra or Xpert MTB/RIF might be used (<a href="./references#CD012768-bbs2-0366" title="World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-operational-handbook-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection (accessed 6 August 2020).">WHO Operational Handbook Diagnosis (Module 3) 2020</a>). The target conditions were extrapulmonary tuberculosis, which includes several forms (e.g. tuberculous meningitis, pleural tuberculosis) and rifampicin resistance. </p> <div class="figure" id="CD012768-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="The clinical pathway describes how patients might present and the point in the pathway at which they would be considered for testing with Xpert Ultra or Xpert MTB/RIF. This algorithm for the use of a molecular WHO‐recommended rapid diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/ RIF, comes from the WHO operational handbook on tuberculosis (WHO Operational Handbook Diagnosis (Module 3) 2020). Copyright © [2020] [World Health Organization]: reproduced with permission.Abbreviations: DST: drug susceptibility testing; INH: isoniazid; MDR‐TB: multidrug‐resistant TB; MTB: Mycobacterium tuberculosis; PLHIV: people living with HIV; RIF: rifampicin; TB: tuberculosis; WRD: WHO‐recommended rapid diagnostic, which includes Xpert Ultra and Xpert MTB/RIF." data-id="CD012768-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The clinical pathway describes how patients might present and the point in the pathway at which they would be considered for testing with Xpert Ultra or Xpert MTB/RIF. This algorithm for the use of a molecular WHO‐recommended rapid diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/ RIF, comes from the WHO operational handbook on tuberculosis (<a href="./references#CD012768-bbs2-0366" title="World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-operational-handbook-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection (accessed 6 August 2020).">WHO Operational Handbook Diagnosis (Module 3) 2020</a>). Copyright © [2020] [World Health Organization]: reproduced with permission. </p> <p>Abbreviations: DST: drug susceptibility testing; INH: isoniazid; MDR‐TB: multidrug‐resistant TB; MTB: Mycobacterium tuberculosis; PLHIV: people living with HIV; RIF: rifampicin; TB: tuberculosis; WRD: WHO‐recommended rapid diagnostic, which includes Xpert Ultra and Xpert MTB/RIF. </p> </div> </div> </div> <p>Before a specimen is tested, patients with presumptive extrapulmonary tuberculosis would have undergone a health examination (history and physical examination) and possibly a chest radiograph. The presentation of extrapulmonary tuberculosis varies depending on the body site affected, and it may imitate other diseases, such as cancer and bacterial and fungal infections. Signs and symptoms of extrapulmonary tuberculosis are often non‐specific and may include fever, night sweats, fatigue, loss of appetite, and weight loss (as seen in pulmonary tuberculosis) or specific complaints related to the involved site (e.g. headache for tuberculous meningitis, back pain for tuberculosis of the spine). The clinical presentation of extrapulmonary disease may be acute but is more often subacute (falling between acute and chronic) or chronic, meaning that patients may have symptoms for days to months before they seek care. </p> <p>We have described in <a href="#CD012768-tbl-0005">Table 1</a> signs and symptoms of the forms of extrapulmonary tuberculosis included in this review. The clinician should take a careful history, noting history of tuberculosis exposure, prior tuberculosis disease, and medical conditions that increase the risk for tuberculosis disease (e.g. HIV, diabetes mellitus, low body weight). In comparison with HIV‐negative people, HIV‐positive people have higher rates of extrapulmonary tuberculosis or mycobacteraemia (tuberculosis bloodstream infection). HIV‐positive patients with signs or symptoms of extrapulmonary tuberculosis should have specimens taken from the suspected site(s) of involvement to increase the likelihood of tuberculosis diagnosis. Tuberculous meningitis is the most severe form of tuberculosis. In tuberculous meningitis, diagnosis is often delayed, with appalling consequences for patients. For all forms of extrapulmonary tuberculosis, patients may be evaluated in primary‐ or secondary‐care settings. However, if more complex or invasive tests are needed, patients may be referred to a tertiary medical centre (<a href="./references#CD012768-bbs2-0298" title="IsemanMD . Extrapulmonary tuberculosis in adults. In: IsemanMD , editors(s). A Clinician’s Guide to Tuberculosis. Philadelphia: Lippincott Williams and Wilkins, 2000:145–97.">Iseman 2000</a>; <a href="./references#CD012768-bbs2-0325" title="ReuterH , WoodR , SchaafHS , DonaldPR . Overview of extrapulmonary tuberculosis in adults and children. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:377-90.">Reuter 2009</a>; <a href="./references#CD012768-bbs2-0338" title="SharmaSK , MohanA . Extrapulmonary tuberculosis. Indian Journal of Medical Research2004;120(4):316-53.">Sharma 2004</a>). </p> <p>The downstream consequences of testing include the following.</p> <p> <ul id="CD012768-list-0001"> <li> <p>True‐positive (TP): patients would benefit from rapid diagnosis and appropriate treatment.</p> </li> <li> <p>True‐negative (TN): patients would be spared unnecessary treatment and would benefit from reassurance and pursuit of an alternative diagnosis. </p> </li> <li> <p>False‐positive (FP): patients would likely experience anxiety and morbidity caused by additional testing, unnecessary treatment, and possible adverse effects; possible stigma associated with a tuberculosis or MDR‐TB diagnosis; and the chance that a false‐positive may halt further diagnostic evaluation. </p> </li> <li> <p>False‐negative (FN): increased risk of morbidity and mortality and delayed treatment initiation for patients. </p> </li> </ul> </p> <p><b>Role of index test(s)</b> </p> <p>We were interested in the following roles for testing.</p> <p><b>I. Xpert Ultra and Xpert MTB/RIF for detection of extrapulmonary tuberculosis</b> </p> <p>Index test used as an initial test replacing usual practice (including conventional microscopy, culture or histopathology) for the diagnosis of extrapulmonary tuberculosis in adults with presumptive extrapulmonary tuberculosis (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). An initial test does not mean that other tests will follow. </p> <p><b>II. Xpert Ultra and Xpert MTB/RIF for detection of rifampicin resistance</b> </p> <p>Index test used as an initial test replacing culture and phenotypic DST for the diagnosis of rifampicin‐resistant tuberculosis in adults with presumptive extrapulmonary tuberculosis (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). </p> <p>As mentioned, in high MDR‐TB settings the presence of rifampicin resistance alone may serve as a proxy for MDR‐TB. Xpert Ultra and Xpert MTB/RIF do not eliminate the need for subsequent culture and phenotypic DST, which are required to monitor treatment progress and to detect resistance to drugs other than rifampicin. </p> <section id="CD012768-sec-0015"> <h4 class="title">Alternative test(s)</h4> <p>For a comprehensive review of new tests not yet in widespread use, we refer the reader to <a href="./references#CD012768-bbs2-0265" title="BraniganD . Pipeline report 2019 tuberculosis diagnostics. www.treatmentactiongroup.org/wp-content/uploads/2019/12/pipeline_tb_diagnotics_2019_db_final.pdf (accessed 4 April 2020).">Branigan 2019</a>; <a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>; <a href="./references#CD012768-bbs2-0349" title="BoyleD . Tuberculosis Diagnostics Technology and Market Landscape. 5th edition. Vernier: World Health Organization Unitaid Secretariat, 2017.">Unitaid 2017</a>. </p> <p>Smear microscopy (light microscopy (Ziehl‐Neelsen), fluorescence microscopy, or light‐emitting diode (LED) fluorescence microscopy) is the examination of smears for acid‐fast bacilli (tuberculosis bacteria) under a microscope. Around 5000 to 10,000 organisms per mL must be present in the specimen for tuberculosis bacteria to be visible by microscopy (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). For extrapulmonary tuberculosis, microscopy can be performed in fluid or tissue specimens from sites of disease involvement, for example, in cerebrospinal fluid (CSF) in presumptive tuberculous meningitis or in lymph node tissue in presumptive lymph node tuberculosis. For most extrapulmonary sites, because there are usually few organisms, the sensitivity of smear microscopy is generally low. Ranges from studies, some with selected cases, are quoted here: 0% to 10% in pleural fluid; 14% to 39% in pleural tissue; 2% to 30% in CSF; &lt; 5% in peritoneal fluid; and 0% to 42% in pericardial fluid. In contrast, the specificity of smear microscopy tends to be quite high, as can be seen in pulmonary tuberculosis (≥ 90%) (<a href="./references#CD012768-bbs2-0300" title="KilpatrickME , GirgisNI , YassinMW , Abu el EllaAA . Tuberculous meningitis-clinical and laboratory review of 100 patients. Journal of Hygiene (London)1986;96(2):231–8.">Kilpatrick 1986</a>; <a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). </p> <p>Mycobacterial culture is a method used to grow bacteria on nutrient‐rich media. In comparison with microscopy, a positive culture requires only around 100 organisms per mL and therefore can detect lower numbers of tuberculosis bacteria (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). Additionally, culture is essential for species identification and DST. However, culture takes several weeks and requires a highly‐equipped laboratory. Culture has reduced sensitivity in paucibacillary disease (reference standards have included culture from a different specimen, such as sputum, smear microscopy, NAATs, presence of granulomatous inflammation, clinical criteria, imaging studies, and response to anti‐tuberculosis therapy, done alone or in various combinations): CSF 45% to 70%; pleural fluid 23% to 58%; urine 80% to 90%; peritoneal tuberculosis 45% to 69%; pericardial tuberculosis 50% to 65% (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>); lymph node tuberculosis (excisional biopsy) 18% to 93%; and lymph node tuberculosis (fine‐needle aspirate) 10% to 67% (<a href="./references#CD012768-bbs2-0284" title="FontanillaJM , BarnesA , Von ReynCF . Current diagnosis and management of peripheral tuberculous lymphadenitis. Clinical Infectious Diseases2011;53(6):555-62.">Fontanilla 2011</a>). </p> <p>Histological examination involves examination of tissue specimens under a microscope. Diagnosis of extrapulmonary tuberculosis by histological examination is based on finding acid‐fast bacilli and granulomatous inflammation, frequently with caseous (cheese‐like) necrosis (necrotizing granulomas). The sensitivity of histology has been reported to vary for different forms of extrapulmonary tuberculosis (reference standards have included smear microscopy, culture, NAATs, clinical criteria, and imaging studies, done alone or in various combinations): 59% to 88% for lymph node tuberculosis (excisional biopsy) (<a href="./references#CD012768-bbs2-0284" title="FontanillaJM , BarnesA , Von ReynCF . Current diagnosis and management of peripheral tuberculous lymphadenitis. Clinical Infectious Diseases2011;53(6):555-62.">Fontanilla 2011</a>); 69% to 97% in pleural tissue (closed pleural biopsy); 86% to 94% in urological tissue; 60% to 70% in endometrial curettage; 79% to 100% in peritoneal biopsy; and 73% to 100% in pericardial tissue (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). Sensitivity has also been observed to vary for different diagnostic techniques. <a href="./references#CD012768-bbs2-0278" title="DiaconAH , Van de WalBW , WyserC , SmedemaJP , BezuidenhoutJ , BolligerCT , et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. European Respiratory Journal2003;22(4):589-91.">Diacon 2003</a> found thoracoscopy to be more sensitive (sensitivity of 100%) than closed‐needle biopsy (sensitivity of 66%) for establishing a diagnosis of pleural tuberculosis (reference standards have included microscopy smear, culture, or presence of granulomatous inflammation with caseous necrosis). Specificity has been observed to be low because of the presence of granulomas in other diseases, both infectious and non‐infectious (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>), although the presence of ‘necrotizing' granulomatous inflammation increases specificity (<a href="./references#CD012768-bbs2-0370" title="WoodardBH , RosenbergSI , FarnhamR , AdamsDO . Incidence and nature of primary granulomatous inflammation in surgically removed material. American Journal of Surgical Pathology1982;6(2):119-29.">Woodard 1982</a>). Histological examination carries the additional concern that invasive procedures that are complex and costly may be required to obtain the necessary specimens (<a href="./references#CD012768-bbs2-0287" title="GoldenMP , VikramHR . Extrapulmonary tuberculosis: an overview. American Family Physician2005;72(9):1761-8.">Golden 2005</a>). </p> <p>Cytopathological examination of fluid specimens (such as pleural and peritoneal fluid) may be performed, first to exclude cancer, and then to obtain material for additional analyses, such as measurement of levels of adenosine deaminase and free interferon‐gamma (IFN‐γ) and cell counts (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>; <a href="./references#CD012768-bbs2-0373" title="WrightCA , BezuidenhoutJ . Histopathology and cytopathology. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:205-15.">Wright 2009a</a>). Advantages of these tests include that they are rapid and simple and can be performed in most clinical laboratories (<a href="./references#CD012768-bbs2-0279" title="DinnesJ , DeeksJ , KunstH , GibsonA , CumminsE , WaughN , et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technology Assessment2007;11(3):1-196.">Dinnes 2007</a>). In pleural, pericardial, and peritoneal fluid, a predominance of lymphocytes, especially in the absence of mesothelial cells, is highly suggestive of tuberculosis (<a href="./references#CD012768-bbs2-0373" title="WrightCA , BezuidenhoutJ . Histopathology and cytopathology. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:205-15.">Wright 2009a</a>). However, in HIV‐positive people, this pattern may not be observed (<a href="./references#CD012768-bbs2-0373" title="WrightCA , BezuidenhoutJ . Histopathology and cytopathology. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:205-15.">Wright 2009a</a>). Adenosine deaminase, an enzyme involved in purine metabolism, has been extensively studied for its potential role in the diagnosis of pleural tuberculosis, peritoneal tuberculosis, and tuberculous meningitis (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). IFN‐γ is released after it is sensitized by T cells in response to specific <i>M tuberculosis</i> antigens. A recent review of the evidence using GRADE provides the following recommendations. </p> <p> <ul id="CD012768-list-0002"> <li> <p>"...cell counts and chemistries be performed on amenable fluid specimens (including include pleural, cerebrospinal, ascitic, and joint fluid) collected from sites of suspected extrapulmonary TB (conditional recommendation, very low‐quality evidence). </p> </li> <li> <p>...adenosine deaminase levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB, TB meningitis, peritoneal TB, or pericardial TB (conditional recommendation, low‐quality evidence). </p> </li> <li> <p>...free IFN‐γ levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB or peritoneal TB (conditional recommendation, low‐quality evidence)" (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). </p> </li> </ul> </p> <p>NAAT is a molecular technique that can detect small quantities of genetic material (DNA or RNA) from micro‐organisms, such as <i>M tuberculosis.</i> The key advantage of NAATs is that they are rapid diagnostic tests, potentially providing results in a few hours. This is a particularly important feature of the test in life‐threatening forms of extrapulmonary tuberculosis, such as tuberculous meningitis. A variety of molecular amplification methods are available, of which PCR is the most common. NAATs are available as commercial kits and in‐house tests (based on a protocol developed in a laboratory) and are used routinely in high‐income countries for tuberculosis detection. In‐house PCR is widely used in low‐income countries because these tests are less expensive than commercial kits. An older editorial summarizing three systematic reviews (140 studies) of commercial and in‐house NAATs (other than Xpert MTB/RIF) for different forms of extrapulmonary tuberculosis found relatively low sensitivity and underscored concerns about the cost and feasibility of this technology in resource‐limited areas (<a href="./references#CD012768-bbs2-0316" title="PaiM , LingDI . Rapid diagnosis of extrapulmonary tuberculosis using nucleic acid amplification tests: what is the evidence?Future Microbiology2008;3(1):1-4.">Pai 2008</a>). Similarly, another systematic review found that NAATs have relatively low sensitivity for extrapulmonary tuberculosis but high specificity (e.g. for tuberculous meningitis, for pleural TB), indicating that these tests cannot be used reliably to rule out tuberculosis (<a href="./references#CD012768-bbs2-0279" title="DinnesJ , DeeksJ , KunstH , GibsonA , CumminsE , WaughN , et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technology Assessment2007;11(3):1-196.">Dinnes 2007</a>). A recent evidence synthesis reported sensitivities of 72% to 88% in lymph node tissue, 28% to 81% in pleural fluid, 90% in pleural tissue, and 31% to 56% in CSF. Specificity ranged from 90% to 100% (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). </p> <p>Alternative molecular methods for DST include the commercial line‐probe assays, GenoType MTBDR<i>plus</i> assay (MTBDR<i>plus,</i> Hain LifeScience, Nehren, Germany), and the Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan), which detect the presence of mutations associated with drug resistance to isoniazid and rifampicin (<a href="./references#CD012768-bbs2-0313" title="NathavitharanaRR , CudahyPG , SchumacherSG , SteingartKR , PaiM , DenkingerCM . Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2017;49(1):pii: 1601075.">Nathavitharana 2017</a>). MTBDR<i>plus</i> is the most widely studied line‐probe assay. Advantages of line‐probe assays are that they can provide a result for detection of tuberculosis and drug resistance in one to two days. Drawbacks are that line‐probe assays are expensive and need to be used in intermediate and central laboratories (<a href="./references#CD012768-bbs2-0349" title="BoyleD . Tuberculosis Diagnostics Technology and Market Landscape. 5th edition. Vernier: World Health Organization Unitaid Secretariat, 2017.">Unitaid 2017</a>). The WHO recommends that for persons with a sputum smear‐positive specimen or a cultured tuberculosis isolate, commercial molecular line‐probe assays may be used as the initial test instead of phenotypic culture‐based DST to detect resistance to rifampicin and isoniazid (conditional recommendation, moderate certainty in the evidence for the test’s accuracy) (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). Other molecular assays for detection of tuberculosis and resistance to rifampicin and isoniazid along with instruments are in development (<a href="./references#CD012768-bbs2-0352" title="WalzlG , McNerneyR , Du PlessisN , BatesM , McHughTD , ChegouNN , et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infectious Diseases2018;18(7):e199-e210.">Walzl 2018</a>). </p> <p>Alere Determine™ TB LAM Ag (AlereLAM) Alere Inc, (Waltham, USA) is a commercially‐available point‐of‐care test for tuberculosis disease (pulmonary and extrapulmonary tuberculosis). The test detects lipoarabinomannan (LAM), a component of the bacterial cell wall, which is present in the urine of some people with tuberculosis. AlereLAM is performed by placing urine on one end of a test strip, with results appearing as a band on the strip if tuberculosis is present. The test is simple, requires no special equipment, and shows results in 25 minutes. This urine test has potential advantages over sputum‐based testing due to ease of sample collection. The accuracy of urinary LAM detection is improved among people living with HIV with advanced immunosuppression (<a href="./references#CD012768-bbs2-0261" title="BjerrumS , SchillerI , DendukuriN , KohliM , NathavitharanaRR , ZwerlingAA , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD011420. [DOI: 10.1002/14651858.CD011420.pub3]">Bjerrum 2019</a>). In two randomized trials, the use of Alere LAM in HIV‐positive adult inpatients was shown to reduce mortality (<a href="./references#CD012768-bbs2-0292" title="Gupta-WrightA , CorbettEL , Van OosterhoutJJ , WilsonD , GrintD , Alufandika-MoyoM , et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Lancet2018;392(10144):292-301. [PMID: 30032978]">Gupta‐Wright 2018</a>; <a href="./references#CD012768-bbs2-0321" title="PeterJG , ZijenahLS , ChandaD , ClowesP , LesoskyM , GinaP , et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet2016;387(10024):1187-97.">Peter 2016</a>). Based on evidence from the randomized trials and a Cochrane Review (<a href="./references#CD012768-bbs2-0261" title="BjerrumS , SchillerI , DendukuriN , KohliM , NathavitharanaRR , ZwerlingAA , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD011420. [DOI: 10.1002/14651858.CD011420.pub3]">Bjerrum 2019</a>), the WHO currently recommends that AlereLAM should be used to assist in the diagnosis of active tuberculosis in HIV‐positive adults, adolescents, and children (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). The key change from the WHO 2015 guidelines is broadening the indication for use of LF‐LAM among HIV‐positive inpatients with signs and symptoms of active tuberculosis (pulmonary and extrapulmonary); the test is now recommended for all such patients, irrespective of their CD4 count. The full recommendations, which differ for inpatients and outpatients, are described here (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). </p> <p>Fujifilm SILVAMP TB LAM (FuijiLAM, co‐developed by Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland and Fujifilm, Tokyo, Japan) is a new, urine‐based, point‐of‐care test for tuberculosis diagnosis in people living with HIV. In an individual participant data meta‐analysis that included five cohorts of people living with HIV, FujiLAM was found to have superior sensitivity, 70.7% (95% CI 59.0% to 80.8%), compared to AlereLAM sensitivity of 42.3% (31.7% to 51.8%), against a microbiological reference standard; FujiLAM had lower specificity, 90.9% (87.2 to 93.7), compared to AlereLAM specificity of 95.3% (92.2 to 97.7) (<a href="./references#CD012768-bbs2-0266" title="BrogerT , NicolMP , SzékelyR , BjerrumS , SossenB , SchutzC , et al. Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: a meta-analysis of individual in- and outpatient data. PLOS Medicine2020;17(5):e1003113.">Broger 2020</a>). At the time of writing, additional prospective clinical trials of FuijiLAM are ongoing to generate data for an updated WHO policy review. </p> </section> </section> <section id="CD012768-sec-0016"> <h3 class="title" id="CD012768-sec-0016">Rationale</h3> <p>Xpert Ultra and Xpert MTB/RIF are rapid tests that may provide benefits for patients (earlier diagnosis and the opportunity to begin earlier, appropriate treatment), especially in high tuberculosis‐burden countries. </p> <p>Since 2010, the WHO has recommended the use of Xpert MTB/RIF as the preferred initial diagnostic test for people thought to have MDR‐TB or HIV‐associated tuberculosis (strong recommendation, moderate‐certainty evidence) (<a href="./references#CD012768-bbs2-0367" title="World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4. www.who.int/tb/publications/tb-amplificationtechnology-statement/en/ 2011 (accessed 2 July 2020).">WHO Xpert MTB/RIF Policy 2011</a>). In 2013, the WHO expanded the recommendations, stating that Xpert MTB/RIF may be used rather than conventional microscopy and culture as the initial diagnostic test in all adults suspected of having tuberculosis (conditional recommendation acknowledging resource implications, high‐quality evidence) (<a href="./references#CD012768-bbs2-0368" title="World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.14. apps.who.int/iris/handle/10665/112472 2013 (accessed 2 July 2020).">WHO Xpert MTB/RIF Policy Update 2013</a>). The 2013 recommendations extended to the diagnosis of several forms of extrapulmonary tuberculosis, including tuberculous meningitis and lymph nodes and other tissue. In addition, the WHO recommended that following an Xpert MTB/RIF test that demonstrates rifampicin resistance, subsequent DST (e.g. using a line‐probe assay to second‐line drugs) remains essential to detect resistance to drugs other than rifampicin (<a href="./references#CD012768-bbs2-0368" title="World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.14. apps.who.int/iris/handle/10665/112472 2013 (accessed 2 July 2020).">WHO Xpert MTB/RIF Policy Update 2013</a>). In 2017, based on a non‐inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF (<a href="./references#CD012768-bbs2-0281" title="DormanSE , SchumacherSG , AllandD , NabetaP , ArmstrongDT , KingB , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases2018;18(1):76-84.">Dorman 2018</a>), the WHO stated that recommendations on the use of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial diagnostic test for all adults and children with signs and symptoms of tuberculosis (<a href="./references#CD012768-bbs2-0369" title="World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. WHO/HTM/TB/2017.04. www.who.int/tb/publications/2017/XpertUltra/en/ 2017 (accessed 2 July 2020).">WHO Xpert Ultra 2017</a>). </p> <p>In December 2019, the WHO convened a Guideline Development Group to update the recommendations on the use of molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary tuberculosis and rifampicin resistance. To extend the work of our previous Cochane Review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>), we performed this review update to inform the WHO policy (<a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). </p> <p>The <a href="#CD012768-sec-0009">Background</a> and <a href="#CD012768-sec-0019">Methods</a> sections of this review include some text that overlaps with some of our other reviews for Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosing tuberculosis (<a href="./references#CD012768-bbs2-0297" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593]">Horne 2019</a>; <a href="./references#CD012768-bbs2-0299" title="KayAW , González FernándezL , TakwoingiY , EisenhutM , VuRD , SteingartKR , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database of Systematic Reviews2020, Issue 8. Art. No: CD013359. [DOI: 10.1002/14651858.CD013359] [PMID: 32853411]">Kay 2020</a>; <a href="./references#CD012768-bbs2-0337" title="ShapiroAE , RossJM , SchillerI , KohliM , DendukuriN , SteingartKR , et al. Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013694. [DOI: 10.1002/14651858.CD013694]">Shapiro 2020</a>; <a href="./references#CD012768-bbs2-0351" title="VonasekB , NessT , TakwoingiY , KayAW , WykSS , OuelletteL , et al. Screening tests for active pulmonary tuberculosis in children. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013693. [DOI: 10.1002/14651858.CD013693]">Vonasek 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012768-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012768-sec-0017"></div> <p>To estimate the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for a) extrapulmonary tuberculosis by site of disease and b) rifampicin resistance, in adults with presumptive extrapulmonary tuberculosis. Presumptive tuberculosis refers to a patient who presents with symptoms or signs suggestive of tuberculosis. </p> <section id="CD012768-sec-0018"> <h3 class="title" id="CD012768-sec-0018">Secondary objectives</h3> <p> <ul id="CD012768-list-0003"> <li> <p>To compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for a) extrapulmonary tuberculosis by site of disease, and b) rifampicin resistance. </p> </li> <li> <p>To investigate the effects of potential sources of heterogeneity on test accuracy across the included studies. </p> </li> </ul> </p> <p>For potential sources of heterogeneity, for extrapulmonary tuberculosis, we included smear status, HIV status, and prevalence of extrapulmonary tuberculosis. For cerebrospinal fluid (CSF), we considered the presence of a concentration step and specimen volume. </p> <p>For rifampicin resistance, we planned to assess the impact of the prevalence of rifampicin resistance on accuracy estimates, but we had insufficient data for this analysis. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012768-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012768-sec-0019"></div> <section id="CD012768-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012768-sec-0021"> <h4 class="title">Types of studies</h4> <p>We included cross‐sectional and cohort studies. In addition, we had planned to include randomized controlled trials that evaluated the use of the index(s) test on patient health outcomes, but that also reported sensitivity and specificity. Although the study design was a randomized trial for the purpose of determining the impact of the test on participant outcomes, the study design was a cross‐sectional study for the purpose of determining the diagnostic accuracy of the index tests in this review. However, we did not identify any randomized controlled trials. We used abstracts to identify published studies and included these when they met the inclusion criteria. We only included studies that reported data comparing the index test(s) to an acceptable reference standard from which we could extract true‐positive (TP), true‐negative (TN), false‐positive (FP), and false‐negative (FN) values. We excluded case‐control studies and case reports. </p> </section> <section id="CD012768-sec-0022"> <h4 class="title">Participants</h4> <p>We included studies where at least 85% of the participants enrolled were adults aged 15 years or older with presumptive extrapulmonary tuberculosis from all settings and countries. Restricting the age group to adults differs from the original review, where we also included children (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). We did this because children are now included in a separate Cochrane Review (<a href="./references#CD012768-bbs2-0299" title="KayAW , González FernándezL , TakwoingiY , EisenhutM , VuRD , SteingartKR , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database of Systematic Reviews2020, Issue 8. Art. No: CD013359. [DOI: 10.1002/14651858.CD013359] [PMID: 32853411]">Kay 2020</a>). We excluded studies where we could not disaggregate data on adults from those in children and studies where we could not tell the age of the participants enrolled. </p> <p>We included non‐respiratory specimens (such as CSF, pleural fluid, lymph node aspirate or tissue). We excluded sputum and other respiratory specimens, such as fluid obtained from bronchial alveolar lavage and tracheal aspiration. As we anticipated finding many studies, we set a bar to exclude smaller studies to reduce unnecessary work. We therefore required studies to provide data for at least five specimens for a given form of extrapulmonary tuberculosis included in the review. We excluded studies evaluating the use of Xpert Ultra and Xpert MTB/RIF to diagnose relapse of previously‐treated extrapulmonary tuberculosis, so as to avoid the selection bias that may arise by limiting to a group that is already at elevated risk of extrapulmonary tuberculosis. We attempted to identify studies that included participants who were not taking anti‐tuberculosis drugs or had taken anti‐tuberculosis drugs for less than seven days. </p> </section> <section id="CD012768-sec-0023"> <h4 class="title">Index tests</h4> <p>The index tests were Xpert Ultra and Xpert MTB/RIF.</p> <p>Index test results are automatically generated (i.e. there is a single threshold), and the user is provided with a printable test result as follows. </p> <p><i>Xpert Ultra</i> </p> <p> <ul id="CD012768-list-0004"> <li> <p>MTB (M tuberculosis) DETECTED HIGH; RIF (rifampicin) Resistance DETECTED</p> </li> <li> <p>MTB DETECTED MEDIUM; RIF Resistance DETECTED</p> </li> <li> <p>MTB DETECTED LOW; RIF Resistance DETECTED</p> </li> <li> <p>MTB DETECTED VERY LOW; RIF Resistance DETECTED</p> </li> <li> <p>MTB DETECTED HIGH; RIF Resistance NOT DETECTED</p> </li> <li> <p>MTB DETECTED MEDIUM; RIF Resistance NOT DETECTED</p> </li> <li> <p>MTB DETECTED LOW; RIF Resistance NOT DETECTED</p> </li> <li> <p>MTB DETECTED VERY LOW; RIF Resistance NOT DETECTED</p> </li> <li> <p>MTB DETECTED HIGH; RIF Resistance INDETERMINATE</p> </li> <li> <p>MTB DETECTED MEDIUM; RIF Resistance INDETERMINATE</p> </li> <li> <p>MTB DETECTED LOW; RIF Resistance INDETERMINATE</p> </li> <li> <p>MTB DETECTED VERY LOW; RIF Resistance INDETERMINATE</p> </li> <li> <p>MTB Trace DETECTED; RIF Resistance INDETERMINATE</p> </li> <li> <p>INVALID (the presence or absence of MTB cannot be determined)</p> </li> <li> <p>ERROR (the presence or absence of MTB cannot be determined)</p> </li> <li> <p>NO RESULT (the presence or absence of MTB cannot be determined)</p> </li> </ul> </p> <p>Xpert Ultra incorporates a semi‐quantitative classification for results: trace, very low, low, moderate, and high. ‘Trace' corresponds to the lowest bacterial burden for detection of <i>M tuberculosis</i> (<a href="./references#CD012768-bbs2-0270" title="ChakravortyS , SimmonsAM , RownekiM , ParmarH , CaoY , RyanJ , et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio2017;8(4):e00812-17. [DOI: 10.1128/mBio.00812-17]">Chakravorty 2017</a>). We considered a trace result to mean MTB (<i>M tuberculosis</i>) DETECTED. However, no rifampicin‐resistance result was available for participants with trace results because the trace sample is always reported as 'INDETERMINATE' for rifampin resistance (<a href="./references#CD012768-bbs2-0268" title="Cepheid. Brochure: Xpert® MTB/RIF Ultra. www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-RIF-Ultra (accessed 26 March 2020).">Cepheid 2018</a>). </p> <p><i>Xpert MTB/RIF</i> </p> <p> <ul id="CD012768-list-0005"> <li> <p>MTB (<i>M tuberculosis</i>) DETECTED; Rif (rifampicin) resistance DETECTED </p> </li> <li> <p>MTB DETECTED; Rif resistance NOT DETECTED</p> </li> <li> <p>MTB detected; Rif resistance INDETERMINATE</p> </li> <li> <p>MTB NOT DETECTED</p> </li> <li> <p>INVALID (the presence or absence of MTB cannot be determined)</p> </li> <li> <p>ERROR (the presence or absence of MTB cannot be determined)</p> </li> <li> <p>NO RESULT (the presence or absence of MTB cannot be determined)</p> </li> </ul> </p> </section> <section id="CD012768-sec-0024"> <h4 class="title">Target conditions</h4> <p>The target conditions were extrapulmonary tuberculosis and rifampicin resistance. We included eight common forms of extrapulmonary tuberculosis and considered subcategories of the target condition as separate diagnostic classifications (<a href="./references#CD012768-bbs2-0267" title="Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2018. www.cdc.gov/tb/statistics/reports/2018/table15.htm (accessed 29 June 2020).">CDC 2018</a>; <a href="./references#CD012768-bbs2-0327" title="SandgrenA , HolloV , Van der WerfMJ . Extrapulmonary tuberculosis in the European Union and European economic area, 2002 to 2011. Euro Surveillance2013;18(12):pii: 20431.">Sandgren 2013</a>; <a href="./references#CD012768-bbs2-0338" title="SharmaSK , MohanA . Extrapulmonary tuberculosis. Indian Journal of Medical Research2004;120(4):316-53.">Sharma 2004</a>). </p> <p> <ul id="CD012768-list-0006"> <li> <p>Tuberculous meningitis.</p> </li> <li> <p>Pleural tuberculosis.</p> </li> <li> <p>Lymph node tuberculosis.</p> </li> <li> <p>Genitourinary tuberculosis.</p> </li> <li> <p>Bone or joint tuberculosis.</p> </li> <li> <p>Peritoneal tuberculosis.</p> </li> <li> <p>Pericardial tuberculosis.</p> </li> <li> <p>Disseminated tuberculosis.</p> </li> </ul> </p> <p><a href="#CD012768-tbl-0005">Table 1</a> lists the forms of extrapulmonary tuberculosis and specimens used for diagnosis in the review. We excluded less common forms, such as cutaneous tuberculosis, ocular tuberculosis, female genital tuberculosis, and tuberculosis of the breast, ear, and paranasal sinuses (<a href="./references#CD012768-bbs2-0338" title="SharmaSK , MohanA . Extrapulmonary tuberculosis. Indian Journal of Medical Research2004;120(4):316-53.">Sharma 2004</a>). </p> </section> <section id="CD012768-sec-0025"> <h4 class="title">Reference standards</h4> <section id="CD012768-sec-0026"> <h5 class="title">Detection of extrapulmonary tuberculosis</h5> <p>We included two reference standards.</p> <p> <ul id="CD012768-list-0007"> <li> <p>Solid or liquid mycobacterial culture.</p> <ul id="CD012768-list-0008"> <li> <p>‘Tuberculosis' was defined as a positive <i>M tuberculosis</i> culture </p> </li> <li> <p>‘Not tuberculosis' was defined as a negative <i>M tuberculosis</i> culture </p> </li> </ul> </li> <li> <p>Composite reference standard.</p> <ul id="CD012768-list-0009"> <li> <p>'Tuberculosis' was defined as a positive <i>M tuberculosis</i> culture or positive composite reference test. </p> </li> <li> <p>‘Not tuberculosis' was defined as a negative <i>M tuberculosis</i> culture and a negative composite reference test. </p> </li> </ul> </li> </ul> </p> <p>The composite reference standard might be based on the results of microbiological tests, culture or NAAT other than Xpert Ultra and Xpert MTB/RIF; imaging studies; histology; and clinical characteristics, and include at least one component test that is positive, according to the definition of the primary study authors. </p> <p>For pleural tuberculosis, we defined the composite reference standard as the presence of granulomatous inflammation or a positive culture. We proposed this definition because we found evidence to support including histopathological examination in the definition. Around 60% of patients undergoing pleural biopsy will show granulomatous inflammation (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). In a prospective cohort study of participants with clinical and radiological findings consistent with pleural tuberculosis, <a href="./references#CD012768-bbs2-0275" title="CondeMB , LoivosAC , RezendeVM , SoaresSL , MelloFC , ReingoldAL , et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. American Journal of Respiratory and Critical Care Medicine2003;167(5):723-5.">Conde 2003</a> found that histological examination of tissue obtained from pleural biopsy had a higher diagnostic yield (78%; 66/84) than that of culture (62%; 52/84). </p> <p>Culture is considered the best reference standard for tuberculosis. However, culture may lead to misclassification of some cases of extrapulmonary tuberculosis as ‘not tuberculosis', owing to the paucibacillary nature of the disease. This means that culture may have low sensitivity for extrapulmonary tuberculosis overall and further that culture sensitivity may differ for different forms of extrapulmonary tuberculosis (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). This misclassification by culture may lead to biased estimates (overestimation or underestimation) of the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF. The extent of bias will depend on the frequency of errors by culture and the degree of correlation in errors by culture and the Xpert assays because culture and Xpert Ultra or Xpert MTB/RIF are likely to pick up cases with a higher bacterial load, and are likely to miss cases with a lower bacterial load. Ignoring this dependence could lead to an overestimation of the sensitivity of Xpert Ultra or Xpert MTB/RIF. </p> <p> <ul id="CD012768-list-0010"> <li> <p>Effect of low sensitivity of culture on Xpert sensitivity: the low sensitivity of culture means that index test FNs may be misclassified as TNs when culture is used as the reference standard. Therefore, when Xpert Ultra or Xpert MTB/RIF is evaluated against culture, the number of FNs (classified as negative by the index test and positive by the reference test) may be decreased and the sensitivity of the index test may be overestimated. </p> </li> <li> <p>Effect of low sensitivity of culture on Xpert specificity: the low sensitivity of culture means that index test TPs may be misclassified as FPs when culture is used as the reference standard. Therefore, when Xpert Ultra or Xpert MTB/RIF is evaluated against culture, the number of FPs (classified as positive by the index test and negative by the reference test) may be increased and specificity of the index test may be underestimated. </p> </li> </ul> </p> <p>In contrast to culture, a composite reference standard that includes culture, other tests, and clinical characteristics may correctly classify index test results as TPs (instead of as FPs with respect to culture), especially in people with paucibacillary disease in whom culture may be negative. However, because of the uncertainties that surround a clinical diagnosis of tuberculosis and, in some instances, the conditional dependence of the index tests and other tests in the composite reference standard (for example, for most of these tests, detection of tuberculosis depends on bacillary load), a reference standard that uses additional tests and clinical characteristics (in culture‐negative people) may incorrectly classify people without tuberculosis as having tuberculosis (<a href="./references#CD012768-bbs2-0311" title="NaaktgeborenCA , BertensLC , Van SmedenM , De GrootJA , MoonsKG , ReitsmaJB . Value of composite reference standards in diagnostic research. BMJ2013;347:f5605.">Naaktgeboren 2013</a>). An additional challenge with including a composite reference standard is that the definition of the composite reference standard may vary across studies, making it difficult to interpret the accuracy estimates. </p> <p>Thus both reference standards, culture and composite, are imperfect and may affect accuracy estimates. In an attempt to improve the estimation of diagnostic accuracy, we applied a latent class meta‐analysis model to the three most commonly studied forms of extrapulmonary tuberculosis. This approach provides the sensitivity and specificity of culture in addition to the accuracy of the index tests, thus adjusting for imperfect culture accuracy. </p> </section> <section id="CD012768-sec-0027"> <h5 class="title">Detection of rifampicin resistance</h5> <p>The reference standard was culture‐based DST using solid or liquid media or line‐probe assays, as recommended by the WHO (<a href="./references#CD012768-bbs2-0357" title="World Health Organization. Updated interim critical concentrations for first-line and second-line DST (as of May 2012). www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf 2012 (accessed 2 July 2020).">WHO 2012</a>; <a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). </p> </section> </section> </section> <section id="CD012768-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies, regardless of language or publication status (published, unpublished, in press, or ongoing). We monitored abstracts to see if these studies were published during the time we performed the review. We included only published studies in the review. </p> <section id="CD012768-sec-0029"> <h4 class="title">Electronic searches</h4> <p>For the original review, we searched the literature on 7 August 2017. For this review update, we searched the literature on 2 August 2019 and again on 28 January 2020, specifically for studies of Xpert Ultra (studies could include Xpert Ultra alone or both Xpert Ultra and Xpert MTB/RIF), using the search terms and strategy described in <a href="./appendices#CD012768-sec-0199">Appendix 1</a>. We searched the following databases: </p> <p> <ul id="CD012768-list-0011"> <li> <p>Cochrane Infectious Diseases Group Specialized Register;</p> </li> <li> <p>MEDLINE (OVID, from 1966);</p> </li> <li> <p>Embase (OVID, from 1974);</p> </li> <li> <p>Science Citation Index ‐ Expanded (from 1900);</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science (CPCI‐S, from 1990);</p> </li> <li> <p>BIOSIS Previews (from 1926), all three from the Web of Science;</p> </li> <li> <p>Scopus (Elsevier, from 1970);</p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) (BIREME, from 1982).</p> </li> </ul> </p> <p>We also searched <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry (ICTRP) Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>), and the International Standard Randomized Controlled Trials Number (ISRCTN) registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) for trials in progress, and ProQuest Dissertations &amp; Theses A&amp;I (<a href="https://www.proquest.com/pqdtglobal" target="_blank">www.proquest.com/pqdtglobal</a>, from 1990) for dissertations. </p> <p>To identify other systematic reviews and meta‐analyses, we performed an additional search on 28 May 2020 in MEDLINE (PubMed), Embase (OVID), and the Cochrane Library, applying filters for systematic reviews (<a href="http://www.sign.ac.uk/search-filters.html" target="_blank">www.sign.ac.uk/search-filters.html</a>) to search terms for Xpert and tuberculosis. </p> </section> <section id="CD012768-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of included articles and any relevant review articles identified through the above methods. We also contacted researchers at FIND and other experts in the field of tuberculosis diagnostics for information on ongoing and unpublished studies. </p> </section> </section> <section id="CD012768-sec-0031"> <h3 class="title" id="CD012768-sec-0031">Data collection and analysis</h3> <section id="CD012768-sec-0032"> <h4 class="title">Selection of studies</h4> <p>We used Covidence to manage the selection of studies (<a href="./references#CD012768-bbs2-0276" title="Veritas Health InnovationCovidence systematic review software. Available at www.covidence.org. Melbourne: Veritas Health Innovation, 2017.">Covidence 2017</a>). Two review authors independently scrutinized titles and abstracts identified by electronic literature searching to identify potentially eligible studies. We selected any citation identified by either review author as potentially eligible for full‐text review. The same review authors independently assessed full‐text papers for study eligibility using predefined inclusion and exclusion criteria, and resolved any discrepancies by discussion. We recorded all studies excluded after full‐text assessment and their reasons for exclusion in <a href="./references#CD012768-sec-0269" title="">Characteristics of excluded studies</a>. We illustrated the study selection process in a PRISMA diagram (<a href="./references#CD012768-bbs2-0310" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLOS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097]">Moher 2009</a>). </p> </section> <section id="CD012768-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Using a previously‐developed form (<a href="./appendices#CD012768-sec-0206">Appendix 2</a>), two review authors worked independently to extract data on the following characteristics. </p> <p> <ul id="CD012768-list-0012"> <li> <p>Author; publication year; country; setting (outpatient, inpatient, or both outpatient and inpatient); study design; manner of participant selection; number of participants enrolled; number of participants for whom results are available. </p> </li> <li> <p>Characteristics of participants: gender; age; HIV status; history of prior tuberculosis; receipt of anti‐tuberculosis treatment. </p> </li> <li> <p>Index test.</p> </li> <li> <p>Target condition and subcategories.</p> </li> <li> <p>Type of reference standard.</p> </li> <li> <p>Quality Assessment of Studies of Diagnostic Accuracy ‐ Revised (QUADAS‐2) items.</p> </li> <li> <p>Details of specimen: type (such as CSF, pleural fluid, or lymph node aspirate or tissue); condition (fresh or frozen); smear‐positive or smear‐negative. </p> </li> <li> <p>Specimen preparation; homogenization step (for tissue specimens); concentration step and specimen volume (for CSF); adherence to WHO standard operating procedures. </p> </li> <li> <p>Number of TP, FP, FN, TN (i.e. true‐positives, false‐positives, false‐negatives, and true‐negatives), and trace results; number of inconclusive results for detection of extrapulmonary tuberculosis; number of indeterminate results for detection of rifampicin resistance. </p> </li> <li> <p>Number of missing or unavailable test results.</p> </li> </ul> </p> <p>We classified country income status as either low‐ and middle‐income or high‐income, according to the World Bank List of Economies (<a href="./references#CD012768-bbs2-0372" title="World Bank. World bank list of economies. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups 2019 (accessed 2 July 2020).">World Bank 2020</a>). </p> <p>We extracted TP, FP, FN, and TN values for the following specimens: CSF, pleural fluid and tissue, lymph node aspirate and tissue (the latter specimen acquired by surgical biopsy), bone or joint aspirate and tissue, urine, peritoneal fluid and tissue, pericardial fluid and tissue, and blood. We extracted these values for each of the specimen types separately. For example, we used one 2 × 2 table for lymph node aspirate, and another 2 × 2 table for lymph node tissue. In situations in which a participant contributed more than one specimen but of different types, we extracted data for all specimens. When a study included data for both raw specimens and concentrated sediment involving the same participants, we preferentially extracted data for raw specimens, except in the case of CSF, for which we extracted data for concentrated sediment as recommended by the WHO (<a href="./references#CD012768-bbs2-0358" title="World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’ practical considerations. apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf 2014 (accessed 2 July 2020).">WHO 2014</a>). We extracted accuracy data according to the defined reference standards (see <a href="#CD012768-sec-0025">Reference standards</a>). We did not encounter any situations in which a subset of participants in a study received the reference standard but others did not. Hence, there was no need to make corrections for verification bias in the statistical analysis (<a href="./references#CD012768-bbs2-0260" title="BeggCB , GreenesRA . Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics1983;39(1):207-15.">Begg 1983</a>). </p> <p>In most studies, the number of specimens was the same as the number of participants. However, in some studies, the number of specimens exceeded the number of participants or study authors reported only the number of specimens. In the previous review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>), we added post hoc a sensitivity analysis limiting inclusion to studies that used one specimen per participant. In this review, we performed a similar sensitivity analysis for Xpert Ultra. </p> <p>We contacted authors of primary studies for missing data or clarifications. We entered all data into Microsoft Excel 2014. </p> </section> <section id="CD012768-sec-0034"> <h4 class="title">Assessment of methodological quality</h4> <p>We used the QUADAS‐2 tool, tailored to this review, to assess the quality of the included studies (<a href="./appendices#CD012768-sec-0231">Appendix 3</a>) (<a href="./references#CD012768-bbs2-0354" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529–36.">Whiting 2011</a>). QUADAS‐2 consists of four domains: patient selection, index test, reference standard, and flow and timing. We assessed all domains for risk of bias and the first three domains for concerns about applicability. Two review authors independently completed QUADAS‐2 and resolved disagreements through discussion. We present the results of this quality assessment in text, tables, and graphs. </p> <p>We followed Cochrane policy, which states that "authors of primary studies will not extract data from their own study or studies. Instead, another author will extract these data, and check the interpretation against the study report and any available study registration details or protocol". </p> </section> <section id="CD012768-sec-0035"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We performed descriptive analyses of the characteristics of included studies using Stata 15 (<a href="./references#CD012768-bbs2-0343" title="Stata Statistical Software: Release 15. StataCorp. College Station, TX: StataCorp LP, 2017.">Stata 2017</a>), and we present key study characteristics in the <a href="./references#CD012768-sec-0268" title="">Characteristics of included studies</a> table. We used data reported in the TP, FP, FN, and TN format to calculate sensitivity and specificity estimates and 95% confidence intervals (CIs) for individual studies. We present individual study results graphically by plotting the estimates of sensitivity and specificity (and their 95% CIs) in forest plots and receiver operating characteristic (ROC) space using Review Manager 5 (RevMan 5) (<a href="./references#CD012768-bbs2-0326" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>When data were sufficient, we performed meta‐analyses to estimate pooled sensitivity and specificity and corresponding 95% credible interval (CrI, defined below) using an adaptation of the bivariate random‐effects approach of <a href="./references#CD012768-bbs2-0324" title="ReitsmaJB , GlasAS , RutjesAW , ScholtenRJ , BossuytPM , ZwindermanAH . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology2005;58(10):982-90.">Reitsma 2005</a>, which uses the exact binomial likelihood for the observed proportions (<a href="./references#CD012768-bbs2-0274" title="ChuH , ColeSR . Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology2006;59(12):1331–2.">Chu 2006</a>). The bivariate random‐effects approach allowed us to calculate the pooled estimates of sensitivity and specificity while dealing with potential sources of variation caused by (1) imprecision of sensitivity and specificity estimates within individual studies; (2) correlation between sensitivity and specificity across studies; and (3) variation in sensitivity and specificity between studies. The model has a hierarchical structure, with the logit sensitivity in individual studies assumed to come from a common probability distribution the mean of which is the pooled logit sensitivity, and the standard deviation is the between‐study standard deviation, and likewise for the specificity. This structure allows for borrowing strength across studies. In the absence of sufficient studies, we simply present descriptive statistics. In addition, we determined predictive values at a pretest probability of 10%, a value suggested by the WHO. </p> <p>We performed separate analyses grouped by type of extrapulmonary specimen (e.g. CSF, pleural fluid, peritoneal fluid) rather than determine summary accuracy estimates for all forms of extrapulmonary tuberculosis combined, because we considered the former approach to be most clinically meaningful. In addition, we performed separate analyses by reference standard. </p> <section id="CD012768-sec-0036"> <h5 class="title">Comparison of Xpert Ultra and Xpert MTB/RIF</h5> <p>We performed comparative meta‐analyses by restricting the analyses to only those studies that made direct comparisons between Xpert Ultra and Xpert MTB/RIF within the same participants (<a href="./references#CD012768-bbs2-0345" title="TakwoingiY , LeeflangMM , DeeksJJ . Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Annals of Internal Medicine2013;158(7):544-54.">Takwoingi 2013</a>). We extracted the median and the 95% CrI for the difference in the pooled sensitivities and the difference in the pooled specificities, respectively, of Xpert Ultra versus Xpert MTB/RIF. We also calculated the probability that the difference exceeds zero in each case. </p> <p>For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection of rifampicin resistance, we include participants who (1) were culture‐positive; (2) had a valid culture‐based DST or line‐probe assay (LPA) result; (3) were Xpert MTB/RIF or Xpert Ultra tuberculosis‐positive; and (4) had a valid Xpert MTB/RIF or Xpert Ultra result for rifampicin resistance, detected or not detected (susceptible). </p> <p> <ul id="CD012768-list-0013"> <li> <p>Sensitivity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance detected/phenotypic DST or LPA rifampicin‐resistant. </p> </li> <li> <p>Specificity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance not detected/phenotypic DST or LPA rifampicin‐susceptible. </p> </li> </ul> </p> <p>For detection of rifampicin resistance, when a study included multiple types of specimens, we based our determination of Xpert Ultra and Xpert MTB/RIF and sensitivity and specificity on all available data in the study, including data for specimens that we did not include in the primary analyses for detection of extrapulmonary tuberculosis. For example, if a study provided data for several specimen types combined (e.g. all tissue specimens) and we could not disaggregate the data for a specific specimen type, we included all data (for all tissue specimens) in the analysis for rifampicin resistance detection. We did this because we did not expect the accuracy of Xpert Ultra or Xpert MTB/RIF for rifampicin resistance to vary by specimen type. We used the bivariate random‐effects model to estimate pooled sensitivity and specificity. </p> <p>We estimated all models using a Bayesian approach with low‐information prior distributions using OpenBUGS software (Version 3.2.3) (<a href="./references#CD012768-bbs2-0304" title="LunnD , SpiegelhalterD , ThomasA , BestN . The BUGS project: evolution, critique, and future directions. Statistics in Medicine2009;28(25):3049-67.">Lunn 2009</a>), along with R (<a href="./references#CD012768-bbs2-0323" title="R Foundation for Statistical ComputingR Core Team (2019). R: A language and environment for statistical computing. Version accessed after 12 June 2020. Vienna, Austria: R Foundation for Statistical Computing, 2019. Available at r-project.org/.">R Core Team 2019</a>). Under the Bayesian approach, all unknown parameters must be provided a prior distribution that defines the range of possible values of the parameter and the weight of each of those values, based on information external to the data. To allow observed data to dominate the final results, we chose to use low‐information prior distributions. We defined prior distributions on the log‐odds scale over the pooled sensitivity and specificity parameters, their corresponding between‐study standard deviations, and the correlation between the sensitivities and specificities across studies. For the pooled log odds of the sensitivity or the pooled log odds of the specificity, we used a normal prior distribution with mean 0 and a wide variance of 4 (or a precision of 0.25). This corresponds to a roughly uniform distribution over the pooled sensitivity and pooled specificity on the probability scale. For the between‐study precision, we used a gamma distribution with a shape parameter of 2 and a rate parameter of 0.5. This corresponds to a 95% prior CrI for the between‐study standard deviation in the log odds of sensitivity or the log odds of specificity ranging from roughly 0.29 to 1.44, corresponding to moderate to high values of between‐study heterogeneity. Covariance terms followed a uniform prior distribution whose upper and lower limits were determined by the sensitivity of the two tests. The OpenBUGS model used appears in <a href="./appendices#CD012768-sec-0252">Appendix 4</a>. It is known that meta‐analysis models can be sensitive to the choice of prior distributions over between‐study standard deviation parameters. We therefore carried out sensitivity analyses and considered alternative prior distributions that are less informative, allowing a wider range of possible values. To study the sensitivity of all results to the choice of prior distributions given above, we considered alternative prior distributions that were less informative, allowing a wider range of possible values. We increased the variance of the normal distributions over the pooled log odds of sensitivity or specificity to 100. We used a uniform prior distribution ranging from 0 to 3 over the between‐study standard deviation on the log odds scale (see programme in <a href="./appendices#CD012768-sec-0252">Appendix 4</a>). We noted no appreciable change in pooled accuracy parameters but found that the posterior CrIs and prediction intervals were slightly wider, as expected. </p> <p>We combined information from the prior distribution with the likelihood of the observed data, in accordance with Bayes’ theorem, using the OpenBUGS programme, which provides a sample from the posterior distribution of each unknown parameter. We were particularly interested in the pooled sensitivity and specificity of Xpert and between‐study variance in the sensitivity and specificity of Xpert on the log‐odds scale. Using a sample from the posterior distribution, we calculated various descriptive statistics of interest. We estimated the median pooled sensitivity and specificity and their 95% CrI. The median or the 50% quantile is the value below which 50% of the posterior sample lies. We report the median because the posterior distributions of some parameters may be skewed and the median would be considered a better point estimate of the unknown parameter than the mean in such cases. The 95% CrI is the Bayesian equivalent of the classical (frequentist) 95% confidence interval (CI) (we will indicate 95% CI for individual study estimates and 95% CrI for pooled study estimates as appropriate). The 95% CrI may be interpreted as an interval that has a 95% probability of capturing the true value of the unknown parameter, given observed data and prior information. We prepared summary receiver operating characteristic (SROC) curves for each meta‐analysis model, using the methods described in <a href="./references#CD012768-bbs2-0294" title="HarbordRM , DeeksJJ , EggerM , WhitingP , SterneJA . A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics2007;8(2):239-51.">Harbord 2007</a>. </p> <p>We also determined the predicted sensitivity and specificity of Xpert MTB RIF and Xpert Ultra and their 95% CrIs. Predicted values represent our best guess for sensitivity and specificity in a future study and will be close to the pooled estimates. However, their CrIs may be different. If there is no heterogeneity at all between studies, the CrI around the predicted estimate will be the same as the CrI around the pooled estimate. On the other hand, if considerable heterogeneity is observed between studies, the CrI around the predicted estimate will be much wider than the CI around the pooled estimate. </p> <p>In addition, we performed latent class analysis for three forms of extrapulmonary tuberculosis: tuberculous meningitis, pleural tuberculosis, and lymph node tuberculosis, using data from the two‐by‐two tables comparing the index test to culture as a reference standard. Latent class analysis is a statistical modelling technique that allows estimation of test accuracy in the absence of an adequate reference standard to define the presence or absence of disease (<a href="./references#CD012768-bbs2-0350" title="vanSmedenM , NaaktgeborenCA , ReitsmaJB , MoonsKG , De GrootJA . Latent class models in diagnostic studies when there is no reference standard - a systematic review. American Journal of Epidemiology2014;179(4):423-31.">Van Smeden 2014</a>). The latent class meta‐analysis model expands the traditional meta‐analysis model in two ways: (1) we added parameters for the sensitivity and specificity of culture; and (2) we added covariance terms to adjust for the dependence between the index test and culture among disease‐positive and disease‐negative participants in each study. We used hierarchical prior distributions over the logit sensitivity and logit specificity of culture. In other words, we assumed that the logit sensitivities in the individual studies come from a common probability distribution whose mean is the pooled mean logit sensitivity of culture and whose standard deviation is the between‐study standard deviation. Likewise for the specificities. We used the same low‐information prior distributions over the pooled logit mean and between‐study standard deviation parameters as we had for the corresponding parameters for the index test. We used uniform prior distributions for covariance terms over their ranges, which are determined by the sensitivities and the specificities of the two tests in each study (see <a href="./appendices#CD012768-sec-0252">Appendix 4</a> for the OpenBUGS model). We found that we did not need to augment observed data with prior information from other sources for most models. However, in a post hoc analysis Xpert MTB/RIF in lymph node aspirate in which we suspected a systematic bias in the performance of culture, we used informative prior distributions over the specificity of culture (ranging from 99% to 100%) and the specificity of Xpert MTB/RIF (ranging from 98% to 100%) (see <a href="./appendices#CD012768-sec-0252">Appendix 4</a>). We added the SROC plots of the latent class meta‐analyses to the SROC plots resulting from the models in which culture was treated as a perfect test, so they could be compared. </p> <p>Based on work evaluating Xpert MTB/RIF for childhood tuberculosis (<a href="./references#CD012768-bbs2-0329" title="SchumacherS , Van SmedenM , DendukuriN , JosephL , NicolM , PaiM , et al. Diagnostic test accuracy in childhood pulmonary tuberculosis: a Bayesian latent class analysis. American Journal of Epidemiology2016;184(9):690-700.">Schumacher 2016</a>), we anticipated that latent class meta‐analyses would lead to a decrease in the estimated pooled sensitivity of Xpert Ultra and Xpert MTB/RIF and an increase in the estimated pooled specificity of Xpert Ultra and Xpert MTB/RIF compared with the primary analyses. In other words, this method should help to correct the biases in Xpert Ultra and Xpert MTB/RIF sensitivity and specificity resulting from treating culture as a perfect reference standard, which we detailed earlier in the section on the reference standard. </p> </section> <section id="CD012768-sec-0037"> <h5 class="title">Approach to inconclusive index test results</h5> <p>The proportion of inconclusive (non‐determinate) rate for detection of pulmonary tuberculosis is the number of tests classified as ‘invalid', ‘error', or ‘no result' divided by the total number of index tests performed. The proportion of inconclusive (indeterminate) rate for detection of rifampicin resistance is the number of tests classified as ‘MTB DETECTED; Rif (rifampicin) resistance INDETERMINATE' divided by the total number of index test‐positive results. For Xpert Ultra, we determined the proportion of inconclusive index test results = number of inconclusive test results divided by the total number of tests. In our previous review, we used a Bayesian hierarchical model for a single proportion to estimate the pooled proportion of inconclusive MTB/RIF test results (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). We reported these findings again in this review update. As we found very few inconclusive results reported, we excluded these results from the quantitative analysis. </p> </section> </section> <section id="CD012768-sec-0038"> <h4 class="title">Investigations of heterogeneity</h4> <p>Initially, we investigated heterogeneity through visual examination of forest plots of sensitivities and specificities and through visual examination of the ROC space of the raw data. When data allowed, we evaluated potential sources of heterogeneity using subgroup analyses and bivariate meta‐regression. We included the following covariates. </p> <p> <ul id="CD012768-list-0014"> <li> <p>HIV status.</p> </li> <li> <p>For tuberculous meningitis, concentration step used for preparing specimen (yes or no). </p> </li> <li> <p>CSF specimen volume used for Xpert MTB/RIF or Xpert Ultra testing.</p> </li> </ul> </p> <p>We had planned to investigate smear status, history of tuberculosis, and whether WHO standard procedures for preparing tissue specimens were followed. However, we had insufficient data to do this. </p> <p>The impact of the prevalence of extrapulmonary tuberculosis on sensitivity and specificity is an important consideration. In a post hoc meta‐regression analysis, for Xpert MTB/RIF we explored this question for CSF, pleural fluid, and lymph node aspirate. For Xpert Ultra we explored this question for CSF. We did not conduct other analyses, owing to an insufficient number of studies. For detection of rifampicin resistance, owing to a small number of studies, we could not assess the impact of prevalence of rifampicin resistance on accuracy estimates. </p> <section id="CD012768-sec-0039"> <h5 class="title">Nontuberculous mycobacteria</h5> <p>Nontuberculous mycobacteria (NTM), such as <i>M avium</i> complex and <i>M intracellulare</i>, constitute a multi‐species group of human pathogens that are ubiquitous in water and soil. NTM can cause severe diseases that share clinical signs with tuberculosis but are treated differently. People living with HIV with severe immunosuppression are particularly vulnerable to infections caused by NTM (<a href="./references#CD012768-bbs2-0288" title="GopinathK , SinghS . Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger?PLOS Neglected Tropical Diseases2010;4(4):e615. [DOI: 10.1371/journal.pntd.0000615]">Gopinath 2010</a>). Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (<a href="./references#CD012768-bbs2-0262" title="BlakemoreR , StoryE , HelbD , KopJ , BanadaP , OwensMR , et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of Clinical Microbiology2010;48(7):2495-501.">Blakemore 2010</a>; <a href="./references#CD012768-bbs2-0296" title="HelbD , JonesM , StoryE , BoehmeC , WallaceE , HoK , et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology2010;48(1):229-37.">Helb 2010</a>). In our original review, we summarized data for NTM separately by determining the percentage of false‐positive Xpert MTB/RIF results in specimens that grew NTMs (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). In this updated review, we therefore summarize data for NTM only for Xpert Ultra. </p> </section> </section> <section id="CD012768-sec-0040"> <h4 class="title">Sensitivity analyses</h4> <p>For Xpert Ultra testing in CSF, we performed sensitivity analyses to explore whether the overall findings were robust to potentially influential decisions. We did this by limiting inclusion in the meta‐analysis to the following. </p> <p> <ul id="CD012768-list-0015"> <li> <p>Studies that used consecutive or random selection of participants.</p> </li> <li> <p>Studies in which the reference standard results were interpreted without knowledge of the index test results. </p> </li> <li> <p>Studies that included only one specimen per participant.</p> </li> </ul> </p> <p>For Xpert Ultra, in CSF, we also planned to perform a sensitivity analysis by limiting studies to those that included only untreated participants. However, we were unable to confirm that studies met this criterion. We planned similar sensitivity analyses for pleural fluid and lymph node aspirate, but these analyses were not carried out owing to an insufficient number of studies. For all other specimen types, we had an insufficient number of studies for sensitivity analyses. </p> <p>For Xpert MTB/RIF, in the original review we performed sensitivity analyses by type of extrapulmonary specimen and found that for most analyses, the sensitivity analyses made little difference to any of these findings (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). However, for Xpert MTB/RIF in CSF, in comparison with all studies, (sensitivity of 71.1% (60.9 to 80.4), and specificity of 98.0% (97.0 to 98.8)), studies that evaluated only one specimen per participant had lower pooled sensitivity at 63.5% (47.6 to 76.3) and lower pooled specificity at 96.1% (94.2 to 97.4). </p> </section> <section id="CD012768-sec-0041"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not perform a formal assessment of publication bias using methods such as funnel plots or regression tests because such techniques have not been helpful for diagnostic test accuracy studies (<a href="./references#CD012768-bbs2-0305" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, C Gatsonis (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available at: methods.cochrane.org/sdt/handbook-dta-reviews.">Macaskill 2010</a>). </p> </section> <section id="CD012768-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of evidence using the GRADE approach for diagnostic studies (<a href="./references#CD012768-bbs2-0258" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401–6.">Balshem 2011</a>; <a href="./references#CD012768-bbs2-0289" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 2 July 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>; <a href="./references#CD012768-bbs2-0331" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ2008;336(7653):1106-10.">Schünemann 2008</a>; <a href="./references#CD012768-bbs2-0332" title="SchünemannHJ , MustafaR , BrozekJ , SantessoN , Alonso-CoelloP , GuyattG , et al. GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology2016;76:89-98. [DOI: 10.1016/j.jclinepi.2016.01.032]">Schünemann 2016</a>). As recommended, we rated the certainty of evidence as either high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the certainty of evidence started as high when there high‐quality studies (cross‐sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels).Two review authors discussed judgments and applied GRADE in the following way (<a href="./references#CD012768-bbs2-0333" title="SchünemannHJ , MustafaR , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al. GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology2020;122:129-41. [DOI: 10.1016/j.jclinepi.2019.12.020]">Schünemann 2020a</a>; <a href="./references#CD012768-bbs2-0334" title="SchünemannHJ , MustafaR , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al. GRADE guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2020;122:142-52. [DOI: 10.1016/j.jclinepi.2019.12.021]">Schünemann 2020b</a>). </p> <p> <ul id="CD012768-list-0016"> <li> <p><i>Assessment of risk of bias</i>. We used QUADAS‐2 to assess risk of bias. </p> </li> <li> <p><i>Indirectness</i>. We assessed indirectness in relation to the population (including disease spectrum), setting, interventions, and outcomes (accuracy measures). We also used prevalence as a guide to whether there was indirectness in the population. </p> </li> <li> <p><i>Inconsistency</i>. GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We carried out prespecified analyses to investigate potential sources of heterogeneity and downgraded when we could not explain inconsistency in the accuracy estimates. </p> </li> <li> <p><i>Imprecision</i>. We considered a precise estimate to be one that would allow a clinically meaningful decision. We considered the width of the CrI (or CI) and asked, “Would we make a different decision if the lower or upper boundary of the CrI (or CI) represented the truth?” In addition, we worked out projected ranges for TP, FN, TN, and FP for a given prevalence of tuberculosis and made judgements on imprecision from these calculations. </p> </li> <li> <p><i>Publication bias</i>. We rated publication bias as undetected (not serious) for several reasons: the comprehensiveness of the literature search and extensive outreach to tuberculosis researchers to identify studies; the presence only of studies that produced precise estimates of high accuracy despite small sample size; and our knowledge about studies that were conducted but not published. </p> </li> </ul> </p> <p>For the 'Summary of findings' tables for CSF and pleural fluid, we provide evidence using culture as the reference standard, which is considered the best reference standard for tuberculosis (<a href="./references#CD012768-bbs2-0302" title="LewinsohnDM , LeonardMK , LoBuePA , CohnDL , DaleyCL , DesmondE , et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases2017;64(2):e1–33. [DOI: 10.1093/cid/ciw694]">Lewinsohn 2017</a>). For lymph node aspirate, we provide evidence using a composite reference because, based on findings from the original review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>), we believe a composite reference standard is preferable for estimating accuracy. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012768-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012768-sec-0043"></div> <section id="CD012768-sec-0044"> <h3 class="title" id="CD012768-sec-0044">Results of the search</h3> <p>We identified and screened a total of 735 records for inclusion in this review update. Of these, we assessed 142 full‐text papers against our inclusion criteria. We excluded 120 papers, mainly for the following reasons: study did not evaluate Xpert Ultra (n = 54); could not extract 2 x 2 values (n = 14); inappropriate reference standard (n = 13); could not extract data by specimen type (n = 12); did not include extrapulmonary specimen (n = 10): duplicate data (n = 4); case‐control study (n = 4); index test other than Xpert MTB/RIF or Xpert Ultra (n = 3); study included children (n = 2); screening study (n = 2); case report (n = 1); and fewer than five specimens for a given specimen type (n = 1). From our previous review, we included 47 studies.<br/>Thus, we included 69 unique studies that met the inclusion criteria in this review update. </p> <p>Sixty‐seven studies evaluated Xpert MTB/RIF (<a href="./references#CD012768-bbs2-0001" title="Ablanedo-TerrazasY , Alvarado-de la BarreraC , Hernandez-JuanR , Ruiz-CruzM , Reyes-TeranG . Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients. Laryngoscope2014;124(6):1382-5. ">Ablanedo‐Terrazas 2014</a>; <a href="./references#CD012768-bbs2-0002" title="AjbaniK , KaziM , NaikS , SomanR , ShettyA , RodriguesC . Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens. Tuberculosis2018;111:54-6. ">Ajbani 2018</a>; <a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0006" title="BahrNC , TugumeL , RajasinghamR , KiggunduR , WilliamsDA , MorawskiB , et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease2015;19(10):1209-15. ">Bahr 2015</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>; <a href="./references#CD012768-bbs2-0009" title="BiadglegneF , MuluA , Rodloff AC , SackU . Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis (Edinburgh, Scotland)2014;94(5):502-5. ">Biadglegne 2014</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0012" title="CheN , YangX , LiuZ , LiK , ChenX . Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. Journal of Clinical Microbiology2017;55(5):1526-32. ">Che 2017</a>; <a href="./references#CD012768-bbs2-0013" title="ChenC , YangCG , GaoX , LuZZ , TangFX , ChengJ , et al. Community-based active case finding for tuberculosis in rural western China: a cross-sectional study. International Journal of Tuberculosis and Lung Disease2017;21(11):1134-9. ">Chen 2019</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0018" title="DhasmanaDJ , RossC , BradleyCJ , ConnellDW , GeorgePM , SinganayagamA , et al. Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound. Annals of the American Thoracic Society2014;11(3):392-6. ">Dhasmana 2014</a>; <a href="./references#CD012768-bbs2-0019" title="DhooriaS , GuptaN , BalA , SehgalIS , AggarwalA , SethiS , et al. Role of Xpert MTB/RIF in differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy undergoing EBUS-TBNA: a study of 147 patients. Sarcoidosis Vasculitis and Diffuse Lung Disease2016;33:258-266. ">Dhooria 2016</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0022" title="El-DinMG , SobhE , AdawyZ , FarghalyN . Diagnostic utility of gene X-pert in the diagnosis of tuberculous pleural effusion. Infectious Diseases2019;51(3):227-9. ">El‐Din 2019</a>; <a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>; <a href="./references#CD012768-bbs2-0024" title="FriedrichSO , Von Groote-BidlingmaierF , DiaconAH . Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. Journal of Clinical Microbiology2011;49(12):4341-2. ">Friedrich 2011</a>; <a href="./references#CD012768-bbs2-0025" title="GharianiA , JaouadiT , SmaouiS , MehiriE , MarouaneC , KammounS , et al. Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia. International Journal of Mycobacteriology2015;4(4):270-5. ">Ghariani 2015</a>; <a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0028" title="HeemskerkAD , DonovanJ , ThuDD , MaraisS , ChaidirL , DungVT , et al. Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. Journal of Infection2018;77(6):509-15. ">Heemskerk 2018</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0033" title="LiangQ , PangY , YangY , LiH , GuoC , YangX , et al. An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. BMC Infectious Diseases2019;19(1):548. ">Liang 2019</a>; <a href="./references#CD012768-bbs2-0034" title="LigthelmLJ , NicolMP , HoekKG , JacobsonR , Van HeldenPD , MaraisBJ , et al. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. Journal of Clinical Microbiology2011;49(11):3967-70. ">Ligthelm 2011</a>; <a href="./references#CD012768-bbs2-0035" title="LusibaJK , NakiyingiL , KirengaBJ , KiraggaA , LukandeR , NserekoM , et al. Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting. PLOS One2014;9(7):e102702. [DOI: 10.1371/journal.pone.0102702]">Lusiba 2014</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0037" title="MeldauR , PeterJ , TheronG , CalligaroG , AllwoodB , SymonsG , et al. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-gamma for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulmonary Medicine2014;14:58. [DOI: 10.1186/1471-2466-14-58]">Meldau 2014</a>; <a href="./references#CD012768-bbs2-0038" title="MeldauR , RandallP , PooranA , LimberisJ , MakambwaE , DhansayM , et al. Same day tools, including Xpert Ultra and unstimulated IFN-gamma, for the rapid diagnosis of pleural tuberculosis - a prospective observational study. Journal of Clinical Microbiology2019;57(9):e00614-19. ">Meldau 2019</a>; <a href="./references#CD012768-bbs2-0039" title="MetcalfT , SoriaJ , MontanoSM , TiconaE , EvansCA , HuarotoL , et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLOS One2018;13(6):e0198695. ">Metcalf 2018</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0041" title="NhuNT , HeemskerkD , Thu doDA , ChauTT , MaiNT , NghiaHD , et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of Clinical Microbiology2014;52(1):226-33. ">Nhu 2014</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0043" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Medicine2014;12:101. [DOI: 10.1186/1741-7015-12-101]">Pandie 2014</a>; <a href="./references#CD012768-bbs2-0044" title="PatelVB , TheronG , LendersL , MatinyenaB , ConnollyC , SinghR , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLOS Medicine2013;10(10):e1001536. [DOI: 10.1371/journal.pmed.1001536]">Patel 2013</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0047" title="RakotoariveloR , AmbrosioniJ , RasolofoV , RaberahonaM , RakotosamimananaN , AndrianasoloR , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar. International Journal of Infectious Diseases2018;69:20-5. ">Rakotoarivelo 2018</a>; <a href="./references#CD012768-bbs2-0048" title="RufaiSB , SinghA , KumarP , SinghJ , SinghS . Performance of Xpert MTB/RIF Assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. Journal of Clinical Microbiology2015;53(11):3636-8. ">Rufai 2015</a>; <a href="./references#CD012768-bbs2-0049" title="RufaiSB , SinghS , SinghA , KumarP , SinghJ , VishalA . Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. Journal of Laboratory Physicians2017;9(1):47-52. ">Rufai 2017a</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>; <a href="./references#CD012768-bbs2-0053" title="ScottLE , BeylisN , NicolM , NkunaG , MolapoS , BerrieL , et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology2014;52(6):1818-23. ">Scott 2014</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0055" title="SharmaJB , KriplaniA , DharmendraS , ChaubeyJ , KumarS , SharmaSK . Role of Gene Xpert in diagnosis of female genital tuberculosis: a preliminary report. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;207:237-8. ">Sharma 2016</a>; <a href="./references#CD012768-bbs2-0056" title="SharmaK , SharmaM , ChaudharyL , ModiM , GoyalM , SharmaN , et al. Comparative evaluation of Xpert MTB/RIF assay with multiplex polymerase chain reaction for the diagnosis of tuberculous meningitis. Tuberculosis (Edinburgh, Scotland) 2018 Dec;113:38-42. ">Sharma 2018</a>; <a href="./references#CD012768-bbs2-0057" title="SiddiqiOK , BirbeckGL , GhebremichaelM , MubangaE , LoveS , BubackC , et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. Journal of Clinical Microbiology2019;57(8):pii: e00652-19. ">Siddiqi 2019</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0060" title="TadesseM , AbebeG , AbdissaK , AragawD , AbdellaK , BekeleA , et al. GeneXpert MTB/RIF assay for the diagnosis of tuberculous lymphadenitis on concentrated fine needle aspirates in high tuberculosis burden settings. PLOS One2015;10(9):e0137471. [DOI: 10.1371/journal.pone.0137471]">Tadesse 2015</a>; <a href="./references#CD012768-bbs2-0061" title="TrajmanA , Da Silva Santos Kleiz de OliveiraEF , BastosML , Belo NetoE , SilvaEM , Da Silva LourencoMC , et al. Accuracy of polymerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine2014;108(6):918-23. ">Trajman 2014</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0064" title="Van RieA , Page-ShippL , MelletK , ScottL , MkhwnaziM , JongE , et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology &amp; Infectious Diseases2013;32(11):1409-15. ">Van Rie 2013</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Eleven studies evaluated Xpert Ultra. Of these 11 studies, nine evaluated both Xpert MTB/RIF and Xpert Ultra (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0038" title="MeldauR , RandallP , PooranA , LimberisJ , MakambwaE , DhansayM , et al. Same day tools, including Xpert Ultra and unstimulated IFN-gamma, for the rapid diagnosis of pleural tuberculosis - a prospective observational study. Journal of Clinical Microbiology2019;57(9):e00614-19. ">Meldau 2019</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>) and two studies evaluated Xpert Ultra alone (<a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>; <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>). All studies but two (one in Spanish: <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>, and one in Turkish: <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>), were written in English. <a href="#CD012768-fig-0002">Figure 2</a> shows the flow of studies in the review. We recorded the excluded studies, including those listed in the previous Cochrane Review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>) and the reasons for their exclusion in the <a href="./references#CD012768-sec-0269" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD012768-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD012768-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD012768-sec-0045"> <h3 class="title">Methodological quality of included studies</h3> <section id="CD012768-sec-0046"> <h4 class="title">Studies evaluating Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis</h4> <p><a href="#CD012768-fig-0003">Figure 3</a> and <a href="#CD012768-fig-0004">Figure 4</a> show risk of bias and applicability concerns for each of the 69 studies included for tuberculosis detection. Risk of bias and applicability concerns are also presented specifically for studies evaluating Xpert Ultra and Xpert MTB/RIF for tuberculous meningitis (<a href="./appendices#CD012768-sec-0253">Appendix 5</a>), pleural tuberculosis (<a href="./appendices#CD012768-sec-0254">Appendix 6</a>), and lymph node tuberculosis (<a href="./appendices#CD012768-sec-0255">Appendix 7</a>). </p> <div class="figure" id="CD012768-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph for tuberculosis detection: review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for tuberculosis detection: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> </div> <div class="figure" id="CD012768-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary for tuberculosis detection: review authors' judgements about each domain for each included study." data-id="CD012768-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary for tuberculosis detection: review authors' judgements about each domain for each included study. </p> </div> </div> </div> <p>In the patient selection domain, we thought that 53 studies (77%) had low risk of bias, and five studies (7%) had high risk of bias for the following reasons: one study selected participants by convenience (<a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>) and four studies had inappropriate exclusions (<a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>; <a href="./references#CD012768-bbs2-0057" title="SiddiqiOK , BirbeckGL , GhebremichaelM , MubangaE , LoveS , BubackC , et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. Journal of Clinical Microbiology2019;57(8):pii: e00652-19. ">Siddiqi 2019</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>). We thought that 11 studies (16%) had unclear risk of bias for the following reasons: the manner of patient selection was unclear in ten studies (<a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0033" title="LiangQ , PangY , YangY , LiH , GuoC , YangX , et al. An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. BMC Infectious Diseases2019;19(1):548. ">Liang 2019</a>; <a href="./references#CD012768-bbs2-0048" title="RufaiSB , SinghA , KumarP , SinghJ , SinghS . Performance of Xpert MTB/RIF Assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. Journal of Clinical Microbiology2015;53(11):3636-8. ">Rufai 2015</a>; <a href="./references#CD012768-bbs2-0049" title="RufaiSB , SinghS , SinghA , KumarP , SinghJ , VishalA . Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. Journal of Laboratory Physicians2017;9(1):47-52. ">Rufai 2017a</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>), and it was unclear whether the study avoided inappropriate exclusions: one study (<a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>). Regarding applicability (patient characteristics and setting), we thought that 17 studies (25%) had low concern because participants were evaluated in local hospitals or primary health settings: three studies (<a href="./references#CD012768-bbs2-0043" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Medicine2014;12:101. [DOI: 10.1186/1741-7015-12-101]">Pandie 2014</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>; <a href="./references#CD012768-bbs2-0061" title="TrajmanA , Da Silva Santos Kleiz de OliveiraEF , BastosML , Belo NetoE , SilvaEM , Da Silva LourencoMC , et al. Accuracy of polymerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine2014;108(6):918-23. ">Trajman 2014</a>), or in the case of tuberculous meningitis, tertiary centres: 14 studies (<a href="./references#CD012768-bbs2-0002" title="AjbaniK , KaziM , NaikS , SomanR , ShettyA , RodriguesC . Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens. Tuberculosis2018;111:54-6. ">Ajbani 2018</a>; <a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0006" title="BahrNC , TugumeL , RajasinghamR , KiggunduR , WilliamsDA , MorawskiB , et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease2015;19(10):1209-15. ">Bahr 2015</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0028" title="HeemskerkAD , DonovanJ , ThuDD , MaraisS , ChaidirL , DungVT , et al. Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. Journal of Infection2018;77(6):509-15. ">Heemskerk 2018</a>; <a href="./references#CD012768-bbs2-0039" title="MetcalfT , SoriaJ , MontanoSM , TiconaE , EvansCA , HuarotoL , et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLOS One2018;13(6):e0198695. ">Metcalf 2018</a>; <a href="./references#CD012768-bbs2-0041" title="NhuNT , HeemskerkD , Thu doDA , ChauTT , MaiNT , NghiaHD , et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of Clinical Microbiology2014;52(1):226-33. ">Nhu 2014</a>; <a href="./references#CD012768-bbs2-0044" title="PatelVB , TheronG , LendersL , MatinyenaB , ConnollyC , SinghR , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLOS Medicine2013;10(10):e1001536. [DOI: 10.1371/journal.pmed.1001536]">Patel 2013</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a><a href="./references#CD012768-bbs2-0057" title="SiddiqiOK , BirbeckGL , GhebremichaelM , MubangaE , LoveS , BubackC , et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. Journal of Clinical Microbiology2019;57(8):pii: e00652-19. ">Siddiqi 2019</a>). Three studies (4%) had high concern because participants were evaluated exclusively as inpatients at a tertiary care centre (<a href="./references#CD012768-bbs2-0012" title="CheN , YangX , LiuZ , LiK , ChenX . Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. Journal of Clinical Microbiology2017;55(5):1526-32. ">Che 2017</a>; <a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>); and 52 (75%) studies had unclear or high concern because we could not tell the clinical setting or a high percentage of participants had received prior testing for tuberculosis (<a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>). </p> <p>In the index test domain, we thought that all studies had low risk of bias because the results of the index tests (Xpert Ultra and Xpert MTB/RIF) are automatically generated, the user is provided with printable test results, and the test threshold is prespecified. Regarding applicability, with respect to Xpert Ultra, we thought that 9/11 studies (82%) had low risk of bias (<a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0038" title="MeldauR , RandallP , PooranA , LimberisJ , MakambwaE , DhansayM , et al. Same day tools, including Xpert Ultra and unstimulated IFN-gamma, for the rapid diagnosis of pleural tuberculosis - a prospective observational study. Journal of Clinical Microbiology2019;57(9):e00614-19. ">Meldau 2019</a>; <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>) and 2/11 studies (18%) had high risk of bias because the index test was not performed according to WHO standard operating procedures (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). With respect to Xpert MTB/RIF, we thought that 45/67 studies (67%) had low concern because at least 75% of the specimen types in these studies were processed according to WHO recommendations; 17/67 studies (25%) had high concern because fewer than 50% of the specimen types in these studies were processed according to WHO recommendations (<a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0012" title="CheN , YangX , LiuZ , LiK , ChenX . Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. Journal of Clinical Microbiology2017;55(5):1526-32. ">Che 2017</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0018" title="DhasmanaDJ , RossC , BradleyCJ , ConnellDW , GeorgePM , SinganayagamA , et al. Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound. Annals of the American Thoracic Society2014;11(3):392-6. ">Dhasmana 2014</a>; <a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>; <a href="./references#CD012768-bbs2-0024" title="FriedrichSO , Von Groote-BidlingmaierF , DiaconAH . Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. Journal of Clinical Microbiology2011;49(12):4341-2. ">Friedrich 2011</a>; <a href="./references#CD012768-bbs2-0028" title="HeemskerkAD , DonovanJ , ThuDD , MaraisS , ChaidirL , DungVT , et al. Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. Journal of Infection2018;77(6):509-15. ">Heemskerk 2018</a>; <a href="./references#CD012768-bbs2-0035" title="LusibaJK , NakiyingiL , KirengaBJ , KiraggaA , LukandeR , NserekoM , et al. Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting. PLOS One2014;9(7):e102702. [DOI: 10.1371/journal.pone.0102702]">Lusiba 2014</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0041" title="NhuNT , HeemskerkD , Thu doDA , ChauTT , MaiNT , NghiaHD , et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of Clinical Microbiology2014;52(1):226-33. ">Nhu 2014</a>; <a href="./references#CD012768-bbs2-0048" title="RufaiSB , SinghA , KumarP , SinghJ , SinghS . Performance of Xpert MTB/RIF Assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. Journal of Clinical Microbiology2015;53(11):3636-8. ">Rufai 2015</a>; <a href="./references#CD012768-bbs2-0049" title="RufaiSB , SinghS , SinghA , KumarP , SinghJ , VishalA . Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. Journal of Laboratory Physicians2017;9(1):47-52. ">Rufai 2017a</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>). We thought that 5/67 studies (7%) had unclear concern because either the manner of specimen processing was not reported (four studies: <a href="./references#CD012768-bbs2-0002" title="AjbaniK , KaziM , NaikS , SomanR , ShettyA , RodriguesC . Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens. Tuberculosis2018;111:54-6. ">Ajbani 2018</a>; <a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>), or only 50% of the specimen types were processed according to WHO recommendations (one study: <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>). </p> <p>In the reference standard domain, 34 studies (49%) had low risk of bias because results of the reference standard were interpreted without knowledge of results of the index test and only non‐sterile specimens were decontaminated (<a href="./references#CD012768-bbs2-0002" title="AjbaniK , KaziM , NaikS , SomanR , ShettyA , RodriguesC . Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens. Tuberculosis2018;111:54-6. ">Ajbani 2018</a>; <a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>; <a href="./references#CD012768-bbs2-0006" title="BahrNC , TugumeL , RajasinghamR , KiggunduR , WilliamsDA , MorawskiB , et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease2015;19(10):1209-15. ">Bahr 2015</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>; <a href="./references#CD012768-bbs2-0012" title="CheN , YangX , LiuZ , LiK , ChenX . Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. Journal of Clinical Microbiology2017;55(5):1526-32. ">Che 2017</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a> ; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0019" title="DhooriaS , GuptaN , BalA , SehgalIS , AggarwalA , SethiS , et al. Role of Xpert MTB/RIF in differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy undergoing EBUS-TBNA: a study of 147 patients. Sarcoidosis Vasculitis and Diffuse Lung Disease2016;33:258-266. ">Dhooria 2016</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>; <a href="./references#CD012768-bbs2-0028" title="HeemskerkAD , DonovanJ , ThuDD , MaraisS , ChaidirL , DungVT , et al. Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. Journal of Infection2018;77(6):509-15. ">Heemskerk 2018</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0033" title="LiangQ , PangY , YangY , LiH , GuoC , YangX , et al. An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/RIF and an anti-LAM antibody-based assay. BMC Infectious Diseases2019;19(1):548. ">Liang 2019</a>; <a href="./references#CD012768-bbs2-0034" title="LigthelmLJ , NicolMP , HoekKG , JacobsonR , Van HeldenPD , MaraisBJ , et al. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. Journal of Clinical Microbiology2011;49(11):3967-70. ">Ligthelm 2011</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0037" title="MeldauR , PeterJ , TheronG , CalligaroG , AllwoodB , SymonsG , et al. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-gamma for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulmonary Medicine2014;14:58. [DOI: 10.1186/1471-2466-14-58]">Meldau 2014</a>; <a href="./references#CD012768-bbs2-0038" title="MeldauR , RandallP , PooranA , LimberisJ , MakambwaE , DhansayM , et al. Same day tools, including Xpert Ultra and unstimulated IFN-gamma, for the rapid diagnosis of pleural tuberculosis - a prospective observational study. Journal of Clinical Microbiology2019;57(9):e00614-19. ">Meldau 2019</a>; <a href="./references#CD012768-bbs2-0041" title="NhuNT , HeemskerkD , Thu doDA , ChauTT , MaiNT , NghiaHD , et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of Clinical Microbiology2014;52(1):226-33. ">Nhu 2014</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0043" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Medicine2014;12:101. [DOI: 10.1186/1741-7015-12-101]">Pandie 2014</a>; <a href="./references#CD012768-bbs2-0044" title="PatelVB , TheronG , LendersL , MatinyenaB , ConnollyC , SinghR , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLOS Medicine2013;10(10):e1001536. [DOI: 10.1371/journal.pmed.1001536]">Patel 2013</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a>; <a href="./references#CD012768-bbs2-0053" title="ScottLE , BeylisN , NicolM , NkunaG , MolapoS , BerrieL , et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology2014;52(6):1818-23. ">Scott 2014</a>; <a href="./references#CD012768-bbs2-0056" title="SharmaK , SharmaM , ChaudharyL , ModiM , GoyalM , SharmaN , et al. Comparative evaluation of Xpert MTB/RIF assay with multiplex polymerase chain reaction for the diagnosis of tuberculous meningitis. Tuberculosis (Edinburgh, Scotland) 2018 Dec;113:38-42. ">Sharma 2018</a>; <a href="./references#CD012768-bbs2-0057" title="SiddiqiOK , BirbeckGL , GhebremichaelM , MubangaE , LoveS , BubackC , et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. Journal of Clinical Microbiology2019;57(8):pii: e00652-19. ">Siddiqi 2019</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0061" title="TrajmanA , Da Silva Santos Kleiz de OliveiraEF , BastosML , Belo NetoE , SilvaEM , Da Silva LourencoMC , et al. Accuracy of polymerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine2014;108(6):918-23. ">Trajman 2014</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0064" title="Van RieA , Page-ShippL , MelletK , ScottL , MkhwnaziM , JongE , et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology &amp; Infectious Diseases2013;32(11):1409-15. ">Van Rie 2013</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>). Five studies (7%) had high risk of bias because results of the reference standard were interpreted with knowledge of results of the index test (<a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Thirty studies (43%) had unclear risk of bias for the following reasons: seven studies did not report whether there was blinding of the reference standard (<a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0022" title="El-DinMG , SobhE , AdawyZ , FarghalyN . Diagnostic utility of gene X-pert in the diagnosis of tuberculous pleural effusion. Infectious Diseases2019;51(3):227-9. ">El‐Din 2019</a>; <a href="./references#CD012768-bbs2-0035" title="LusibaJK , NakiyingiL , KirengaBJ , KiraggaA , LukandeR , NserekoM , et al. Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting. PLOS One2014;9(7):e102702. [DOI: 10.1371/journal.pone.0102702]">Lusiba 2014</a>; <a href="./references#CD012768-bbs2-0039" title="MetcalfT , SoriaJ , MontanoSM , TiconaE , EvansCA , HuarotoL , et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLOS One2018;13(6):e0198695. ">Metcalf 2018</a>; <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>); 21 studies decontaminated specimens generally considered to be sterile (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0009" title="BiadglegneF , MuluA , Rodloff AC , SackU . Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis (Edinburgh, Scotland)2014;94(5):502-5. ">Biadglegne 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0013" title="ChenC , YangCG , GaoX , LuZZ , TangFX , ChengJ , et al. Community-based active case finding for tuberculosis in rural western China: a cross-sectional study. International Journal of Tuberculosis and Lung Disease2017;21(11):1134-9. ">Chen 2019</a>; <a href="./references#CD012768-bbs2-0018" title="DhasmanaDJ , RossC , BradleyCJ , ConnellDW , GeorgePM , SinganayagamA , et al. Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound. Annals of the American Thoracic Society2014;11(3):392-6. ">Dhasmana 2014</a>; <a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0024" title="FriedrichSO , Von Groote-BidlingmaierF , DiaconAH . Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. Journal of Clinical Microbiology2011;49(12):4341-2. ">Friedrich 2011</a>; <a href="./references#CD012768-bbs2-0025" title="GharianiA , JaouadiT , SmaouiS , MehiriE , MarouaneC , KammounS , et al. Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia. International Journal of Mycobacteriology2015;4(4):270-5. ">Ghariani 2015</a>; <a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0047" title="RakotoariveloR , AmbrosioniJ , RasolofoV , RaberahonaM , RakotosamimananaN , AndrianasoloR , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar. International Journal of Infectious Diseases2018;69:20-5. ">Rakotoarivelo 2018</a>; <a href="./references#CD012768-bbs2-0048" title="RufaiSB , SinghA , KumarP , SinghJ , SinghS . Performance of Xpert MTB/RIF Assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. Journal of Clinical Microbiology2015;53(11):3636-8. ">Rufai 2015</a>; <a href="./references#CD012768-bbs2-0049" title="RufaiSB , SinghS , SinghA , KumarP , SinghJ , VishalA . Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. Journal of Laboratory Physicians2017;9(1):47-52. ">Rufai 2017a</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0055" title="SharmaJB , KriplaniA , DharmendraS , ChaubeyJ , KumarS , SharmaSK . Role of Gene Xpert in diagnosis of female genital tuberculosis: a preliminary report. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;207:237-8. ">Sharma 2016</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0060" title="TadesseM , AbebeG , AbdissaK , AragawD , AbdellaK , BekeleA , et al. GeneXpert MTB/RIF assay for the diagnosis of tuberculous lymphadenitis on concentrated fine needle aspirates in high tuberculosis burden settings. PLOS One2015;10(9):e0137471. [DOI: 10.1371/journal.pone.0137471]">Tadesse 2015</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>); and two studies did not report blinding and decontaminated specimens generally considered to be sterile (<a href="./references#CD012768-bbs2-0001" title="Ablanedo-TerrazasY , Alvarado-de la BarreraC , Hernandez-JuanR , Ruiz-CruzM , Reyes-TeranG . Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients. Laryngoscope2014;124(6):1382-5. ">Ablanedo‐Terrazas 2014</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>). </p> <p>Regarding applicability of the reference standard, we thought that 53 studies (77%) had low concern because these studies performed a test to identify <i>M tuberculosis</i> species (speciation) and 16 studies (23%) had unclear concern because we could not tell whether the study performed speciation (<a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>; <a href="./references#CD012768-bbs2-0019" title="DhooriaS , GuptaN , BalA , SehgalIS , AggarwalA , SethiS , et al. Role of Xpert MTB/RIF in differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy undergoing EBUS-TBNA: a study of 147 patients. Sarcoidosis Vasculitis and Diffuse Lung Disease2016;33:258-266. ">Dhooria 2016</a>; <a href="./references#CD012768-bbs2-0022" title="El-DinMG , SobhE , AdawyZ , FarghalyN . Diagnostic utility of gene X-pert in the diagnosis of tuberculous pleural effusion. Infectious Diseases2019;51(3):227-9. ">El‐Din 2019</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0035" title="LusibaJK , NakiyingiL , KirengaBJ , KiraggaA , LukandeR , NserekoM , et al. Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting. PLOS One2014;9(7):e102702. [DOI: 10.1371/journal.pone.0102702]">Lusiba 2014</a>; <a href="./references#CD012768-bbs2-0039" title="MetcalfT , SoriaJ , MontanoSM , TiconaE , EvansCA , HuarotoL , et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLOS One2018;13(6):e0198695. ">Metcalf 2018</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>; <a href="./references#CD012768-bbs2-0061" title="TrajmanA , Da Silva Santos Kleiz de OliveiraEF , BastosML , Belo NetoE , SilvaEM , Da Silva LourencoMC , et al. Accuracy of polymerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine2014;108(6):918-23. ">Trajman 2014</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). </p> <p>In the flow and timing domain, we considered almost all studies to have low risk of bias, noting that all participants were accounted for in the analysis. One study included fewer than 50% of eligible participants in the analysis (<a href="./references#CD012768-bbs2-0061" title="TrajmanA , Da Silva Santos Kleiz de OliveiraEF , BastosML , Belo NetoE , SilvaEM , Da Silva LourencoMC , et al. Accuracy of polymerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine2014;108(6):918-23. ">Trajman 2014</a>). </p> </section> <section id="CD012768-sec-0047"> <h4 class="title">Studies evaluating Xpert Ultra for detection of rifampicin resistance</h4> <p><a href="#CD012768-fig-0005">Figure 5</a> and <a href="#CD012768-fig-0006">Figure 6</a> show risk‐of‐bias and applicability concerns for each of the five studies included for rifampicin resistance detection. </p> <div class="figure" id="CD012768-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> </div> <div class="figure" id="CD012768-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain for each included study." data-id="CD012768-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain for each included study. </p> </div> </div> </div> <p>In the patient selection domain, we thought that four studies (80%) had low risk of bias (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>) and one study (20%) had unclear risk of bias as the manner of patient selection was unclear (<a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). We thought that one study (20%) had low concern because participants were evaluated exclusively as inpatients at a tertiary care centre (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>) and four studies (80%) had unclear concern because we could not tell the details of the clinical setting (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). </p> <p>In the index test domain, we thought that all studies had low risk of bias because the results of the index tests are automatically generated, the user is provided with printable test results, and the test threshold is prespecified. For applicability, with respect to Xpert Ultra, we thought that three studies (60%) had low concern because at least 75% of the specimen types in these studies were processed according to WHO recommendations (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>); two studies (40%) had high concern because fewer than 50% of the specimen types in these studies were processed according to WHO recommendations (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). </p> <p>In the reference standard domain, two studies (40%) had low risk of bias because results of the reference standard were interpreted without knowledge of results of the index test and only non‐sterile specimens were decontaminated (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). Three studies (60%) had unclear risk of bias as it was unclear whether blinding of the reference standard was performed (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>). For applicability of the reference standard, we thought that all studies had low concern because detection of rifampicin resistance occurs only when the <i>M tuberculosis</i> target is present within the specimen. </p> <p>In the flow and timing domain, we considered all studies to have low risk of bias, noting that all participants were accounted for in the analysis. </p> </section> </section> <section id="CD012768-sec-0048"> <h3 class="title" id="CD012768-sec-0048">Findings</h3> <p>The 69 studies were conducted in 28 different countries. Most of the studies were conducted in China (n = 10), India (n = 13), South Africa (n = 10), and Uganda (n = 6). Seven studies exclusively or mainly included HIV‐positive participants (<a href="./references#CD012768-bbs2-0001" title="Ablanedo-TerrazasY , Alvarado-de la BarreraC , Hernandez-JuanR , Ruiz-CruzM , Reyes-TeranG . Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients. Laryngoscope2014;124(6):1382-5. ">Ablanedo‐Terrazas 2014</a>; <a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0006" title="BahrNC , TugumeL , RajasinghamR , KiggunduR , WilliamsDA , MorawskiB , et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease2015;19(10):1209-15. ">Bahr 2015</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>; <a href="./references#CD012768-bbs2-0064" title="Van RieA , Page-ShippL , MelletK , ScottL , MkhwnaziM , JongE , et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology &amp; Infectious Diseases2013;32(11):1409-15. ">Van Rie 2013</a>). Most studies performed the index tests and culture on the same specimen type, except for one study in which Xpert MTB/RIF was performed on blood and culture was performed on sputum (<a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>). Most studies did not report the exact number of cultures used to confirm a diagnosis of tuberculosis, but it is likely that many studies used a single culture. We present key characteristics of the included studies in the <a href="./references#CD012768-sec-0268" title="">Characteristics of included studies</a> table. </p> <section id="CD012768-sec-0049"> <h4 class="title">I. Detection of extrapulmonary tuberculosis</h4> <p>Xpert Ultra: of the 11 studies, the number evaluating different specimens was as follows: tuberculous meningitis (CSF) six studies; pleural tuberculosis (pleural fluid) four studies; lymph node tuberculosis (lymph node aspirate) one study; genitourinary tuberculosis (urine) one study; bone or joint tuberculosis (bone or joint aspirate) two studies; and peritoneal tuberculosis (peritoneal fluid) one study. </p> <p>Xpert MTB/RIF: of the 67 studies, the number of studies evaluating different specimens was as follows: tuberculous meningitis (CSF) 33 studies; pleural tuberculosis (fluid) 27 studies; lymph node tuberculosis (aspirate 15 studies, biopsy 11 studies); genitourinary tuberculosis (urine) 15 studies; bone or joint tuberculosis (aspirate 12 studies, tissue 3 studies); peritoneal tuberculosis (fluid 17 studies, tissue 1 study); pericardial tuberculosis (fluid 14 studies, tissue 2 studies); and disseminated tuberculosis (blood 2 studies). Several studies included more than one type of specimen. </p> <p><a href="#CD012768-tbl-0006">Table 2</a> presents Xpert Ultra and Xpert MTB/RIF pooled sensitivity and specificity estimates and predictive values by reference standard for all forms of extrapulmonary tuberculosis and specimen types included in the review. </p> <div class="table" id="CD012768-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary accuracy of Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis and rifampicin resistance</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference standard</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number studies (participants)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number (%) with TB or rifampicin resistance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Positive predictive value (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Negative predictive value (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (18.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.4% (79.1 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2% (83.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0% (36.6 to 69.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.7% (97.5 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (496)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (32.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.7% (45.7 to 77.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (96.6 to 99.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9% (65.5 to 99.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0% (94.2 to 97.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1% (62.8 to 79.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9% (95.4 to 98.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8% (62.3 to 80.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8% (95.9 to 97.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (2203)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>862 (39.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.3% (32.1 to 52.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8% (99.3 to 100.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.3% (87.2 to 100.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.0% (93.0 to 95.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ultra, direct comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.0% (77.9 to 95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.0% (82.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.2% (35.6 to 69.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.7% (97.3 to 99.4)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF, direct comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (18.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2% (43.7 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8% (93.4 to 98.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.4% (49.0 to 83.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.8% (93.9 to 97.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (398)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 (39.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0% (58.0 to 86.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0% (63.1 to 97.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.8% (17.9 to 79.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9% (94.5 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5% (39.8 to 59.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.9% (97.6 to 99.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.2% (68.9 to 94.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.6% (93.7 to 95.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1024)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616 (60.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9%</p> <p>(11.5 to 27.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.3%</p> <p>(98.1 to 99.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.6% (49.2 to 91.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7% (91.0 to 92.5)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9% (82.7 to 93.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2% (78.0 to 92.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.7% (31.4 to 55.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.6% (97.9 to 99.2)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (679)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (55.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.6%</p> <p>(61.9 to 93.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.4%</p> <p>(91.3 to 98.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0% (51.1 to 86.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9% (95.8 to 99.2)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node biopsy</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (786)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 (28.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4%</p> <p>(73.5 to 89.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.3%</p> <p>(60.3 to 91.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6% (18.7 to 51.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6% (96.2 to 98.6)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Urine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (943)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (7.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.9%</p> <p>(71.4 to 94.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.1%</p> <p>(93.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.0% (58.3 to 96.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.4% (96.9 to 99.4)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bone or joint aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (471)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (23.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9%</p> <p>(93.1 to 99.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.4%</p> <p>(80.2 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.7% (35.4 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8% (99.2 to 100.0)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Peritoneal fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (580)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (16.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1%</p> <p>(42.1 to 76.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6%</p> <p>(95.4 to 98.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.0% (58.2 to 86.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5% (93.8 to 97.4)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pericardial fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (181)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (31.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4%</p> <p>(32.4 to 82.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.7%</p> <p>(74.9 to 99.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4% (18.3 to 88.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.4% (92.1 to 97.9)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rifampicin resistance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSTor LPA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (129)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (18.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (95.1 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (99.0 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.9% (91.7 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (99.5 to 100.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rifampicin resistance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSTor LPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (970)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 (15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.5% (91.9 to 98.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (98.0 to 99.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.0% (84.3 to 97.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.6% (99.1 to 99.9)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; CSF: cerebrospinal fluid; LPA: Line probe assay; TB: tuberculosis. </p> <p>Studies included in the table are limited to those that report data for both sensitivity and specificity; thus the number of studies (specimens) may differ slightly from those reported in the main text of the review. For tuberculosis detection, the reference standard was culture and a composite reference standard. For rifampicin resistance detection, the reference standards were culture‐based drug susceptibility testing or line probe assay. Pooled sensitivity and pooled specificity are posterior median estimates. </p> </div> </div> <section id="CD012768-sec-0050"> <h5 class="title">A: Xpert MTB/RIF and Xpert Ultra testing in cerebrospinal fluid for tuberculous meningitis</h5> <section id="CD012768-sec-0051"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0052"> <p><b>Culture reference standard</b></p> <p>Six studies evaluated Xpert Ultra in cerebrospinal fluid (CSF) specimens against culture (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>). Xpert Ultra sensitivity ranged from 80% to 100% and specificity ranged from 50% to 100% (<a href="#CD012768-fig-0007">Figure 7</a>). <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a> reported the lowest specificity (50%). In this study, the investigators inoculated uncentrifuged CSF which could have led to lower culture positivity, thus resulting in a higher number of false positives. <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a> (specificity 100%) contributed only one participant to this analysis. In CSF, Xpert Ultra pooled sensitivity and specificity (95% Crl) against culture were 89.4% (79.1 to 95.6) and 91.2% (83.2 to 95.7), (6 studies; 475 participants, 89 (18.7%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>. </p> <div class="figure" id="CD012768-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> </section> <section id="CD012768-sec-0053"> <p><b>Composite reference standard</b></p> <p>In CSF, Xpert Ultra pooled sensitivity and specificity against a composite reference standard were 62.7% (45.7 to 77.0) and 99.1% (96.6 to 99.9), (4 studies; 496 participants); <a href="#CD012768-tbl-0006">Table 2</a>, <a href="#CD012768-fig-0007">Figure 7</a>. </p> </section> <section id="CD012768-sec-0054"> <p><b>Latent class meta‐analysis</b></p> <p>We had insufficient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in CSF. </p> </section> </section> <section id="CD012768-sec-0055"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0056"> <p><b>Culture reference standard</b></p> <p>Thirty‐three studies evaluated Xpert MTB/RIF in CSF specimens against culture (<a href="./references#CD012768-bbs2-0002" title="AjbaniK , KaziM , NaikS , SomanR , ShettyA , RodriguesC . Utility of pyrosequencing for rapid detection of tubercular meningitis (TBM) and associated susceptibility directly from CSF specimens. Tuberculosis2018;111:54-6. ">Ajbani 2018</a>; <a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0005" title="AzevedoRG , DinalloFS , De LaurentisLS , BoulwareDR , VidalJE . Xpert MTB/RIF((R)) assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease2018;22(6):706-7. ">Azevedo 2018</a>; <a href="./references#CD012768-bbs2-0006" title="BahrNC , TugumeL , RajasinghamR , KiggunduR , WilliamsDA , MorawskiB , et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease2015;19(10):1209-15. ">Bahr 2015</a>; <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>; <a href="./references#CD012768-bbs2-0016" title="CresswellFV , BangdiwalaAS , BahrNC , TrautnerE , NuwagiraE , EllisJ , et al. Can improved diagnostics reduce mortality from tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research2018;3:64. ">Cresswell 2018</a>; <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>; <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0039" title="MetcalfT , SoriaJ , MontanoSM , TiconaE , EvansCA , HuarotoL , et al. Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLOS One2018;13(6):e0198695. ">Metcalf 2018</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0041" title="NhuNT , HeemskerkD , Thu doDA , ChauTT , MaiNT , NghiaHD , et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of Clinical Microbiology2014;52(1):226-33. ">Nhu 2014</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0044" title="PatelVB , TheronG , LendersL , MatinyenaB , ConnollyC , SinghR , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLOS Medicine2013;10(10):e1001536. [DOI: 10.1371/journal.pmed.1001536]">Patel 2013</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0047" title="RakotoariveloR , AmbrosioniJ , RasolofoV , RaberahonaM , RakotosamimananaN , AndrianasoloR , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar. International Journal of Infectious Diseases2018;69:20-5. ">Rakotoarivelo 2018</a>; <a href="./references#CD012768-bbs2-0050" title="RufaiSB , SinghA , SinghJ , KumarP , SankarMM , SinghS . Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Journal of Infection2017;75(2):125-31. ">Rufai 2017b</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0057" title="SiddiqiOK , BirbeckGL , GhebremichaelM , MubangaE , LoveS , BubackC , et al. Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia. Journal of Clinical Microbiology2019;57(8):pii: e00652-19. ">Siddiqi 2019</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Xpert MTB/RIF sensitivity ranged from 0% to 100% and specificity ranged from 78% to 100% (<a href="#CD012768-fig-0008">Figure 8</a>). For sensitivity, we thought that differences in CSF volume and processing could partly explain the heterogeneity. Three studies (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>) did not contribute data to the meta‐analysis because sensitivity was not estimable. </p> <div class="figure" id="CD012768-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plots of Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> <p>In CSF, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) against culture were 71.1% (62.8 to 79.1) and 96.9% (95.4 to 98.0), respectively (30 studies; 3395 participants, 571 (16.8%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>, <a href="#CD012768-fig-0008">Figure 8</a>. </p> </section> <section id="CD012768-sec-0057"> <p><b>Composite reference standard</b></p> <p>In CSF, Xpert MTB/RIF pooled sensitivity and specificity against a composite reference standard were 42.3% (32.1 to 52.8) and 99.8% (99.3 to 100.0), (14 studies; 2203 participants); <a href="#CD012768-tbl-0006">Table 2</a>, <a href="#CD012768-fig-0008">Figure 8</a>. </p> </section> <section id="CD012768-sec-0058"> <p><b>Latent class meta‐analysis</b></p> <p>Based on the latent class meta‐analysis model, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) for tuberculous meningitis were 74.7% (65.5 to 84.0) and 99.5% (99.1 to 99.7) (30 studies; 3395 participants); <a href="#CD012768-tbl-0007">Table 3</a>. The pooled sensitivity of culture at 80.8% (72.5 to 88.5) was estimated to be lower than 100%. The pooled specificity of culture was estimated to be 99.2% (98.7 to 99.5); <a href="#CD012768-tbl-0007">Table 3</a>. </p> <div class="table" id="CD012768-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Latent class meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of extrapulmonary tuberculosis, type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Culture‐confirmed tuberculosis (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Positive predictive value (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Negative predictive value (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Accuracy estimates of Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tuberculous meningitis, cerebrospinal fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7% (65.5 to 84.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.5% (99.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5% (89.7 to 96.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.3% (96.3 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pleural tuberculosis, fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.1% (42.8 to 64.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.6% (99.3 to 99.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7% (89.5 to 96.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0% (94.0 to 96.2)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lymph node tuberculosis, aspirate</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.5% (85.2 to 95.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.5%</p> <p>(99.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.2% (91.4 to 97.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (98.4 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Accuracy estimates of culture</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tuberculous meningitis, cerebrospinal fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8% (72.5 to 88.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.2% (98.7 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (86.9 to 95.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9% (97.0 to 98.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pleural tuberculosis, fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5% (80.5 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.0% (98.2 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8% (84.2 to 94.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8% (97.9 to 99.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lymph node tuberculosis, aspirate</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.9% (69.9 to 91.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8% (97.8 to 99.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.7% (80.1 to 94.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.1% (96.7 to 99.1)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> <p>We generally used non‐informative priors in the latent class model.<br/>Accuracy estimates were determined using a bivariate random‐effects approach for comparison. </p> </div> </div> </section> </section> <section id="CD012768-sec-0059"> <h6 class="title">Xpert Ultra versus Xpert MTB/RIF</h6> <p>In comparative accuracy studies evaluating both index tests, Xpert Ultra pooled sensitivity and specificity (95% CrI) against culture were 89.0% (77.9 to 95.2) and 91.0% (82.7 to 95.6) and Xpert MTB/RIF pooled sensitivity and specificity were 62.2% (43.7 to 78.1) and 96.8% (93.4 to 98.6), (5 studies; 471 participants), direct comparison, <a href="#CD012768-tbl-0006">Table 2</a>; <a href="#CD012768-fig-0009">Figure 9</a>; <a href="#CD012768-fig-0010">Figure 10</a>. For CSF, the difference between the sensitivities of Xpert Ultra and Xpert MTB/RIF was 26.2% (9.1 to 44.4). We estimated the probability that the pooled sensitivity of Xpert Ultra exceeds that of Xpert MTB/RIF was 0.997. The difference between the specificities of Xpert Ultra and Xpert MTB/RIF was −5.6% (−12.9 to −0.1). We estimated the probability that the pooled specificity of Xpert Ultra was less than that of Xpert MTB/RIF was 0.978; <a href="#CD012768-tbl-0008">Table 4</a>. </p> <div class="figure" id="CD012768-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid, comparative studies. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid, comparative studies. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> <div class="figure" id="CD012768-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Summary plots of the sensitivity and specificity of Xpert Ultra (A) (5 studies) and Xpert MTB/RIF (B) (5 studies) in cerebrospinal fluid for detection of tuberculous meningitis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region." data-id="CD012768-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary plots of the sensitivity and specificity of Xpert Ultra (A) (5 studies) and Xpert MTB/RIF (B) (5 studies) in cerebrospinal fluid for detection of tuberculous meningitis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region. </p> </div> </div> </div> <div class="table" id="CD012768-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Accuracy of Xpert Ultra versus Xpert MTB/RIF in cerebrospinal fluid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Detection of tuberculosis in CSF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Test (studies, participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Xpert Ultra (5, 471)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Xpert MTB/RIF (5, 471)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (Xpert Ultra minus Xpert MTB/RIF)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (Xpert Ultra minus Xpert MTB/RIF)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.0% (77.9 to 95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.2% (43.7 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.2% (9.1 to 44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.997</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.0% (82.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8% (93.4 to 98.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.6% (−12.9 to −0.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.022</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD012768-sec-0060"> <h5 class="title">Investigations of heterogeneity</h5> <section id="CD012768-sec-0061"> <h6 class="title">Xpert Ultra versus Xpert MTB/RIF testing in people living with HIV</h6> <p>We identified two studies that directly compared Xpert Ultra and Xpert MTB/RIF, both against culture, in people living with HIV. Sensitivity (95% CI) was 90% (55 to 100) (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>) and 89% (71 to 98) (<a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>) for Xpert Ultra and 60% (26 to 88) (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>) and 70% (50 to 86) (<a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>) for Xpert MTB/RIF. Specificity (95% CI) was 90% (83 to 95) (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>) and 92% (86 to 95) (<a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>) for Xpert Ultra and 97% (95% CI 92 to 99) (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>) and 97% (93 to 99) (<a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>) for Xpert MTB/RIF; <a href="#CD012768-fig-0011">Figure 11</a>. </p> <div class="figure" id="CD012768-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid in HIV‐positive people, with respect to culture. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. ." data-id="CD012768-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid in HIV‐positive people, with respect to culture. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. . </p> </div> </div> </div> </section> <section id="CD012768-sec-0062"> <h6 class="title">Specimen concentration</h6> <section id="CD012768-sec-0063"> <p><b>Xpert Ultra</b></p> <p>We found that concentrating CSF improved both Xpert Ultra sensitivity and specificity. Xpert Ultra pooled sensitivity in concentrated specimens was 90.5% (76.7 to 97.0) (3 studies; 421 participants) versus 88.4% (67.8 to 97.5) (3 studies; 54 participants) in unconcentrated specimens. Xpert Ultra pooled specificity in concentrated specimens was 91.9% (84.5 to 96.1) versus 88.6% (58.4 to 99.0) in unconcentrated specimens; <a href="#CD012768-tbl-0009">Table 5</a>. The probability that Xpert Ultra sensitivity and specificity are higher with concentrated CSF compared to unconcentrated CSF were 0.630 and 0.653, respectively. </p> <div class="table" id="CD012768-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Impact of concentrating cerebrospinal fluid on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Covariate (number of studies, participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Concentration step, Xpert Ultra</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Concentrated specimen (3, 421)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.5% (76.7 to 97.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (84.5 to 96.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Unconcentrated specimen (3, 54)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.4% (67.8 to 97.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (58.4 to 99.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6% (−13.9 to 24.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4% (−9.5 to 32.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probability (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.653</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Concentration step, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Concentrated specimen (14, 2279)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6% (67.2 to 85.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.4% (96.1 to 98.4)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Unconcentrated specimen (17, 1123)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.4% (48.3 to 70.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8% (94.0 to 98.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.4% (2.8 to 32.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6% (−1.7 to 3.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.696</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> </div> </div> </section> <section id="CD012768-sec-0064"> <p><b>Xpert MTB/RIF</b></p> <p>We found that concentrating CSF improved both Xpert MTB/RIF sensitivity and specificity. Xpert MTB/RIF pooled sensitivity in concentrated specimens was 77.6% (67.2 to 85.9) (14, 2279 participants) versus 59.4% (48.3 to 70.5) (17,1123 participants) in unconcentrated specimens. Xpert MTB/RIF pooled specificity in concentrated specimens was 97.4% (96.1 to 98.4) versus 96.8% (94.0 to 98.7) in unconcentrated specimens, <a href="#CD012768-tbl-0009">Table 5</a>. The probability that Xpert MTB/RIF sensitivity and specificity are higher with concentrated CSF compared to unconcentrated CSF were 0.989 and 0.696, respectively. </p> </section> </section> <section id="CD012768-sec-0065"> <h6 class="title">Cerebrospinal fluid collection volumes</h6> <section id="CD012768-sec-0066"> <p><b>Xpert Ultra</b></p> <p>Two studies reported the volume of CSF collected for Xpert Ultra testing, 3 mL in both studies. Sensitivities were similar: 90% (55 to 100) in <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a> and 89% (71 to 98) in <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>. Specificities were also similar 90% (83 to 95) in <a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a> and 92% (86 to 95) in <a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020.</a> </p> </section> </section> <section id="CD012768-sec-0067"> <h6 class="title">Impact of tuberculosis prevalence on sensitivity and specificity</h6> <p>For Xpert Ultra, we found lower sensitivity in settings with higher tuberculosis prevalence (threshold 30%) than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 88.3% (68.3 to 97.0) versus 90.8% (77.3 to 96.9). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 88.0% (64.3 to 97.9) versus 91.9% (82.5 to 96.6). In both analyses, the 95% Crls overlapped; <a href="#CD012768-tbl-0010">Table 6</a>. </p> <div class="table" id="CD012768-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysis, (number of studies, specimens)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Cerebrospinal fluid, Xpert Ultra</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Among studies with prevalence ≥ 30% (3, 54)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.3% (68.3 to 97.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0% (64.3 to 97.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Among studies with prevalence &lt; 30% (3, 421)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8% (77.3 to 96.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (82.5 to 96.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.2% (−23.0 to 13.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.8% (−27.7 to 9.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probability (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.308</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Cerebrospinal fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 30% (6, 610)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.0% (49.0 to 81.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.1% (86.8 to 97.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 30% (24, 2785)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0% (62.4 to 81.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.3% (95.9 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.8% (−25.5 to 12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.1% (−10.5 to 0.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.071</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Cerebrospinal fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 10% (19, 2190)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.7% (58.5 to 78.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1% (92.7 to 96.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 10% (11, 1205)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.2% (57.4 to 86.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.6% (97.5 to 99.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 10% group minus &lt; 10% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.5% (‐21.2 to 13.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.5% (‐6.0 to ‐1.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 10% group minus &lt; 10% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Pleural fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 50% (6, 627)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.7% (11.2 to 33.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.6% (97.9 to 99.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 50% (4, 397)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5% (6.5 to 30.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.0% (96.9 to 99.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 50% group minus &lt; 50% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1% (−11.8 to 21.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5% (−1.2 to 2.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 50% group minus &lt; 50% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.759</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Lymph node aspirate, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 35 (9, 911)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.1% (88.9 to 96.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.2% (69.5 to 92.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 35% (5, 677)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.2% (64.9 to 87.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.0% (78.3 to 95.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 35% group minus &lt; 35% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.7% (5.4 to 28.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.4% (−21.3 to 76)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 35% group minus &lt; 35% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.158</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> <p>Prevalence refers to the percentage of culture‐confirmed tuberculosis specimens or confirmed rifampicin‐resistant specimens in the study. We selected prevalence levels to approximate the lower bound of the interquartile range or in consideration of the range of prevalences reported in the included studies. </p> </div> </div> <p>Similarly, for Xpert MTB/RIF, we found lower sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity of 67.0% (49.0 to 81.5) versus 72.0% (62.4 to 81.2). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 94.1% (86.8 to 97.9) versus 97.3% (95.9 to 98.3). In both analyses, the 95% Crls overlapped; <a href="#CD012768-tbl-0010">Table 6</a>. When we repeated the analysis at lower tuberculosis prevalence (threshold 10%), in the case of specificity, accuracy in the two groups was significantly different (probability of specificity being lower in the high tuberculosis prevalence group = 0.999); <a href="#CD012768-tbl-0010">Table 6</a>. </p> </section> <section id="CD012768-sec-0068"> <h6 class="title">Sensitivity analyses</h6> <p>Overall, the sensitivity analyses made little difference to the findings; <a href="#CD012768-tbl-0011">Table 7</a> </p> <div class="table" id="CD012768-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses, Xpert Ultra in cerebrospinal fluid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies (specimens)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Predicted sensitivity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Predicted specificity (95% Crl)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>All participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.4% (79.1 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2% (83.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0% (36.6 to 69.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.7% (97.5 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Consecutive participant selection</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9% (76.4 to 94.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4% (81.1 to 95.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0% (65.2 to 96.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.5% (65.5 to 97.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference standard blinding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5% (74.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.1% (76.9 to 94.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (63.4 to 97.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.2% (61.0 to 97.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Single specimen per participant</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5% (74.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.1% (76.9 to 94.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (63.4 to 97.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.2% (61.0 to 97.1)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> </div> </div> </section> <section id="CD012768-sec-0069"> <h6 class="title">Inconclusive Xpert Ultra and Xpert MTB/RIF results</h6> <section id="CD012768-sec-0070"> <p><b>Xpert Ultra</b></p> <p>None of the studies evaluating Xpert Ultra for tuberculous meningitis reported this information. </p> </section> <section id="CD012768-sec-0071"> <p><b>Xpert MTB/RIF</b></p> <p>We previously reported that for CSF, of 2096 tests performed, the pooled proportion of inconclusive Xpert MTB/RIF results was 0.9% (95% CrI 0.3 to 1.9) (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> </section> <section id="CD012768-sec-0072"> <h5 class="title">B: Xpert Ultra and Xpert MTB/RIF testing in pleural fluid for pleural tuberculosis</h5> <section id="CD012768-sec-0073"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0074"> <p><b>Culture reference standard</b></p> <p>Four studies evaluated Xpert Ultra in pleural fluid with respect to culture (<a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). Xpert Ultra sensitivity ranged from 48% to 84% and specificity ranged from 65% to 100%; <a href="#CD012768-fig-0012">Figure 12</a>. </p> <div class="figure" id="CD012768-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in pleural fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in pleural fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> <p>In pleural fluid, Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) and 87.0% (63.1 to 97.9), (4 studies; 398 participants, 158 (39.7%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>; <a href="./appendices#CD012768-sec-0256">Appendix 8</a>. </p> </section> <section id="CD012768-sec-0075"> <p><b>Composite reference standard</b></p> <p>Two studies evaluated Xpert Ultra in pleural fluid with respect to a composite reference standard (<a href="./references#CD012768-bbs2-0038" title="MeldauR , RandallP , PooranA , LimberisJ , MakambwaE , DhansayM , et al. Same day tools, including Xpert Ultra and unstimulated IFN-gamma, for the rapid diagnosis of pleural tuberculosis - a prospective observational study. Journal of Clinical Microbiology2019;57(9):e00614-19. ">Meldau 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>); <a href="#CD012768-fig-0012">Figure 12</a>; <a href="./appendices#CD012768-sec-0256">Appendix 8</a>. Sensitivity ranged from 38% to 61%, and specificity ranged from 96% to 99%. We could not explain the variability in the sensitivity estimates and did not perform a meta‐analysis. </p> </section> <section id="CD012768-sec-0076"> <p><b>Latent class meta‐analysis</b></p> <p>We had insufficient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in pleural fluid. </p> </section> </section> <section id="CD012768-sec-0077"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0078"> <p><b>Culture reference standard</b></p> <p>Twenty‐eight studies evaluated Xpert MTB/RIF in pleural fluid with respect to culture (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0012" title="CheN , YangX , LiuZ , LiK , ChenX . Rapid detection of cell-free Mycobacterium tuberculosis DNA in tuberculous pleural effusion. Journal of Clinical Microbiology2017;55(5):1526-32. ">Che 2017</a>; <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>; <a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0024" title="FriedrichSO , Von Groote-BidlingmaierF , DiaconAH . Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. Journal of Clinical Microbiology2011;49(12):4341-2. ">Friedrich 2011</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0037" title="MeldauR , PeterJ , TheronG , CalligaroG , AllwoodB , SymonsG , et al. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-gamma for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulmonary Medicine2014;14:58. [DOI: 10.1186/1471-2466-14-58]">Meldau 2014</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0047" title="RakotoariveloR , AmbrosioniJ , RasolofoV , RaberahonaM , RakotosamimananaN , AndrianasoloR , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar. International Journal of Infectious Diseases2018;69:20-5. ">Rakotoarivelo 2018</a>; <a href="./references#CD012768-bbs2-0048" title="RufaiSB , SinghA , KumarP , SinghJ , SinghS . Performance of Xpert MTB/RIF Assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. Journal of Clinical Microbiology2015;53(11):3636-8. ">Rufai 2015</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0053" title="ScottLE , BeylisN , NicolM , NkunaG , MolapoS , BerrieL , et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology2014;52(6):1818-23. ">Scott 2014</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Xpert MTB/RIF sensitivity ranged from 0% to 100% and specificity ranged from 82% to 100% (<a href="#CD012768-fig-0012">Figure 12</a>). Three studies (<a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>) did not contribute data to the meta‐analysis because sensitivity was not estimable. </p> <p>In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) and 98.9% (97.6 to 99.7) (25 studies; 3065 participants, 644 (21.0%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>; <a href="./appendices#CD012768-sec-0256">Appendix 8</a>. </p> </section> <section id="CD012768-sec-0079"> <p><b>Composite reference standard</b></p> <p>In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity against a composite reference standard were 18.9% (11.5 to 27.9) and 99.3% (98.1 to 99.8), (10 studies; 1024 participants) <a href="#CD012768-tbl-0006">Table 2</a>; <a href="#CD012768-fig-0012">Figure 12</a>. </p> </section> <section id="CD012768-sec-0080"> <p><b>Latent class meta‐analysis</b></p> <p>Based on the latent class meta‐analysis model, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) in pleural fluid were 53.1% (42.8 to 64.1) and 99.6% (99.3 to 99.8) (25 studies; 3065 participants) <a href="#CD012768-tbl-0007">Table 3</a>. Xpert MTB/RIF pooled sensitivity was slightly higher and its pooled specificity comparable to what was obtained when culture was treated as having perfect accuracy, with pooled sensitivity of 49.5% (39.8 to 59.9) and pooled specificity of 98.8% (97.6 to 99.7). The pooled sensitivity of culture at 89.5% (80.5 to 96.3) was estimated to be lower than 100%. The pooled specificity of culture was estimated to be 99.0% (98.2 to 99.5). </p> </section> </section> <section id="CD012768-sec-0081"> <h6 class="title">Xpert Ultra versus Xpert MTB/RIF</h6> <p>We had insufficient data for this analysis.</p> </section> <section id="CD012768-sec-0082"> <h6 class="title">Impact of tuberculosis prevalence on sensitivity and specificity</h6> <p>For Xpert Ultra, we had insufficient data for this analysis.</p> <p>For Xpert MTB/RIF, we found higher sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 20.7% (11.2 to 33.7) versus 15.5% (6.5 to 30.1). We found similar specificity in settings with higher tuberculosis prevalence and in those with lower tuberculosis prevalence: pooled specificity of 99.6% (97.9 to 99.9) versus 99.0% (96.9 to 99.8). In both analyses, the 95% Crls overlapped; <a href="#CD012768-tbl-0010">Table 6</a>. </p> </section> <section id="CD012768-sec-0083"> <h6 class="title">Sensitivity analyses</h6> <p>For Xpert Ultra, we had insufficient data for these analyses.</p> </section> <section id="CD012768-sec-0084"> <h6 class="title">Inconclusive Xpert Ultra and Xpert MTB/RIF results</h6> <section id="CD012768-sec-0085"> <p><b>Xpert Ultra</b></p> <p>Of the total 1013 tests performed, the percentage of inconclusive Xpert Ultra results was 0.3%. Only one study reported this information (<a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>). </p> </section> <section id="CD012768-sec-0086"> <p><b>Xpert MTB/RIF</b></p> <p>We previously reported that for pleural fluid, of 1416 tests performed the pooled proportion of inconclusive Xpert MTB/RIF results was 1.2% (95% CrI 0.4 to 2.6) (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> </section> <section id="CD012768-sec-0087"> <h5 class="title">C: Xpert Ultra and Xpert MTB/RIF testing in pleural tissue for pleural tuberculosis</h5> <section id="CD012768-sec-0088"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0089"> <p><b>Culture reference standard</b></p> <p>We did not identify any studies evaluating Xpert Ultra in pleural tissue against culture.</p> </section> <section id="CD012768-sec-0090"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies evaluating Xpert Ultra in pleural tissue against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0091"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0092"> <p><b>Culture reference standard</b></p> <p>Four studies evaluated Xpert MTB/RIF in pleural tissue with respect to culture (<a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>; <a href="./references#CD012768-bbs2-0021" title="DuJ , HuangZ , LuoQ , XiongG , XuX , LiW , et al. Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research In Medical Sciences2015;20(1):26-31. ">Du 2015</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>). Xpert MTB/RIF sensitivity ranged from 0% to 85% and specificity ranged from 97% to 100%; <a href="#CD012768-fig-0012">Figure 12</a>. One study reported zero tuberculosis cases (<a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>). We did not perform a meta‐analysis. </p> </section> <section id="CD012768-sec-0093"> <p><b>Composite reference standard</b></p> <p>In pleural tissue, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 0% (0 to 23) and 98% (87 to 100) (1 study; 55 participants; <a href="./references#CD012768-bbs2-0015" title="ChristopherDJ , SchumacherSG , MichaelJS , LuoR , BalamugeshT , DuraikannanP , et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. European Respiratory Journal2013;42(5):1427-9. ">Christopher 2013</a>); <a href="#CD012768-fig-0012">Figure 12</a>. </p> </section> </section> </section> <section id="CD012768-sec-0094"> <h5 class="title">D: Xpert MTB/RIF and Xpert Ultra testing in lymph node aspirate for lymph node tuberculosis</h5> <section id="CD012768-sec-0095"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0096"> <p><b>Culture reference standard</b></p> <p>In lymph node aspirates, Xpert Ultra sensitivity and specificity against culture were 78% (40 to 97) and 78% (66 to 87), (1 study; 73 participants; 9 (12.3%) with tuberculosis; <a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>); <a href="#CD012768-fig-0013">Figure 13</a>. </p> <div class="figure" id="CD012768-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in lymph node aspirate by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in lymph node aspirate by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> </section> <section id="CD012768-sec-0097"> <p><b>Composite reference standard</b></p> <p>In lymph node aspirates, Xpert Ultra sensitivity and specificity against a composite reference standard were 70% (51 to 85) and 100% (92 to 100), (1 study; 73 participants; 9 (12.3%) with tuberculosis; <a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>); <a href="#CD012768-fig-0013">Figure 13</a>. Of note, with a composite reference standard, specificity was higher (100%) than that observed when using culture as the reference standard (78%). </p> </section> <section id="CD012768-sec-0098"> <p><b>Latent class meta‐analysis</b></p> <p>We had insufficient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in lymph node aspirate. </p> </section> </section> <section id="CD012768-sec-0099"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0100"> <p><b>Culture reference standard</b></p> <p>Fifteen studies evaluated Xpert MTB/RIF in lymph node aspirates with for culture (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0009" title="BiadglegneF , MuluA , Rodloff AC , SackU . Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis (Edinburgh, Scotland)2014;94(5):502-5. ">Biadglegne 2014</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0018" title="DhasmanaDJ , RossC , BradleyCJ , ConnellDW , GeorgePM , SinganayagamA , et al. Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound. Annals of the American Thoracic Society2014;11(3):392-6. ">Dhasmana 2014</a>; <a href="./references#CD012768-bbs2-0019" title="DhooriaS , GuptaN , BalA , SehgalIS , AggarwalA , SethiS , et al. Role of Xpert MTB/RIF in differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy undergoing EBUS-TBNA: a study of 147 patients. Sarcoidosis Vasculitis and Diffuse Lung Disease2016;33:258-266. ">Dhooria 2016</a>; <a href="./references#CD012768-bbs2-0025" title="GharianiA , JaouadiT , SmaouiS , MehiriE , MarouaneC , KammounS , et al. Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia. International Journal of Mycobacteriology2015;4(4):270-5. ">Ghariani 2015</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0034" title="LigthelmLJ , NicolMP , HoekKG , JacobsonR , Van HeldenPD , MaraisBJ , et al. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. Journal of Clinical Microbiology2011;49(11):3967-70. ">Ligthelm 2011</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0053" title="ScottLE , BeylisN , NicolM , NkunaG , MolapoS , BerrieL , et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology2014;52(6):1818-23. ">Scott 2014</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0060" title="TadesseM , AbebeG , AbdissaK , AragawD , AbdellaK , BekeleA , et al. GeneXpert MTB/RIF assay for the diagnosis of tuberculous lymphadenitis on concentrated fine needle aspirates in high tuberculosis burden settings. PLOS One2015;10(9):e0137471. [DOI: 10.1371/journal.pone.0137471]">Tadesse 2015</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0064" title="Van RieA , Page-ShippL , MelletK , ScottL , MkhwnaziM , JongE , et al. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology &amp; Infectious Diseases2013;32(11):1409-15. ">Van Rie 2013</a>). Xpert MTB/RIF sensitivity ranged from 59% to 100% and specificity from 57% to 100%; <a href="#CD012768-fig-0013">Figure 13</a>. Xpert MTB/RIF specificity in lymph node aspirates was considerably more heterogeneous than in CSF and pleural fluid. The variability in Xpert MTB/RIF specificity in lymph node aspirates was unexpected and may be the result of a systematic, unexplained bias in some studies. One study did not contribute data to the meta‐analysis because sensitivity was not estimable (<a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>). </p> <p>In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and specificity against culture were 88.9% (82.7 to 93.6) and 86.2% (78.0 to 92.3) (14 studies; 1588 participants, 627 (39.5%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>. </p> </section> <section id="CD012768-sec-0101"> <p><b>Composite reference standard</b></p> <p>In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and specificity against a composite reference standard were 81.6% (61.9 to 93.3) and 96.4% (91.3 to 98.6), (4 studies; 679 participants); <a href="#CD012768-tbl-0006">Table 2</a>; <a href="#CD012768-fig-0013">Figure 13</a>. Of note, with a composite reference standard, specificity was less variable and pooled specificity higher than that observed when using culture as the reference standard (86.0%). </p> </section> <section id="CD012768-sec-0102"> <p><b>Latent class meta‐analysis</b></p> <p>Based on the latent class meta‐analysis model, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) in lymph node aspirate were 91.3% (84.9 to 96.3) and 99.5% (99.1 to 99.7) (14 studies; 1588 participants); <a href="#CD012768-tbl-0007">Table 3</a>. Xpert MTB/RIF pooled sensitivity and pooled specificity were higher than when culture was treated as having perfect accuracy, with pooled sensitivity of 88.9% (82.7 to 93.6) and pooled specificity of 86.2% (78.0 to 92.3). The pooled sensitivity of culture at 84.9% (74.0 to 92.8) was estimated to be lower than 100%. The pooled specificity of culture was estimated to be 98.8% (97.7 to 99.4); <a href="#CD012768-tbl-0007">Table 3</a>. The latent class meta‐analysis resulted in high precision in the specificity of Xpert MTB/RIF across studies. This was the result of adjustments for the imperfect and heterogeneous accuracy of culture across studies. </p> </section> </section> <section id="CD012768-sec-0103"> <h6 class="title">Xpert Ultra versus Xpert MTB/RIF</h6> <p>We had insufficient data for this analysis.</p> </section> <section id="CD012768-sec-0104"> <h6 class="title">Impact of tuberculosis prevalence on sensitivity and specificity</h6> <p>For Xpert Ultra, we had insufficient data for this analysis.</p> <p>For Xpert MTB/RIF, we found higher sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 93.1% (88.9 to 96.3) versus 72.2% (64.9 to 87.2). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 83.2% (69.5 to 92.1) versus 90.0% (78.3 to 95.9). In the case of sensitivity, accuracy in the two groups was significantly different (probability of sensitivity being lower in the high tuberculosis prevalence group = 0.999); <a href="#CD012768-tbl-0010">Table 6</a>. </p> </section> <section id="CD012768-sec-0105"> <h6 class="title">Sensitivity analyses</h6> <p>For Xpert Ultra, we had insufficient data for these analyses.</p> </section> <section id="CD012768-sec-0106"> <h6 class="title">Inconclusive Xpert MTB/RIF and Xpert Ultra results</h6> <section id="CD012768-sec-0107"> <p><b>Xpert Ultra</b></p> <p>None of the studies reported this information.</p> </section> <section id="CD012768-sec-0108"> <p><b>Xpert MTB/RIF</b></p> <p>We previously reported that for lymph node aspirates, in the 1134 tests performed, the pooled proportion of inconclusive Xpert MTB/RIF results was 1.0% (95% CrI 0.4 to 2.0) (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> </section> <section id="CD012768-sec-0109"> <h5 class="title">E: Xpert MTB/RIF and Xpert Ultra in lymph node biopsies for lymph node tuberculosis</h5> <section id="CD012768-sec-0110"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0111"> <p><b>Culture reference standard</b></p> <p>In lymph node biopsies, Xpert Ultra sensitivity and specificity against culture were 90% (55 to 100) and 87% (77 to 94) (<a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>) and 100% (75 to 100) and 38% (22 to 55) (<a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>), (2 studies; 131 participants, 23 (17.6%) with tuberculosis); <a href="#CD012768-fig-0014">Figure 14</a>. </p> <div class="figure" id="CD012768-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIFsensitivity and specificity in lymph node biopsy by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIFsensitivity and specificity in lymph node biopsy by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> </section> <section id="CD012768-sec-0112"> <p><b>Composite reference standard</b></p> <p>In lymph node biopsies, Xpert Ultra sensitivity and specificity against a composite reference standard were 73% (50 to 89) and 96% (88 to 100) (<a href="./references#CD012768-bbs2-0004" title="AntelK , OosthuizenJ , MalherbeF , LouwVJ , NicolMP , MaartensG , et al. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infectious Diseases2020;20(1):33. ">Antel 2020</a>), (1 study; 81 participants); <a href="#CD012768-fig-0014">Figure 14</a>. </p> </section> </section> <section id="CD012768-sec-0113"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0114"> <p><b>Culture reference standard</b></p> <p>Eleven studies evaluated Xpert MTB/RIF in lymph node biopsies against culture (<a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0025" title="GharianiA , JaouadiT , SmaouiS , MehiriE , MarouaneC , KammounS , et al. Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia. International Journal of Mycobacteriology2015;4(4):270-5. ">Ghariani 2015</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>). Xpert MTB/RIF sensitivity ranged from 50% to 100% and specificity ranged from 0% to 100%; <a href="#CD012768-fig-0014">Figure 14</a>. We could not explain the heterogeneity in accuracy estimates by study quality, small numbers, or other factors. </p> <p>In lymph node biopsies, Xpert MTB/RIF pooled sensitivity and specificity against culture were 82.4% (73.5 to 89.7) and 80.3% (60.3 to 91.5), (11 studies; 786 participants, 220 (28.0%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>. </p> </section> <section id="CD012768-sec-0115"> <p><b>Composite reference standard</b></p> <p>In lymph node biopsies, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (27 to 40) and 85% (73 to 93) (<a href="./references#CD012768-bbs2-0052" title="SarfarazS , IftikharS , MemonY , ZahirN , HerekerFF , SalahuddinN . Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis. International Journal of Infectious Diseases2018;76:73-81. ">Sarfaraz 2018</a>) and 76% (50 to 93) and specificity of 100% (66 to 100) (<a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>) (2 studies; 288 participants); <a href="#CD012768-fig-0014">Figure 14</a>. </p> </section> </section> </section> <section id="CD012768-sec-0116"> <h5 class="title">F: Xpert Ultra and Xpert MTB/RIF testing in urine for genitourinary tuberculosis</h5> <section id="CD012768-sec-0117"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0118"> <p><b>Culture reference standard</b></p> <p>In urine, Xpert Ultra sensitivity and specificity against culture were 100% (74 to 100) and 100% (74 to 100), (1 study; 24 participants, 12 (50%) with tuberculosis) (<a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>); <a href="#CD012768-fig-0015">Figure 15</a>. </p> <div class="figure" id="CD012768-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in urine by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in urine by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> </section> <section id="CD012768-sec-0119"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in urine against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0120"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0121"> <p><b>Culture reference standard</b></p> <p>Fifteen studies evaluated Xpert MTB/RIF in urine against culture (<a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0013" title="ChenC , YangCG , GaoX , LuZZ , TangFX , ChengJ , et al. Community-based active case finding for tuberculosis in rural western China: a cross-sectional study. International Journal of Tuberculosis and Lung Disease2017;21(11):1134-9. ">Chen 2019</a>; <a href="./references#CD012768-bbs2-0027" title="HanifSN , EldeenHS , AhmadS , MokaddasE . GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease2011;15(9):1274-5. ">Hanif 2011</a>; <a href="./references#CD012768-bbs2-0029" title="HillemannD , Rusch-GerdesS , BoehmeC , RichterE . Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology2011;49(4):1202-5. ">Hillemann 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Xpert MTB/RIF sensitivity ranged from 0% to 100% (sensitivity of 0% was reported by <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a> that had only one culture positive, which was Xpert negative) and specificity from 33% to 100% (<a href="#CD012768-fig-0015">Figure 15</a>). Six studies (<a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>) did not contribute data to the meta‐analysis because either sensitivity or specificity was not estimable. </p> <p>In urine, Xpert MTB/RIF pooled sensitivity and specificity against culture were 85.9% (71.4 to 94.3) and 98.1% (93.1 to 99.7) (9 studies; 943 participants, 72 (7.6%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>. </p> </section> <section id="CD012768-sec-0122"> <p><b>Composite reference standard</b></p> <p>In urine, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (1 to 91) and 100% (92 to 100) (<a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>), and 41% (33 to 50 ) and 100% (99 to 100) (<a href="./references#CD012768-bbs2-0013" title="ChenC , YangCG , GaoX , LuZZ , TangFX , ChengJ , et al. Community-based active case finding for tuberculosis in rural western China: a cross-sectional study. International Journal of Tuberculosis and Lung Disease2017;21(11):1134-9. ">Chen 2019</a>) (2 studies; 463 participants); <a href="#CD012768-fig-0015">Figure 15</a>. </p> </section> </section> </section> <section id="CD012768-sec-0123"> <h5 class="title">G: Xpert Ultra and Xpert MTB/RIF testing in bone or joint aspirate for bone or joint tuberculosis </h5> <section id="CD012768-sec-0124"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0125"> <p><b>Culture reference standard</b></p> <p>In bone or joint aspirate, Xpert Ultra sensitivity and specificity against culture were 88% (47 to 100) (specificity was not estimable) (<a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a>), and 96% (87 to 100) and 97% (85 to 100) (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>) (2 studies; 94 participants, 60 (63.8%) with tuberculosis); <a href="./appendices#CD012768-sec-0257">Appendix 9</a>. </p> </section> <section id="CD012768-sec-0126"> <p><b>Composite reference standard</b></p> <p>In bone or joint aspirate, Xpert Ultra sensitivity and specificity against a composite reference standard were 96% (91 to 99) and 97% (85 to 100), (1 study; 145 participants; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>); <a href="./appendices#CD012768-sec-0257">Appendix 9</a>. </p> </section> </section> <section id="CD012768-sec-0127"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0128"> <p><b>Culture reference standard</b></p> <p>Twelve studies evaluated Xpert MTB/RIF in bone or joint fluid for culture (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0040" title="NatarajG , KanadeS , MehtaP . Xpert((R)) MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India. International Journal of Tuberculosis and Lung Disease2016;20(7):890-4. ">Nataraj 2016</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>). Xpert MTB/RIF sensitivity ranged from 96% to 100% and specificity ranged from 53% to 100%; <a href="./appendices#CD012768-sec-0257">Appendix 9</a>. </p> <p>In bone or joint aspirate, Xpert MTB/RIF pooled sensitivity and specificity against culture were 97.9% (93.1 to 99.6) and 97.4% (80.2 to 100.0); (6 studies; 471 participants, 110 (23.4%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a> </p> </section> <section id="CD012768-sec-0129"> <p><b>Composite reference standard</b></p> <p>In bone or joint aspirate, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 82% (69 to 91) and 100% (69 to 100) (<a href="./references#CD012768-bbs2-0026" title="GuY , WangG , DongW , LiY , MaY , ShangY , et al. Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases2015;36:27-30. ">Gu 2015</a>), and 94% (87 to 97) and 100% (90 to 100) (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>); (2 studies; 205 participants); <a href="./appendices#CD012768-sec-0257">Appendix 9</a>. </p> </section> </section> </section> <section id="CD012768-sec-0130"> <h5 class="title">H: Xpert Ultra and Xpert MTB/RIF testing in tissue for bone or joint tuberculosis</h5> <section id="CD012768-sec-0131"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0132"> <p><b>Culture reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in tissue for bone or joint tuberculosis against culture. </p> </section> <section id="CD012768-sec-0133"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in tissue for bone or joint tuberculosis against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0134"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0135"> <p><b>Culture reference standard</b></p> <p>Three studies evaluated Xpert MTB/RIF in bone or joint tissue against culture. Xpert MTB/RIF sensitivity ranged from 50% to 100% and specificity ranged from 94% to 100% (<a href="./appendices#CD012768-sec-0257">Appendix 9</a>). </p> <p>In bone or joint tissue, Xpert MTB/RIF sensitivity and specificity (95% CI) against culture were 100% (3 to 100) and 100% (48 to 100) (<a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>), 100% (3 to 100) and 100% (40 to 100) (<a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>), and 50% (1 to 99) and 94% (71 to 100) (<a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>); (3 studies; 30 participants, 4 (13.3%) with tuberculosis). </p> </section> <section id="CD012768-sec-0136"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert MTB/RIF in tissue for bone or joint tuberculosis against a composite reference standard. </p> </section> </section> </section> <section id="CD012768-sec-0137"> <h5 class="title">J: Xpert Ultra and Xpert MTB/RIF testing in peritoneal fluid for peritoneal tuberculosis</h5> <section id="CD012768-sec-0138"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0139"> <p><b>Culture reference standard</b></p> <p>In peritoneal fluid, Xpert Ultra sensitivity against culture was 33% (1 to 91) and specificity was not estimable (<a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018)</a> (1 study; 3 participants); <a href="./appendices#CD012768-sec-0258">Appendix 10</a>. </p> </section> <section id="CD012768-sec-0140"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in peritoneal fluid against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0141"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0142"> <p><b>Culture reference standard</b></p> <p>Seventeen studies evaluated Xpert MTB/RIF in peritoneal fluid against culture (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0032" title="LiY , PangY , ZhangT , XianX , WangX , YangJ , et al. Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology2017;66(7):910-4. ">Li 2017</a>; <a href="./references#CD012768-bbs2-0036" title="MalbrunyB , Le MarrecG , CourageuxK , LeclercqR , CattoirV . Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease2011;15(4):553-5. ">Malbruny 2011</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0049" title="RufaiSB , SinghS , SinghA , KumarP , SinghJ , VishalA . Performance of Xpert MTB/RIF on ascitic fluid samples for detection of abdominal tuberculosis. Journal of Laboratory Physicians2017;9(1):47-52. ">Rufai 2017a</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0053" title="ScottLE , BeylisN , NicolM , NkunaG , MolapoS , BerrieL , et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology2014;52(6):1818-23. ">Scott 2014</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Four studies (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0030" title="IramS , ZeenatA , HussainS , Wasim YusufN , AslamM . Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - report from a developing country. Pakistan Journal of Medical Sciences2015;31(1):105-10. ">Iram 2015</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>) did not contribute data to the meta‐analysis because sensitivity was not estimable. In individual studies, Xpert MTB/RIF sensitivity ranged from 33% to 100% and specificity ranged from 90% to 100%; <a href="#CD012768-fig-0016">Figure 16</a>; <a href="./appendices#CD012768-sec-0258">Appendix 10</a>. </p> <div class="figure" id="CD012768-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Forest plots of Xpert MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> <p>In peritoneal fluid, Xpert MTB/RIF pooled sensitivity and specificity against culture were 59.1% (42.1 to 76.2) and 97.6% (95.4 to 98.9), (13 studies; 580 participants, 94 (16.2%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>. </p> </section> <section id="CD012768-sec-0143"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert MTB/RIF in peritoneal fluid against a composite reference standard. </p> </section> </section> </section> <section id="CD012768-sec-0144"> <h5 class="title">K: Xpert Ultra and Xpert MTB/RIF testing in tissue for peritoneal tuberculosis</h5> <section id="CD012768-sec-0145"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0146"> <p><b>Culture reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in peritoneal tissue against culture. </p> </section> <section id="CD012768-sec-0147"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in peritoneal tissue against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0148"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0149"> <p><b>Culture reference standard</b></p> <p>In peritoneal tissue, Xpert MTB/RIF sensitivity and specificity against culture were 50% (7 to 93) and 92% (73 to 99) (1 study; 28 participants; <a href="./references#CD012768-bbs2-0008" title="BeraC , MichaelJS , BuradD , ShirlySB , GibikoteS , RamakrishnaB , et al. Tissue XpertTM MTB/Rif assay is of limited use in diagnosing peritoneal tuberculosis in patients with exudative ascites. Indian Journal of Gastroenterology2015;34(5):395-8. ">Bera 2015</a>); <a href="./appendices#CD012768-sec-0258">Appendix 10</a>. </p> </section> <section id="CD012768-sec-0150"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert MTB/RIF in peritoneal tissue against a composite reference standard. </p> </section> </section> </section> <section id="CD012768-sec-0151"> <h5 class="title">L: Xpert Ultra and Xpert MTB/RIF testing in pericardial fluid for pericardial tuberculosis</h5> <section id="CD012768-sec-0152"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0153"> <p><b>Culture reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in pericardial fluid against culture. </p> </section> <section id="CD012768-sec-0154"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in pericardial fluid against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0155"> <h6 class="title">Xpert MTB/RIF</h6> <section id="CD012768-sec-0156"> <p><b>Culture reference standard</b></p> <p>Fourteen studies evaluated Xpert MTB/RIF in pericardial fluid against culture (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0043" title="PandieS , PeterJG , KerbelkerZS , MeldauR , TheronG , GovenderU , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Medicine2014;12:101. [DOI: 10.1186/1741-7015-12-101]">Pandie 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0054" title="SharmaSK , KohliM , ChaubeyJ , YadavRN , SharmaR , SinghBK , et al. Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal2014;44(4):1090-3. ">Sharma 2014</a>; <a href="./references#CD012768-bbs2-0059" title="SuzanaS , NinanMM , GowriM , VenkateshK , RupaliP , MichaelJS . Xpert MTB/Rif for the diagnosis of extrapulmonary tuberculosis - an experience from a tertiary care centre in South India. Tropical Medicine &amp; International Health2016;21(3):385-92. ">Suzana 2016</a>; <a href="./references#CD012768-bbs2-0062" title="UllahI , JavaidA , MasudH , AliM , BasitA , AhmadW , et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology2017;66(4):412-8. ">Ullah 2017</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0068" title="ZekaAN , TasbakanS , CavusogluC . Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Microbiology2011;49(12):4138-41. ">Zeka 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). Xpert MTB/RIF sensitivity ranged from 0% to 100% and specificity ranged from 69% to 100% (Appendix 10). Nine studies (<a href="./references#CD012768-bbs2-0003" title="Al-AteahSM , Al-DowaidiMM , El-KhizziNA . Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Medical Journal2012;33(10):1100-5. ">Al‐Ateah 2012</a>; <a href="./references#CD012768-bbs2-0010" title="BlaichA , FreiR . Performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting. Journal of Clinical Microbiology2014;52(2):706. ">Blaich 2014</a>; <a href="./references#CD012768-bbs2-0011" title="CausseM , RuizP , Gutierrez-ArocaJB , CasalM . Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology2011;49(8):3065-7. ">Causse 2011</a>; <a href="./references#CD012768-bbs2-0031" title="KimYW , KwakN , SeongMW , KimEC , YooCG , KimYW , et al. Accuracy of the Xpert(R) MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease2015;19(1):81-6. ">Kim 2015a</a>; <a href="./references#CD012768-bbs2-0042" title="OzkutukN , SurucuogluS . Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting [Orta Prevalanslı Bölgede Akciğer ve Akciğer DışıTüberküloz Tanısında Xpert MTB/RIF Testinin Değerlendirilmesi]. Mikrobiyoloji Bulteni2014;48(2):223-32. ">Ozkutuk 2014</a>; <a href="./references#CD012768-bbs2-0045" title="PeñataA , SalazarR , CastanoT , BustamanteJ , OspinaS . Molecular diagnosis of extrapulmonary tuberculosis and sensitivity to rifampicin with an automated real-time method [Diagnóstico molecular de tuberculosis extrapulmonary sensibilidad a rifampicina con un método automatizado en tiempo real]. Biomedica2016;36(Suppl 1):78-89. ">Peñata 2016</a>; <a href="./references#CD012768-bbs2-0051" title="SafianowskaA , WalkiewiczR , Nejman-GryzP , Grubek-JaworskaH . Two selected commercially based nucleic acid amplification tests for the diagnosis of tuberculosis. Pneumonologia Alergologia Polska2012;80(1):6-12. ">Safianowska 2012</a>; <a href="./references#CD012768-bbs2-0063" title="VadwaiV , BoehmeC , NabetaP , ShettyA , AllandD , RodriguesC . Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?Journal of Clinical Microbiology2011;49(7):2540-5. ">Vadwai 2011</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>) did not contribute data to the meta‐analysis because either sensitivity or specificity was not estimable. </p> <p>In pericardial fluid, Xpert MTB/RIF pooled sensitivity and specificity against culture were 61.4% (32.4 to 82.4) and 89.7% (74.9 to 99.0), (5 studies; 181 participants, 57 (31.5%) with tuberculosis); <a href="#CD012768-tbl-0006">Table 2</a>; <a href="./appendices#CD012768-sec-0258">Appendix 10</a>. </p> </section> <section id="CD012768-sec-0157"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert MTB/RIF in pericardial fluid against a composite reference standard. </p> </section> </section> </section> <section id="CD012768-sec-0158"> <h5 class="title">M: Xpert Ultra and Xpert MTB/RIF testing in blood for disseminated tuberculosis</h5> <section id="CD012768-sec-0159"> <h6 class="title">Xpert Ultra</h6> <section id="CD012768-sec-0160"> <p><b>Culture reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in blood against culture.</p> </section> <section id="CD012768-sec-0161"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert Ultra in blood against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0162"> <h6 class="title">Xpert MTB/RIF</h6> <p><i>Culture reference standard</i> </p> <p>Two studies evaluated Xpert MTB/RIF in blood against culture (<a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013</a>; <a href="./references#CD012768-bbs2-0069" title="ZmakL , JankovicM , JankovicVK . Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology2013;2(3):179-82. ">Zmak 2013</a>). However, only one of these studies reported tuberculosis culture‐positives. Xpert MTB/RIF sensitivity and specificity against culture were 56% (21 to 86) and 94% (85 to 98) (1 study; 74 participants, 9 (12.2%) with tuberculosis (<a href="./references#CD012768-bbs2-0023" title="FeaseyNA , BanadaPP , HowsonW , SloanDJ , MdoloA , BoehmeC , et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of Clinical Microbiology2013;51(7):2311-6. ">Feasey 2013)</a>); <a href="./appendices#CD012768-sec-0258">Appendix 10</a>. </p> <section id="CD012768-sec-0163"> <p><b>Composite reference standard</b></p> <p>We did not identify any studies that evaluated Xpert MTB/RIF in blood against a composite reference standard. </p> </section> </section> <section id="CD012768-sec-0164"> <h6 class="title">Nontuberculous mycobacteria</h6> <p>For Xpert Ultra, two studies provided data on a variety of NTMs that grew from the specimens tested to look for evidence of cross‐reactivity. <a href="./references#CD012768-bbs2-0020" title="DonovanJ , Anh ThuDD , PhuNH , DungVT , QuangTP , NghiaHDT , et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Disease2020;20:299-307. ">Donovan 2020</a> assessed Xpert Ultra specificity in CSF from more than 100 participants with nontuberculous meningitis and found zero positive Xpert Ultra results in those with a probable or possible diagnosis of tuberculous meningitis and in any participant with a confirmed diagnosis of nontuberculous meningitis. <a href="./references#CD012768-bbs2-0046" title="Perez-RiscoD , Rodriguez-TemporalD , Valledor-SanchezI , AlcaideF . Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. Journal of Clinical Microbiology2018;56(9):pii: e00659-18. ">Perez‐Risco 2018</a> assessed Xpert Ultra specificity using 20 culture‐positive NTM specimens (covering a total of 18 species) and found that Xpert Ultra was negative for all specimens. </p> <p>For Xpert MTB/RIF, we previously reported that in 10 studies involving 6975 specimens with 141 NTMs, Xpert MTB/RIF was negative in all specimens (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> </section> <section id="CD012768-sec-0165"> <h4 class="title">II. Detection of rifampicin resistance</h4> <section id="CD012768-sec-0166"> <h5 class="title">Xpert Ultra and Xpert MTB/RIF testing for rifampicin resistance</h5> <section id="CD012768-sec-0167"> <h6 class="title">Xpert Ultra</h6> <p>Five studies evaluated Xpert Ultra for detection of rifampicin resistance. Xpert Ultra sensitivity estimates varied from 50% to 100%; specificity varied from 93% to 100%; <a href="#CD012768-fig-0017">Figure 17</a>. One study reported zero participants with rifampicin resistance and thus sensitivity was not estimable (<a href="./references#CD012768-bbs2-0014" title="ChinJH , MusubireAK , MorganN , PellinenJ , GrossmanS , BhattJM , et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology2019;57(6):pii: e00249-19. ">Chin 2019</a>). Four studies contributed data to the bivariate meta‐analysis (<a href="./references#CD012768-bbs2-0058" title="SunQ , WangS , DongW , JiangG , HuoF , MaY , et al. Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection 2019 August;79(2):153-8. ">Sun 2019</a>; <a href="./references#CD012768-bbs2-0065" title="WangG , WangS , JiangG , YangX , HuangM , HuoF , et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. Journal of Infection2019;78(4):311-6. ">Wang 2019</a>; <a href="./references#CD012768-bbs2-0066" title="WangG , WangS , YangX , SunQ , JiangG , HuangM , et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest2020;157(2):268-75. ">Wang 2020</a>; <a href="./references#CD012768-bbs2-0067" title="WuX , TanG , GaoR , YaoL , BiD , GuoY , et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. International Journal of Infectious Diseases2019;81:91-6. ">Wu 2019</a>). Xpert Ultra pooled sensitivity and specificity were 100.0% (95.1 to 100.0) and 100.0% (99.0 to 100.0), (4 studies; 129 participants, 24 (18.6%) with rifampicin resistance); <a href="#CD012768-tbl-0006">Table 2</a>. </p> <div class="figure" id="CD012768-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> </div> </section> <section id="CD012768-sec-0168"> <h6 class="title">Xpert MTB/RIF</h6> <p>Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9 to 98.8) and 99.1% (98.0 to 99.7) (19 studies; 970 participants, 148 (15.3%) with rifampicin resistance); <a href="#CD012768-tbl-0006">Table 2</a>; <a href="#CD012768-fig-0017">Figure 17</a>. </p> </section> <section id="CD012768-sec-0169"> <h6 class="title">Indeterminate Xpert Ultra and Xpert MTB/RIF results for rifampicin resistance</h6> <section id="CD012768-sec-0170"> <p><b>Xpert Ultra</b></p> <p>Of the total 391 tests positive by Xpert Ultra, the proportion of indeterminate Xpert Ultra results for RIF resistance was 36.1%. All of these indeterminate results were Xpert Ultra trace‐positive. </p> </section> <section id="CD012768-sec-0171"> <p><b>Xpert MTB/RIF</b></p> <p>We previously reported that for rifampicin resistance testing, of 1003 tests performed, the pooled proportion of indeterminate Xpert MTB/RIF results was 2.6% (95% CrI 1.4 to 4.3) (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012768-sec-0172" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012768-sec-0172"></div> <section id="CD012768-sec-0173"> <h3 class="title" id="CD012768-sec-0173">Summary of main results</h3> <p>This systematic review update summarizes the current literature and includes 69 unique studies on the accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin resistance. We identified 11 studies evaluating Xpert Ultra, an increase of 10 new studies since the original review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). Unlike the original review, we limited inclusion to adults aged 15 years and older. We also include a composite reference standard in addition to a culture reference standard, and have stratified all analyses by type of reference standard. Major findings from our review include the following. </p> <p> <ul id="CD012768-list-0017"> <li> <p>Xpert Ultra sensitivity for tuberculosis varied across different types of specimens (from 75.0% in pleural fluid to 89.4% in cerebrospinal fluid); <a href="#CD012768-tbl-0006">Table 2</a> </p> </li> <li> <p>Xpert MTB/RIF sensitivity for tuberculosis varied across different types of specimens (from 49.5% in pleural fluid to 97.9% in bone or joint aspirate); <a href="#CD012768-tbl-0006">Table 2</a> </p> </li> <li> <p>Xpert MTB/RIF specificity in cerebrospinal fluid, pleural fluid, urine, bone or joint aspirate, and peritoneal fluid was ≥ 96.9%, against culture; overall, Xpert Ultra specificities were lower than those of Xpert MTB/RIF against culture, but against a composite reference standard results for both index tests were similar; <a href="#CD012768-tbl-0006">Table 2</a> </p> </li> <li> <p>In cerebrospinal fluid, Xpert Ultra sensitivity and specificity were 89.4% (79.1 to 95.6) and 91.2% (83.2 to 95.7) against culture; <a href="./full#CD012768-tbl-0001">summary of findings Table 1</a>. </p> </li> <li> <p>In cerebrospinal fluid, Xpert MTB/RIF sensitivity and specificity were 71.1% (62.8 to 79.1) and 96.9% (95.4 to 98.0) against culture; <a href="./full#CD012768-tbl-0001">summary of findings Table 1</a> </p> </li> <li> <p>In pleural fluid, Xpert Ultra sensitivity and specificity were 75.0% (58.0 to 86.4) and 87.0% (63.1 to 97.9) against culture; <a href="./full#CD012768-tbl-0002">summary of findings Table 2</a> </p> </li> <li> <p>In pleural fluid, Xpert MTB/RIF sensitivity and specificity were 49.5% (39.8 to 59.9) and 98.9% (97.6 to 99.7) against culture; <a href="./full#CD012768-tbl-0002">summary of findings Table 2</a> </p> </li> <li> <p>In lymph node aspirate, Xpert Ultra sensitivity and specificity were 70% (51 to 85) and 100% (92 to 100) against a composite reference standard (1 study); <a href="./full#CD012768-tbl-0003">summary of findings Table 3</a> </p> </li> <li> <p>In lymph node aspirate, Xpert MTB/RIF sensitivity and specificity were 81.6% (61.9 to 93.3) and 96.4% (91.3 to 98.6) against a composite reference standard; <a href="./full#CD012768-tbl-0003">summary of findings Table 3</a> </p> </li> <li> <p>For rifampicin resistance, Xpert Ultra sensitivity and specificity were 100.0% (95.1 to 100.0) and 100.0% (99.0 to 100.0); <a href="./full#CD012768-tbl-0004">summary of findings Table 4</a> </p> </li> <li> <p>For rifampicin resistance, Xpert MTB/RIF sensitivity and specificity were 96.5% (91.9 to 98.8) and 99.1% (98.0 to 99.7); <a href="./full#CD012768-tbl-0004">summary of findings Table 4</a> </p> </li> </ul> </p> <section id="CD012768-sec-0174"> <h4 class="title">Xpert Ultra and Xpert MTB/RIF testing in cerebrospinal fluid</h4> <p>(<a href="./full#CD012768-tbl-0001">summary of findings Table 1</a>) </p> <section id="CD012768-sec-0175"> <h5 class="title">Xpert Ultra</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have tuberculosis meningitis on culture, 168 would be Xpert Ultra‐positive: of these, 79 (47%) would not have tuberculosis (false‐positives); and 832 would be Xpert Ultra‐negative: of these, 11 (1%) would have tuberculosis (false‐negatives). </p> </section> <section id="CD012768-sec-0176"> <h5 class="title">Xpert MTB/RIF</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have tuberculosis meningitis on culture, 99 would be Xpert MTB/RIF‐positive: of these, 28 (28%) would not have tuberculosis (false‐positives); and 901 would be Xpert MTB/RIF‐negative: of these, 29 (3%) would have tuberculosis (false‐negatives). </p> <p>Rapid diagnosis of tuberculous meningitis is critical so that lifesaving treatment can be started promptly. Around 50% of those affected die or experience disabling consequences (<a href="./references#CD012768-bbs2-0348" title="ThwaitesGE , Van ToornR , SchoemanJ . Tuberculous meningitis: more questions, still too few answers. Lancet Neurology2013;12(10):999-1010.">Thwaites 2013</a>). Xpert Ultra was designed to improve tuberculosis detection, in particular in people with paucibacillary disease. The limit of detection for MTB is lower with Xpert Ultra (16 bacterial colony‐forming units (cfu) per mL) than with Xpert MTB/RIF (131 cfu per mL) (<a href="./references#CD012768-bbs2-0270" title="ChakravortyS , SimmonsAM , RownekiM , ParmarH , CaoY , RyanJ , et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. MBio2017;8(4):e00812-17. [DOI: 10.1128/mBio.00812-17]">Chakravorty 2017</a>). In studies that compared Xpert Ultra and Xpert MTB/RIF in the same participants, we found Xpert Ultra to have higher pooled sensitivity (89.0%) than Xpert MTB/RIF (62.2%), and lower pooled specificity (91.0%) than Xpert MTB/RIF (96.8%) for tuberculous meningitis. In addition, in subgroup analyses we found slightly higher Xpert Ultra accuracy in studies that concentrated the cerebrospinal fluid (CSF): pooled sensitivity of 90.5% in concentrated specimens versus 88.4% in unconcentrated specimens; and pooled specificity of 91.9% in concentrated specimens versus 88.6% in unconcentrated specimens. We note that subgroup findings should be interpreted with caution, as there were only three studies and a small number of tuberculous meningitis cases included. The Tuberculous Meningitis International Research Consortium has recommended increasing the volume of CSF collected for diagnosis followed by centrifugation as a way of improving Xpert MTB/RIF assay sensitivity (<a href="./references#CD012768-bbs2-0257" title="BahrNC , MaraisS , CawsM , Van CrevelR , WilkinsonRJ , TyagiJS , et al, Tuberculous Meningitis International Research Consortium. GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last. Clinical Infectious Diseases2016;62(9):1133-5.">Bahr 2016</a>); however, we did not have sufficient data to investigate CSF collection volume. Increased Xpert MTB/RIF sensitivity in HIV‐positive people compared with HIV‐negative people has been reported, with the increased bacterial burden in tuberculosis and HIV co‐infection proposed as the reason (<a href="./references#CD012768-bbs2-0044" title="PatelVB , TheronG , LendersL , MatinyenaB , ConnollyC , SinghR , et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLOS Medicine2013;10(10):e1001536. [DOI: 10.1371/journal.pmed.1001536]">Patel 2013</a>). We had limited data to investigate this for Xpert Ultra as we identified only two studies in HIV‐positive people, with sensitivities of 90% (<a href="./references#CD012768-bbs2-0007" title="BahrNC , NuwagiraE , EvansEE , CresswellFV , BystromPV , ByamukamaA , et al. Diagnostic accuracy of Xpert MTB/Rif Ultra for TB meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases2017;18(1):68-75. ">Bahr 2017</a>) and 89% (<a href="./references#CD012768-bbs2-0017" title="CresswellFV , TugumeL , BahrNC , KwizeraR , BangdiwalaAS , MusubireAK , et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Disease2020;20(3):308-17. ">Cresswell 2020</a>). </p> </section> </section> <section id="CD012768-sec-0177"> <h4 class="title">Xpert Ultra and Xpert MTB/RIF testing in pleural fluid</h4> <p>(<a href="./full#CD012768-tbl-0002">summary of findings Table 2</a>) </p> <section id="CD012768-sec-0178"> <h5 class="title">Xpert Ultra</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have pleural tuberculosis on culture, 192 would be Xpert Ultra‐positive: of these, 117 (61%) would not have tuberculosis (false‐positives); and 808 would be Xpert Ultra‐negative: of these, 25 (3%) would have tuberculosis (false‐negatives). </p> </section> <section id="CD012768-sec-0179"> <h5 class="title">Xpert MTB/RIF</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have pleural tuberculosis on culture, 60 would be Xpert MTB/RIF‐positive: of these, 10 (17%) would not have tuberculosis (false‐positives); and 940 would be Xpert MTB/RIF‐negative: of these, 50 (5%) would have tuberculosis (false‐negatives). </p> <p>With the bivariate model, we found Xpert Ultra to have higher pooled sensitivity (75.0%) than Xpert MTB/RIF (49.6%) and lower pooled specificity (87.0%) than Xpert MTB/RIF (98.7%) in pleural fluid against a culture reference standard, between‐study comparison. Based on the latent class meta‐analysis model, Xpert Ultra pooled sensitivity was comparable (76.0%) and specificity higher (99.5%) than what was obtained when culture was treated as having perfect accuracy. Xpert Ultra pooled sensitivity in pleural fluid was lower than that of CSF. One reason for the lower sensitivity of Xpert Ultra in pleural fluid could be the paucibacillary nature of pleural tuberculosis. Other possible reasons are contamination of blood or the presence of certain polymerase chain reaction (PCR) inhibitors in the pleural fluid (<a href="./references#CD012768-bbs2-0315" title="PaiM , FloresLL , HubbardA , RileyLW , Colford JM Jr. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infectious Diseases2004;4:6. [DOI: 10.1186/1471-2334-4-6]">Pai 2004</a>; <a href="./references#CD012768-bbs2-0371" title="WoodsGL . Molecular techniques in mycobacterial detection. In: Archives of Pathology &amp; Laboratory Medicine. Vol. 125. Geneva: World Health Organization, 2001:122-6.">Woods 2001</a>). However, Theron and colleagues found that extrapulmonary specimens showed less evidence of PCR inhibition than pulmonary specimens, with bacterial load being more important for a positive Xpert MTB/RIF result (<a href="./references#CD012768-bbs2-0239" title="TheronG , PeterJ , CalligaroG , MeldauR , HanrahanC , KhalfeyH , et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Scientific Reports2014;4:5658. [DOI: 10.1038/srep05658]">Theron 2014b</a>). Given that false‐negative results were common (low sensitivity), a negative Xpert Ultra or Xpert MTB/RIF result may not be relied on to exclude tuberculosis. </p> </section> </section> <section id="CD012768-sec-0180"> <h4 class="title">Xpert Ultra testing in lymph node aspirates</h4> <section id="CD012768-sec-0181"> <h5 class="title">Xpert Ultra</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have lymph node tuberculosis verified by a composite reference standard, 70 would be Xpert Ultra‐positive: of these, 0 (0%) would not have tuberculosis (false‐positives); and 930 would be Xpert Ultra‐negative: of these, 30 (3%) would have tuberculosis (false‐negatives). </p> </section> <section id="CD012768-sec-0182"> <h5 class="title">Xpert MTB/RIF</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have lymph node tuberculosis verified by a composite reference standard, 118 would be Xpert MTB/RIF‐positive: of these 37 (31%) would not have tuberculosis (false‐positives); and 882 would be Xpert MTB/RIF‐negative: of these 19 (2%) would have tuberculosis (false‐negatives). </p> <p>Regarding Xpert testing for lymph node aspirate, it important to point out that although tissue biopsy provides material for histological examination which may be of substantial diagnostic value, a fluid specimen may be collected more easily. In addition, fine‐needle aspiration of lymph nodes is well suited for use in resource‐limited settings because the procedure is simple, easy to learn, minimally invasive, and inexpensive (<a href="./references#CD012768-bbs2-0374" title="WrightCA , HesselingAC , BamfordC , BurgessSM , WarrenR , MaraisBJ . Fine-needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy?International Journal of Tuberculosis and Lung Disease2009;13(11):1373-9.">Wright 2009b</a>). Thus clinicians may want to consider fine‐needle aspiration of lymph nodes before surgical biopsy. </p> <p>In our review, using a standard bivariate meta‐analysis model, Xpert MTB/RIF pooled specificity (defined by culture) in lymph node aspirate was 86.0%, whereas with a composite reference standard pooled specificity increased to 95.9%. Using a latent class meta‐analysis model with informative priors, Xpert MTB/RIF pooled specificity increased to 99.5%. In previous meta‐analyses, Xpert MTB/RIF specificity for lymph node tuberculosis (aspirate and tissue) against culture as a reference standard was 94% (<a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a>), 93% (<a href="./references#CD012768-bbs2-0307" title="Maynard-SmithL , LarkeN , PetersJA , LawnSD . Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infectious Diseases2014;14:709. [DOI: 10.1186/s12879-014-0709-7]">Maynard‐Smith 2014</a>), and 92% (<a href="./references#CD012768-bbs2-0319" title="PenzE , BoffaJ , RobertsDJ , FisherD , CooperR , RonksleyPE , et al. Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. International Journal of Tuberculosis and Lung Disease2015;19(3):278-84.">Penz 2015</a>). See <a href="#CD012768-tbl-0012">Table 8</a>. Using a composite reference standard (defined by the primary study authors), <a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a> found increased Xpert MTB/RIF specificity of 99% for lymph node tuberculosis (5 studies, 728 specimens). Thus, it appears that accuracy results depend in part on the choice of reference standard. Regarding the use of a composite reference standard, owing to differing definitions and difficulty in interpreting them, there is a risk of bias (<a href="./references#CD012768-bbs2-0328" title="SchillerI , Van SmedenM , HadguA , LibmanM , ReitsmaJB , DendukuriN . Bias due to composite reference standards in diagnostic accuracy studies. Statistics in Medicine2016;35(9):1454-70.">Schiller 2016</a>) (see section <a href="#CD012768-sec-0186">Strengths and weaknesses of the review</a>). </p> <div class="table" id="CD012768-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Systematic reviews of Xpert MTB/RIF and Xpert Ultra for extrapulmonary tuberculosis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Systematic review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Search period</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (total number of extrapulmonary specimens)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Forms of extrapulmonary TB or types of specimens</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Accuracy against culture reference standard</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Tuberculous meningitis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pleural tuberculosis (pleural fluid)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymph node tuberculosis</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0271" title="ChangK , LuW , WangJ , ZhangK , JiaS , LiF , et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection2012;64(6):580-8.">Chang 2012</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 1 October 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1058)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple forms combined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 15</p> <p>October 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (4461)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 81%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 46%; specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 83%; specificity 94%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0307" title="Maynard-SmithL , LarkeN , PetersJA , LawnSD . Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infectious Diseases2014;14:709. [DOI: 10.1186/s12879-014-0709-7]">Maynard‐Smith 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 November 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (6026)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF, other forms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median sensitivity 85% (IQR 75% to 100%); median specificity 100% (IQR 98% to 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 34%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 96%; specificity 93%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0319" title="PenzE , BoffaJ , RobertsDJ , FisherD , CooperR , RonksleyPE , et al. Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. International Journal of Tuberculosis and Lung Disease2015;19(3):278-84.">Penz 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 15 August 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (9523)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF, other forms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 69%; specificity 97%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 37%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 87%; specificity 92%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0335" title="SehgalIS , DhooriaS , AggarwalAN , BeheraD , AgarwalR . Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: systematic review and meta-analysis. Journal of Clinical Microbiology2016;54(4):1133-6.">Sehgal 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 31 August 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (2486)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 51%;</p> <p>specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0303" title="LiS , LiuB , PengM , ChenM , YinW , TangH , et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLOS One2017;12(7):e0180725. [DOI: 10.1371/journal.pone.0180725]">Li Y 2017</a><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 20 June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple forms combined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0291" title="GuptaR , TalwarP , TalwarP , KhuranaS , KushwahaS , JalanN , et al. Diagnostic accuracy of nucleic acid amplification based assays for tuberculous meningitis: a meta-analysis. Journal of Infection2018;77(4):302-13.">Gupta 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 25 March 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (8977)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 57%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0322" title="PormohammadA , NasiriMJ , McHughTD , RiahiSM , BahrNC . A systematic review and meta-analysis of the diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis. Journal of Clinical Microbiology2019;57(6):e01113-18.">Pormohammad 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upto 11 Nov 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 61%; specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0375" title="YuG , ZhongF , YeB , XuX , ChenD , ShenY . Diagnostic accuracy of the Xpert MTB/RIF assay for lymph node tuberculosis: a systematic review and meta-analysis. BioMed Research International2019;2019:4878240.">Yu 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 July 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21(1629)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 84%; specificity: 91%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012768-bbs2-0376" title="ZhangM , XueM , HeJQ . Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases2020;90:35-45.">Zhang 2020</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 20 May 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1500)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple specimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; CSF: cerebrospinal fluid: IQR: interquartile range; TB: tuberculosis. </p> <p><sup>a</sup>For all forms of extrapulmonary tuberculosis combined, <a href="./references#CD012768-bbs2-0271" title="ChangK , LuW , WangJ , ZhangK , JiaS , LiF , et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection2012;64(6):580-8.">Chang 2012</a> reported pooled sensitivity and specificity of 80.4% (95% confidence interval (CI) 75.0 to 85.1) and 86.1% (95% CI 83.5 to 88.4), respectively.<br/><sup>b</sup>Using a composite reference standard, <a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a> found the following pooled sensitivity and specificity estimates: lymph node tuberculosis (aspirate or tissue) 81.2% (95% CI 72.4 to 87.7) and 99.1% (95% CI 94.5 to 99.9); pleural tuberculosis 21.4% (95% CI 8.8 to 33.9) and 100% (95% CI 99.4 to 100); and meningeal TB 62.8% (95% CI 47.7 to 75.8) and 98.8% (95% CI 95.7 to 100), respectively.<br/><sup>c</sup>For both pulmonary and extrapulmonary tuberculosis, review authors included 106 studies involving 52,410 specimens. For all forms of extrapulmonary tuberculosis combined, <a href="./references#CD012768-bbs2-0303" title="LiS , LiuB , PengM , ChenM , YinW , TangH , et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLOS One2017;12(7):e0180725. [DOI: 10.1371/journal.pone.0180725]">Li Y 2017</a> reported pooled sensitivity and specificity of 80% (95% CI 69 to 88) and 97% (95% CI 94 to 98), respectively.<br/><sup>d</sup><a href="./references#CD012768-bbs2-0376" title="ZhangM , XueM , HeJQ . Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases2020;90:35-45.">Zhang 2020</a> included 7 studies involving 1500 specimens. For all forms of extrapulmonary tuberculosis combined, pooled sensitivity and specificity were 85.1% (95% CI 76.7 to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), respectively. </p> <p><a href="./references#CD012768-bbs2-0340" title="ShenY , YuG , ZhongF , KongX . Diagnostic accuracy of the Xpert MTB/RIF assay for bone and joint tuberculosis: a meta-analysis. PLOS One2019;14(8):e0221427.">Shen 2019</a> provided pooled estimates for bone or joint tuberculosis. The review included 14 studies with 1884 specimens with a pooled sensitivity of 96% and specificity of 85%. </p> </div> </div> <p>We considered several reasons why the specificity of Xpert Ultra (78%) and Xpert MTB/RIF (86.0%) in lymph node aspirate against culture would be lower than in other extrapulmonary specimens. Although not always reported, studies may have included participants receiving tuberculosis treatment. We previously reported that in a sensitivity analysis limiting inclusion to studies that involved participants not receiving tuberculosis treatment, specificity increased from 86% to 89% (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). We considered the type of culture used in the included studies because liquid culture is more sensitive than solid culture (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). Most studies used liquid culture or a combination of solid and liquid culture. The single study evaluating Xpert Ultra used liquid culture. Only two of the 15 studies (13%) evaluating Xpert MTB/RIF exclusively used solid culture. Culture results may also be negative owing to inefficient specimen collection or errors in sampling, differing bacterial load, and contamination (<a href="./references#CD012768-bbs2-0374" title="WrightCA , HesselingAC , BamfordC , BurgessSM , WarrenR , MaraisBJ . Fine-needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy?International Journal of Tuberculosis and Lung Disease2009;13(11):1373-9.">Wright 2009b</a>). Negative culture results in lymph node tuberculosis have previously been reported (<a href="./references#CD012768-bbs2-0284" title="FontanillaJM , BarnesA , Von ReynCF . Current diagnosis and management of peripheral tuberculous lymphadenitis. Clinical Infectious Diseases2011;53(6):555-62.">Fontanilla 2011</a>). </p> <p>Another reason for negative culture results is that there may have been a decrease in live tuberculosis bacteria during processing with N‐acetyl‐L‐cysteine‐sodium hydroxide, which is routinely used to homogenize, decontaminate, and liquefy non‐sterile specimens, such as sputum, for mycobacterial culture (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). Harsh decontamination practices have been noted to contribute to false‐negative culture results, especially in paucibacillary specimens (<a href="./references#CD012768-bbs2-0283" title="Foundation for Innovative New Diagnsotics (FIND). Report for WHO: a multicentre non-inferiority diagnostic accuracy study of the Ultra assay compared to the Xpert MTB/RIF assay. www.finddx.org/publication/ultra-report/ (accessed 2 July 2020);(version 1.8):1-82.">FIND 2017</a>). Standards specify, "specimens collected from normally sterile sites may be placed directly into the culture medium” (<a href="./references#CD012768-bbs2-0256" title="American Thoracic Society, the Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal Respiratory and Critical Care Medicine2000;161(4 Pt 1):1376-95.">American Thoracic Society 2000</a>). CSF, pleural fluid, and lymph node aspirates are usually considered to be sterile specimens. It is our understanding that some laboratories do decontaminate sterile site specimens as a precaution against non‐sterile collection procedures. In this review, 47% of the studies reported decontaminating lymph node aspirates before culture inoculation. We did not have sufficient data to further investigate laboratory practices. </p> <p>In summary, several factors probably contributed to low Xpert MTB/RIF specificity against culture in lymph node aspirate. The 'true' specificity of Xpert MTB/RIF in lymph node aspirate is likely to be higher owing to the aforementioned reasons. Xpert MTB/RIF specificity was higher against a composite reference standard and with application of latent class analysis, similar to that found in CSF, pleural fluid, and other specimens (<a href="#CD012768-tbl-0006">Table 2</a>; <a href="#CD012768-tbl-0007">Table 3</a>). </p> <p>We investigated the prevalence of extrapulmonary tuberculosis (confirmed by culture) as a potential source of heterogeneity because changes in disease prevalence have often been found to be associated with other important changes, such as changes in the disease spectrum, which may affect diagnostic accuracy estimates (<a href="./references#CD012768-bbs2-0301" title="LeeflangMM , RutjesAW , ReitsmaJB , HooftL , BossuytPM . Variation of a test's sensitivity and specificity with disease prevalence. Canadian Medical Association Journal2013;185(11):E537-44. [DOI: 10.1503/cmaj.121286]">Leeflang 2013</a>). For Xpert MTB/RIF, for pleural fluid and lymph node aspirate, we found that pooled sensitivity was higher in settings with higher tuberculosis prevalence. In all analyses, for both Xpert Ultra (CSF) and Xpert MTB/RIF (CSF, pleural fluid, and lymph node aspirate), specificity in settings with higher tuberculosis prevalence was similar or lower than in settings with lower tuberculosis prevalence. Findings from additional analyses are available in the previous version of this review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> </section> <section id="CD012768-sec-0183"> <h4 class="title">Xpert Ultra and Xpert MTB/RIF testing for rifampicin resistance</h4> <p>(<a href="./full#CD012768-tbl-0004">summary of findings Table 4</a>) </p> <section id="CD012768-sec-0184"> <h5 class="title">Xpert Ultra</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have rifampicin resistance, 100 would be Xpert Ultra‐positive (resistant): of these, zero (0%) would not have rifampicin resistance (false‐positives); and 900 would be Xpert Ultra‐negative (susceptible): of these, zero (0%) would have rifampicin resistance. </p> </section> <section id="CD012768-sec-0185"> <h5 class="title">Xpert MTB/RIF</h5> <p>Results of these studies indicate that in theory, for a population of 1000 people where 100 have rifampicin resistance, 105 would be Xpert MTB/RIF‐positive (resistant): of these, 8 (8%) would not have rifampicin resistance; and 895 would be Xpert MTB/RIF‐negative (susceptible): of these, 3 (0.3%) would have rifampicin resistance. </p> <p>For detection of rifampicin resistance in extrapulmonary specimens, we found the sensitivity of Xpert Ultra (100%) and Xpert MTB/RIF (96.7%) and the specificity of Xpert Ultra (100%) and Xpert MTB/RIF (99.1%), to be comparable to estimates in pulmonary specimens: sensitivity (96%) and specificity (98%) (<a href="./references#CD012768-bbs2-0297" title="HorneDJ , KohliM , ZifodyaJS , SchillerI , DendukuriN , TollefsonD , et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593]">Horne 2019</a>). We caution that the results for Xpert Ultra are based on only four studies, involving 129 participants, 24 (18.6%) with rifampicin resistance. Nonetheless, these findings suggest that the use of Xpert Ultra and Xpert MTB/RIF in extrapulmonary specimens could assist in rapid diagnosis of rifampicin‐resistant tuberculosis and early initiation of treatment for multidrug‐resistant tuberculosis (MDR‐TB). </p> <p>Notably, concerns have been raised about rapid drug susceptibility testing (DST) methods, in particular automated mycobacteria growth indicator tube (MGIT) 960 for tuberculosis drug resistance using the recommended critical concentrations. As a priority, the WHO is planning to re‐evaluate the critical concentrations for rifampicin (<a href="./references#CD012768-bbs2-0360" title="World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis (WHO/CDS/TB/2018.5). who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/ (accessed 2 July 2020).">WHO 2018</a>). </p> <p>For Xpert Ultra, we found a high rate (36.1%) of indeterminate rifampicin resistance results, all owing to trace call results. This finding was expected since, for trace call results, rifampicin resistance cannot be determined. Xpert Ultra incorporates two new multi‐copy amplification targets (IS<i>6110</i> and IS<i>1081</i> ). Trace call indicates that only the multi‐copy targets were detected, and not the tuberculosis‐specific regions in the <i>rpoB</i> gene. Resistance to rifampicin has mainly been associated mainly with mutations in a limited region of the <i>rpoB</i> gene (<a href="./references#CD012768-bbs2-0346" title="TelentiA , ImbodenP , MarchesiF , LowrieD , ColeS , ColstonMJ , et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis . Lancet1993;341(8846):647-50.">Telenti 1993</a>). </p> <p>People‐important outcomes, such as mortality, are especially relevant to patients, decision‐makers, and the wider tuberculosis community. While performing this systematic review, we did not identify direct evidence of studies linking true‐positives, false‐positives, true‐negatives, and false‐negatives to people‐important outcomes when either Xpert Ultra or Xpert MTB/RIF was used to diagnose extrapulmonary tuberculosis. To our knowledge, for pulmonary tuberculosis, there have been two systematic reviews of randomized trials on the impact of the use of Xpert MTB/RIF on health outcomes. Both reviews compared the effect of Xpert MTB/RIF and smear microscopy on all‐cause mortality; Di Tanna and colleagues summarized the accuracy of Xpert MTB/RIF in an individual patient‐level data meta‐analysis (3 trials, 8143 participants) (<a href="./references#CD012768-bbs2-0280" title="Di TannaGL , KhakiAR , TheronG , McCarthyK , CoxH , MupfumiL , et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Global Health2019;7:e191-99.">Di Tanna 2019</a>) and Haraka and colleagues performed a random‐effects meta‐analysis, (5 trials, 10,409 participants (<a href="./references#CD012768-bbs2-0293" title="HarakaF , NathavitharanaRR , SchumacherSG , KakolwaM , DenkingerCM , GagneuxS , et al. Impact of diagnostic test Xpert MTB/RIF® on health outcomes for tuberculosis. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012972. [DOI: 10.1002/14651858.CD012972]">Haraka 2018</a>; <a href="./references#CD012768-bbs2-0362" title="World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection 2020 (accessed 2 July 2020).">WHO Consolidated Guidelines (Module 3) 2020</a>). In both reviews, Xpert MTB/RIF did not show a statistically significant effect on all‐cause mortality, although the direction of effect was towards mortality reduction. Insufficient power to detect mortality in randomized trials measuring the impact of diagnostic tests on patient‐important outcomes has been discussed previously as a limitation of such trials (<a href="./references#CD012768-bbs2-0280" title="Di TannaGL , KhakiAR , TheronG , McCarthyK , CoxH , MupfumiL , et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Global Health2019;7:e191-99.">Di Tanna 2019</a>; <a href="./references#CD012768-bbs2-0330" title="SchumacherSG , DenkingerCM . The impact of Xpert MTB/RIF-do we have a final answer?Lancet Global Health2019;7(2):e161-e162.">Schumacher 2019</a>). Larger sample sizes are needed to evaluate the effect of Xpert MTB/RIF on mortality, but achieving this is difficult in pragmatic situations. For example, <a href="./references#CD012768-bbs2-0330" title="SchumacherSG , DenkingerCM . The impact of Xpert MTB/RIF-do we have a final answer?Lancet Global Health2019;7(2):e161-e162.">Schumacher 2019</a> showed that a sample size of 31,000 participants would be needed if researchers were to plan a cluster‐randomized diagnostic trial using the baseline mortality and effect size demonstrated by the individual patient data from <a href="./references#CD012768-bbs2-0280" title="Di TannaGL , KhakiAR , TheronG , McCarthyK , CoxH , MupfumiL , et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Global Health2019;7:e191-99.">Di Tanna 2019</a>. </p> <p>This review represents the most comprehensive review of the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis in adults. For Xpert MTB/RIF, our previous review (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>) provides additional findings. These reviews provide evidence that may help countries to make decisions about scaling up the tests for programmatic management of tuberculosis and drug‐resistant tuberculosis. Although the information in this review will help to inform such decisions, other factors such as resource requirements and feasibility (including stable electrical power supply, temperature control, and maintenance of the cartridge modules) will also be important considerations. </p> </section> </section> </section> <section id="CD012768-sec-0186"> <h3 class="title" id="CD012768-sec-0186">Strengths and weaknesses of the review</h3> <section id="CD012768-sec-0187"> <h4 class="title">Completeness of evidence</h4> <p>This is a reasonably complete data set. We included any non‐English studies that we found from which we could obtain accuracy data. However, we acknowledge that we may have missed some studies despite the comprehensive search and our outreach to investigators. We included eight common forms of extrapulmonary tuberculosis in the review. However, for some of these forms, such as disseminated tuberculosis, data were insufficient to allow us to determine summary accuracy estimates. We did not include less common forms, such as cutaneous tuberculosis, ocular tuberculosis, female genital tuberculosis, and tuberculosis of the breast. We followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses of Diagnostic Test Accuracy (PRISMA‐DTA) (<a href="./references#CD012768-bbs2-0308" title="McInnesMD , MoherD , ThombsBD , McGrathTA , BossuytPM , et al, anad the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA statement [published correction appears in JAMA. 2019 Nov 26;322(20):2026]. JAMA2018;319(4):388-96. [DOI: 10.1001/jama.2017.19163]">McInnes 2018</a>). </p> </section> <section id="CD012768-sec-0188"> <h4 class="title">Accuracy of the reference standards used</h4> <p>In a systematic review of diagnostic test accuracy studies, the reference standard is the best available test to determine the presence or absence of the target condition. In this review, we used two reference standards: culture and a composite reference standard, both of which are known to be imperfect. While the composite reference standard is designed to have improved accuracy compared to culture alone, it may still lead to biased accuracy estimates of the index test, depending on various factors such as the accuracy of the different components; decision rules for combining them; prevalence of the target condition; and conditional dependence between the components and the index test (<a href="./references#CD012768-bbs2-0328" title="SchillerI , Van SmedenM , HadguA , LibmanM , ReitsmaJB , DendukuriN . Bias due to composite reference standards in diagnostic accuracy studies. Statistics in Medicine2016;35(9):1454-70.">Schiller 2016</a>). Conditional dependence between two imperfect tests arises when both tests make the same false‐positive or false‐negative errors more often than expected by chance (<a href="./references#CD012768-bbs2-0311" title="NaaktgeborenCA , BertensLC , Van SmedenM , De GrootJA , MoonsKG , ReitsmaJB . Value of composite reference standards in diagnostic research. BMJ2013;347:f5605.">Naaktgeboren 2013</a>). Hence, conditional dependence may arise between the index test and both reference standards we have used, as they are imperfect. As a consequence, we may over‐ or underestimate the diagnostic accuracy of the index tests. An additional challenge with including a composite reference standard is that the definition of the composite reference standard may vary across studies, making it difficult to interpret the accuracy estimates. To adjust for the imperfect accuracy of culture, we applied a latent class model when evaluating Xpert MTB/RIF sensitivity and specificity, for which there were a larger number of studies. We added parameters for the sensitivity and specificity of culture and terms for conditional dependence to adjust for the dependence between Xpert MTB/RIF and culture among disease‐positive and disease‐negative participants. In this way, we were able to improve estimation of both the pooled sensitivity and specificity of Xpert MTB/RIF, as well as between‐study variability. An adequate number of studies is needed for a sufficiently robust model to estimate these additional parameters. We therefore found that we were unable to do the same for meta‐analyses of the accuracy for Xpert Ultra owing to the small number of studies, many of which had small sample sizes resulting in zero cell counts. </p> <p>Several factors may have contributed to false‐negative culture results for the accuracy of the reference standard for lymph node aspirate in particular, including inefficient specimen collection and overly harsh decontamination. For this particular analysis, we were able to take advantage of the Bayesian estimation approach to incorporate prior information on Xpert MTB/RIF and culture specificity. This allowed us to make the best use of data from the included studies and our knowledge of the performance of Xpert MTB/RIF. We had insufficient data to apply the latent class model to data from the single study evaluating Xpert Ultra in lymph node aspirates. </p> <p>Establishing a diagnosis of extrapulmonary tuberculosis would ideally include pursuing the diagnosis of pulmonary tuberculosis as well, because participants with tuberculosis may have both pulmonary and extrapulmonary tuberculosis and the lung may be the only site where the presence of tuberculosis can be established. Because of the difficulties involved in diagnosing HIV‐associated tuberculosis, it is recommended that multiple cultures from sputum and other types of specimens be evaluated in people living with HIV (<a href="./references#CD012768-bbs2-0261" title="BjerrumS , SchillerI , DendukuriN , KohliM , NathavitharanaRR , ZwerlingAA , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD011420. [DOI: 10.1002/14651858.CD011420.pub3]">Bjerrum 2019</a>; <a href="./references#CD012768-bbs2-0336" title="ShahM , HanrahanC , WangZY , DendukuriN , LawnSD , DenkingerCM , et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD011420. [DOI: 10.1002/14651858.CD011420.pub2]">Shah 2016b</a>). Given the limitations in the reference standard, we recommend that future studies consider using liquid culture because this is more sensitive than solid culture, and that researchers obtain multiple specimens for culture to confirm the diagnosis of extrapulmonary tuberculosis (<a href="./references#CD012768-bbs2-0282" title="DrainPK , GardinerJ , HannahH , BrogerT , DhedaK , FieldingK , et al. Guidance for studies evaluating the accuracy of biomarker-based nonsputum tests to diagnose tuberculosis. Journal of Infectious Diseases2019;220(Suppl 3):S108-S115.">Drain 2019</a>). </p> <p>Most studies included in this review used culture‐based DST (either Löwenstein‐Jensen (LJ) or mycobacteria growth indicator tube (MGIT) 960) as the reference standard for detection of rifampicin resistance. Concerns have been raised about rapid DST methods, in particular automated MGIT 960, for tuberculosis drug resistance using the recommended critical concentrations. The WHO is planning to prioritise a re‐evaluation of the critical concentrations for rifampicin (<a href="./references#CD012768-bbs2-0360" title="World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis (WHO/CDS/TB/2018.5). who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/ (accessed 2 July 2020).">WHO 2018</a>). </p> <p>We assessed the number of specimens with nontuberculous mycobacteria (NTMs) that were Xpert Ultra‐positive. In two studies that reported 120 NTMs, Xpert Ultra was negative in all specimens. In the previous version of this review, among 10 studies that reported information comprising 141 NTMs, Xpert MTB/RIF was negative in all specimens (<a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>). </p> </section> <section id="CD012768-sec-0189"> <h4 class="title">Quality and quality of reporting of the included studies</h4> <p>Risk of bias was low for the participant selection, index test, and flow and timing domains and was high or unclear for the reference standard domain (most of these studies performed specimen decontamination before culture inoculation). A limitation was that several studies included more than one specimen per participant, which artificially inflated the sample size of the study and may have led to overestimation or underestimation of the accuracy estimates. In general, studies were fairly well reported, although we corresponded with almost all primary study authors to ask for additional data and missing information. In several studies, accuracy data by site of extrapulmonary disease were not reported, and in a minority of studies, blinding was not reported. We strongly encourage the authors of future studies to follow the recommendations provided in the updated Standards for Reporting Diagnostic Accuracy (STARD) statement to improve the quality of reporting (<a href="./references#CD012768-bbs2-0264" title="BossuytPM , ReitsmaJB , BrunsDE , GatsonisCA , GlasziouPP , IrwigL , et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ2015;351:h5527. [DOI: 10.1136/bmj.h5527]">Bossuyt 2015</a>). </p> </section> <section id="CD012768-sec-0190"> <h4 class="title">Interpretability of subgroup analyses</h4> <p>We investigated potential sources of heterogeneity in the different extrapulmonary specimens. Importantly, we found slightly higher Xpert Ultra accuracy in studies with concentrated cerebrospinal fluid (CSF) in comparison to unconcentrated specimens. We note that subgroup findings should be interpreted with caution, as there were only three studies and a small number of tuberculous meningitis cases included in these analyses. </p> </section> <section id="CD012768-sec-0191"> <h4 class="title">Comparison with other systematic reviews</h4> <p>We are aware of several systematic reviews previously published on this topic that estimated summary accuracy of Xpert MTB/RIF for distinct forms of extrapulmonary tuberculosis, as well as different forms of extrapulmonary tuberculosis combined (<a href="#CD012768-tbl-0012">Table 8</a>). We identified one systematic review that estimated summary accuracy of Xpert Ultra that found, for all forms of extrapulmonary tuberculosis combined, pooled sensitivity and specificity of 85.1% (95% CI 76.7 to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), (7 studies; 1500 specimens) (<a href="./references#CD012768-bbs2-0376" title="ZhangM , XueM , HeJQ . Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases2020;90:35-45.">Zhang 2020)</a>. </p> <p>Compared with previous systematic reviews, our review extends the date of the search for potential studies for inclusion. Our strict inclusion criteria, e.g. excluding case‐control studies, meant that some of the studies included in other reviews were excluded from ours. </p> </section> </section> <section id="CD012768-sec-0192"> <h3 class="title" id="CD012768-sec-0192">Applicability of findings to the review question</h3> <p>For the participant selection domain, most studies had high or unclear concern for applicability because either participants were evaluated exclusively as inpatients in tertiary care or we were not sure about the clinical settings. We therefore cannot be sure about the applicability of our findings to primary care. Studies that take place in referral settings may include participants whose condition is more difficult to diagnose than are seen at lower levels of the health system. However, we recognize that classifying studies as primary, secondary, or tertiary care may not adequately account for differences in disease spectrum (<a href="./references#CD012768-bbs2-0301" title="LeeflangMM , RutjesAW , ReitsmaJB , HooftL , BossuytPM . Variation of a test's sensitivity and specificity with disease prevalence. Canadian Medical Association Journal2013;185(11):E537-44. [DOI: 10.1503/cmaj.121286]">Leeflang 2013</a>). For the index and reference test domains, most studies had low concern for applicability. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012768-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-01" target="_blank"><b></b></a></p> </div><img alt="The clinical pathway describes how patients might present and the point in the pathway at which they would be considered for testing with Xpert Ultra or Xpert MTB/RIF. This algorithm for the use of a molecular WHO‐recommended rapid diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/ RIF, comes from the WHO operational handbook on tuberculosis (WHO Operational Handbook Diagnosis (Module 3) 2020). Copyright © [2020] [World Health Organization]: reproduced with permission.Abbreviations: DST: drug susceptibility testing; INH: isoniazid; MDR‐TB: multidrug‐resistant TB; MTB: Mycobacterium tuberculosis; PLHIV: people living with HIV; RIF: rifampicin; TB: tuberculosis; WRD: WHO‐recommended rapid diagnostic, which includes Xpert Ultra and Xpert MTB/RIF." data-id="CD012768-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>The clinical pathway describes how patients might present and the point in the pathway at which they would be considered for testing with Xpert Ultra or Xpert MTB/RIF. This algorithm for the use of a molecular WHO‐recommended rapid diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/ RIF, comes from the WHO operational handbook on tuberculosis (<a href="./references#CD012768-bbs2-0366" title="World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-operational-handbook-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection (accessed 6 August 2020).">WHO Operational Handbook Diagnosis (Module 3) 2020</a>). Copyright © [2020] [World Health Organization]: reproduced with permission. </p> <p>Abbreviations: DST: drug susceptibility testing; INH: isoniazid; MDR‐TB: multidrug‐resistant TB; MTB: Mycobacterium tuberculosis; PLHIV: people living with HIV; RIF: rifampicin; TB: tuberculosis; WRD: WHO‐recommended rapid diagnostic, which includes Xpert Ultra and Xpert MTB/RIF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012768-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for tuberculosis detection: review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for tuberculosis detection: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary for tuberculosis detection: review authors' judgements about each domain for each included study." data-id="CD012768-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary for tuberculosis detection: review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain for each included study." data-id="CD012768-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary for rifampicin resistance detection in comparative studies of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid, comparative studies. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid, comparative studies. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Summary plots of the sensitivity and specificity of Xpert Ultra (A) (5 studies) and Xpert MTB/RIF (B) (5 studies) in cerebrospinal fluid for detection of tuberculous meningitis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region." data-id="CD012768-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Summary plots of the sensitivity and specificity of Xpert Ultra (A) (5 studies) and Xpert MTB/RIF (B) (5 studies) in cerebrospinal fluid for detection of tuberculous meningitis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid in HIV‐positive people, with respect to culture. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. ." data-id="CD012768-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid in HIV‐positive people, with respect to culture. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. . </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in pleural fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-15.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in pleural fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in lymph node aspirate by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-17.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in lymph node aspirate by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-18" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIFsensitivity and specificity in lymph node biopsy by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-18.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIFsensitivity and specificity in lymph node biopsy by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-19" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in urine by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-19.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in urine by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-21" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-21.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-22" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-22.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for tuberculous meningitis (cerebrospinal fluid): review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for tuberculous meningitis (cerebrospinal fluid): review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for pleural tuberculosis (pleural fluid): review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for pleural tuberculosis (pleural fluid): review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for lymph node tuberculosis (lymph node aspirate): review authors' judgements about each domain presented as percentages across included studies." data-id="CD012768-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for lymph node tuberculosis (lymph node aspirate): review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Summary plots of the sensitivity and specificity of Xpert Ultra (A) (4 studies) and Xpert MTB/RIF (B) (25 studies) in pleural fluid for detection of pleural tuberculosis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region." data-id="CD012768-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-16.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Summary plots of the sensitivity and specificity of Xpert Ultra (A) (4 studies) and Xpert MTB/RIF (B) (25 studies) in pleural fluid for detection of pleural tuberculosis. Each individual study is represented by a shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-FIG-20" target="_blank"><b></b></a></p> </div><img alt="Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in bone or joint fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD012768-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-20.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-FIG-20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in bone or joint fluid and tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/appendices#CD012768-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-FIG-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-001" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert Ultra, culture" data-id="CD012768-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-001.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-001.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-002" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert Ultra, composite reference standard" data-id="CD012768-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-002.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-002.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert Ultra, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-003" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert MTB/RIF, culture" data-id="CD012768-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-003.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-003.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-004" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-004.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-004.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-005" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert Ultra, HIV positive" data-id="CD012768-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-005.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-005.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert Ultra, HIV positive</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-006" target="_blank"><b></b></a></p> </div><img alt="Cerebrospinal fluid, Xpert MTB/RIF, HIV positive" data-id="CD012768-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-006.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-006.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>Cerebrospinal fluid, Xpert MTB/RIF, HIV positive</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-007" target="_blank"><b></b></a></p> </div><img alt="Pleural fluid, Xpert Ultra, culture" data-id="CD012768-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-007.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-007.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>Pleural fluid, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-008" target="_blank"><b></b></a></p> </div><img alt="Pleural fluid, Xpert Ultra, composite reference standard" data-id="CD012768-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-008.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-008.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p>Pleural fluid, Xpert Ultra, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-008.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-009" target="_blank"><b></b></a></p> </div><img alt="Pleural fluid, Xpert MTB/RIF, culture" data-id="CD012768-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-009.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-009.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 9</div> <div class="figure-caption"> <p>Pleural fluid, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-009.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-010" target="_blank"><b></b></a></p> </div><img alt="Pleural fluid, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-010.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-010.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 10</div> <div class="figure-caption"> <p>Pleural fluid, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-010.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-011" target="_blank"><b></b></a></p> </div><img alt="Pleural tissue, Xpert MTB/RIF, culture" data-id="CD012768-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-011.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-011.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 11</div> <div class="figure-caption"> <p>Pleural tissue, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-011.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-012" target="_blank"><b></b></a></p> </div><img alt="Pleural tissue, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-012.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-012.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 12</div> <div class="figure-caption"> <p>Pleural tissue, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-012.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-013" target="_blank"><b></b></a></p> </div><img alt="Lymph node aspirate, Xpert Ultra, culture" data-id="CD012768-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-013.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-013.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 13</div> <div class="figure-caption"> <p>Lymph node aspirate, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-013.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-014" target="_blank"><b></b></a></p> </div><img alt="Lymph node aspirate, Xpert Ultra, composite reference standard" data-id="CD012768-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-014.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-014.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 14</div> <div class="figure-caption"> <p>Lymph node aspirate, Xpert Ultra, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-014.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-015" target="_blank"><b></b></a></p> </div><img alt="Lymph node aspirate, Xpert MTB/RIF, culture" data-id="CD012768-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-015.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-015.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 15</div> <div class="figure-caption"> <p>Lymph node aspirate, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-015.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-016" target="_blank"><b></b></a></p> </div><img alt="Lymph node aspirate, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-016.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-016.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 16</div> <div class="figure-caption"> <p>Lymph node aspirate, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-016.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-017" target="_blank"><b></b></a></p> </div><img alt="Lymph node biopsy, Xpert Ultra, culture" data-id="CD012768-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-017.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-017.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 17</div> <div class="figure-caption"> <p>Lymph node biopsy, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-017.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-018" target="_blank"><b></b></a></p> </div><img alt="Lymph node biopsy, Xpert Ultra, composite reference standard" data-id="CD012768-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-018.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-018.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 18</div> <div class="figure-caption"> <p>Lymph node biopsy, Xpert Ultra, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-018.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-019" target="_blank"><b></b></a></p> </div><img alt="Lymph node biopsy, Xpert MTB/RIF, culture" data-id="CD012768-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-019.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-019.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 19</div> <div class="figure-caption"> <p>Lymph node biopsy, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-019.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-020" target="_blank"><b></b></a></p> </div><img alt="Lymph node biopsy, Xpert MTB/RIF, composite" data-id="CD012768-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-020.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-020.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 20</div> <div class="figure-caption"> <p>Lymph node biopsy, Xpert MTB/RIF, composite</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-020.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-021" target="_blank"><b></b></a></p> </div><img alt="Urine, Xpert Ultra, culture" data-id="CD012768-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-021.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-021.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 21</div> <div class="figure-caption"> <p>Urine, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-021.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-022" target="_blank"><b></b></a></p> </div><img alt="Urine, Xpert MTB/RIF, culture" data-id="CD012768-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-022.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-022.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 22</div> <div class="figure-caption"> <p>Urine, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-022.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-023" target="_blank"><b></b></a></p> </div><img alt="Urine, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-023.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-023.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 23</div> <div class="figure-caption"> <p>Urine, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-023.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-024" target="_blank"><b></b></a></p> </div><img alt="Bone or joint aspirate, Xpert Ultra, culture" data-id="CD012768-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-024.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-024.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 24</div> <div class="figure-caption"> <p>Bone or joint aspirate, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-024.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-025" target="_blank"><b></b></a></p> </div><img alt="Bone or joint aspirate, Xpert Ultra, composite reference standard" data-id="CD012768-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-025.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-025.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 25</div> <div class="figure-caption"> <p>Bone or joint aspirate, Xpert Ultra, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-025.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-026" target="_blank"><b></b></a></p> </div><img alt="Bone or joint aspirate, Xpert MTB/RIF, culture" data-id="CD012768-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-026.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-026.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 26</div> <div class="figure-caption"> <p>Bone or joint aspirate, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-026.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-027" target="_blank"><b></b></a></p> </div><img alt="Bone or Joint aspirate, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-027.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-027.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 27</div> <div class="figure-caption"> <p>Bone or Joint aspirate, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-027.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-028" target="_blank"><b></b></a></p> </div><img alt="Bone or joint tissue, Xpert MTB/RIF, culture" data-id="CD012768-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-028.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-028.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 28</div> <div class="figure-caption"> <p>Bone or joint tissue, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-028.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-029" target="_blank"><b></b></a></p> </div><img alt="Peritoneal fluid, Xpert Ultra, culture" data-id="CD012768-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-029.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-029.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 29</div> <div class="figure-caption"> <p>Peritoneal fluid, Xpert Ultra, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-029.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-030" target="_blank"><b></b></a></p> </div><img alt="Peritoneal fluid, Xpert MTB/RIF, culture" data-id="CD012768-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-030.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-030.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 30</div> <div class="figure-caption"> <p>Peritoneal fluid, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-030.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-031" target="_blank"><b></b></a></p> </div><img alt="Peritoneal tissue, Xpert MTB/RIF, culture" data-id="CD012768-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-031.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-031.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 31</div> <div class="figure-caption"> <p>Peritoneal tissue, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-031.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-032" target="_blank"><b></b></a></p> </div><img alt="Pericardial fluid, Xpert MTB/RIF, culture" data-id="CD012768-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-032.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-032.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 32</div> <div class="figure-caption"> <p>Pericardial fluid, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-032.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-033" target="_blank"><b></b></a></p> </div><img alt="Pericardial fluid, Xpert MTB/RIF, composite reference standard" data-id="CD012768-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-033.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-033.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 33</div> <div class="figure-caption"> <p>Pericardial fluid, Xpert MTB/RIF, composite reference standard</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-033.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-034" target="_blank"><b></b></a></p> </div><img alt="Blood, Xpert MTB/RIF, culture" data-id="CD012768-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-034.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-034.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 34</div> <div class="figure-caption"> <p>Blood, Xpert MTB/RIF, culture</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-034.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-035" target="_blank"><b></b></a></p> </div><img alt="Rifampicin resistance, Xpert Ultra" data-id="CD012768-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-035.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-035.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 35</div> <div class="figure-caption"> <p>Rifampicin resistance, Xpert Ultra</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-035.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012768-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/urn:x-wiley:14651858:media:CD012768:CD012768-TST-036" target="_blank"><b></b></a></p> </div><img alt="Rifampicin resistance, Xpert MTB/RIF" data-id="CD012768-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-036.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_t/tCD012768-TST-036.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 36</div> <div class="figure-caption"> <p>Rifampicin resistance, Xpert MTB/RIF</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/media/CDSR/CD012768/image_n/nCD012768-TST-036.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012768-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in cerebrospinal fluid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have tuberculous meningitis </p> <p><b>Prior testing:</b> people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and possibly received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> solid or liquid culture </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> participants were evaluated exclusively as inpatients at a tertiary care centre, or, if the clinical setting was not reported, Xpert was performed at a reference laboratory rather than at primary care facilities and local hospitals </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 89.4% (79.1 to 95.6); pooled specificity (95% CrI): 91.2% (83.2 to 95.7)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 71.1% (62.8 to 79.1); pooled specificity (95% CrI): 96.9% (95.4 to 98.0)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert</b> Ultra<b>(95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (participants with TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(20 to 24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> <p>(79 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> <p>(158 to 191)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>89 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (participants incorrectly classified as not having TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> <p>(1 to 5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(4 to 21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(9 to 42)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (participants without TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>889</p> <p>(811 to 933)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>821</p> <p>(749 to 861)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730</p> <p>(666 to 766)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>386 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (participants incorrectly classified as having TB meningitis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> <p>(42 to 164)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(39 to 151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(34 to 134)</p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert</b> <b>MTB/RIF (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (participants with TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> <p>(16 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> <p>(63 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> <p>(126 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>571 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (participants incorrectly classified as not having TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> <p>(5 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>(21 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(42 to 74)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (participants without TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>945</p> <p>(930 to 956)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872</p> <p>(859 to 882)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>775</p> <p>(763 to 784)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2824 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (participants incorrectly classified as having TB meningitis) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(19 to 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> <p>(18 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(16 to 37)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was 35.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 15.2%. </p> <p>Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity. </p> <p><sup>a</sup>There were few participants in this analysis. The very wide 95% CrI around true‐positives and false‐negatives may lead to different decisions, depending on which credible limits are assumed. We downgraded two levels for imprecision.<br/><sup>b</sup>The wide 95% CrI around true‐negatives and false‐positives would likely lead to different decisions, depending on which credible limits are assumed. We downgraded one level for imprecision.<br/><sup>c</sup>The wide 95% CrI around true‐positives and false‐negatives may lead to different decisions, depending on which credible limits are assumed. We downgraded one level for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in cerebrospinal fluid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012768-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in pleural fluid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have pleural tuberculosis </p> <p><b>Prior testing:</b> people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice, which may include more invasive tests, such as pleural biopsy </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> solid or liquid culture </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laboratory </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 75.0% (58.0 to 86.4); pooled specificity (95% CrI): 87.0% (63.1 to 97.9)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 49.5% (39.8 to 59.9); pooled specificity (95% CrI): 98.9% (97.6 to 99.7)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert Ultra (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (patients with pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(14 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> <p>(58 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> <p>(116 to 173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (patients incorrectly classified as not having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> <p>(3 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(14 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(27 to 84)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (patients without pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848</p> <p>(615 to 955)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>783</p> <p>(568 to 881)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>696</p> <p>(505 to 783)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (patients incorrectly classified as having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> <p>(20 to 360)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> <p>(19 to 332)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> <p>(17 to 295)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert MTB/RIF (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Pr<b>evalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐positives</b> (patients with pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(10 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(40 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> <p>(80 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>644 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g,h</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐negatives</b> (patients incorrectly classified as not having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> <p>(10 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> <p>(40 to 60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> <p>(80 to 120)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>True‐negatives</b> (patients without pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>964</p> <p>(952 to 972)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890</p> <p>(878 to 897)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>791</p> <p>(781 to 798)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2421 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>False‐positives</b> (patients incorrectly classified as having pleural TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(3 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(3 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> <p>(2 to 19)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: CrI: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was 46.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 19.8%. </p> <p><sup>a</sup>We were interested in how Xpert Ultra performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness.<br/><sup>b</sup>For individual studies, sensitivity estimates ranged from 48% to 84%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>c</sup>There was a low number of participants contributing to this analysis for the observed sensitivity. As we had already downgraded for inconsistency, we downgraded one level for imprecision.<br/><sup>d</sup>For individual studies, specificity estimates ranged from 65% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>e</sup>We thought the wide 95% CrI around false‐positives and true‐negatives would likely lead to different decisions depending on which confidence limits are assumed. As we had already downgraded for inconsistency, we downgraded one level for imprecision.<br/><sup>f</sup>We were interested in how Xpert MTB/RIF performed in participants presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness.<br/><sup>g</sup>For individual studies, sensitivity estimates ranged from 10% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency.<br/><sup>h</sup>As we had already downgraded for inconsistency, we did not downgrade further for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in pleural fluid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012768-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in lymph node aspirate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people presumed to have lymph node tuberculosis </p> <p><b>Prior testing:</b> people who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly received a chest radiograph </p> <p><b>Role:</b> initial test, replacement for usual practice, which may include more invasive tests, such as biopsy of affected organs </p> <p><b>Settings:</b> primarily tertiary care centres (the index test was often run in reference laboratories) </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> composite reference standard </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Limitations:</b> in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laboratory performed at a reference laboratory </p> <p><b>Xpert Ultra sensitivity (95% CI): 70% (51 to 85); specificity: 100% (92 to 100)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 81.6% (61.9 to 93.3); pooled specificity: 96.4% (91.3 to 98.6)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert Ultra</b> <br/><b>(95% Cl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients with lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (13 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (51 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 (102 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as not having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (4 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (15 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (30 to 98)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients without lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>975 (897 to 975)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>900 (828 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800 (736 to 800)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 to 64)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for TB using Xpert MTB/RIF (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2.5%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 20%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients with lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (16 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81 (62 to 92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 (124 to 184)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as not having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (8 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (16 to 76)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients without lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>935 (878 to 958)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863 (811 to 885)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>767 (721 to 786)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as having lymph node TB) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (17 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (15 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (14 to 79)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the prevalence of tuberculosis in the included study was 41%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 55.5%. </p> <p><sup>a</sup>We identified only one study, which was conducted at a tertiary referral centre in South Africa, a high TB burden country. Most participants (84%) were seen as outpatients. With only one study, applicability to other settings comes with some uncertainty. We downgraded one level for indirectness.<br/><sup>b</sup>There were very few participants contributing to this analysis. The 95% CI was very wide. We downgraded two levels for imprecision.<br/><sup>c</sup>There were very few participants contributing to this analysis. The 95% CI was wide. We downgraded two levels for imprecision.<br/><sup>d</sup>The composite reference standard was defined by the primary study authors and therefore, was not uniform. We downgraded one level for risk of bias.<br/><sup>e</sup>For indirectness, regarding applicability, for the patient population, we considered most studies to have unclear concern. We were interested in how Xpert MTB/RIF performed in patients presumed to have extrapulmonary TB who were evaluated as they would be in routine practice. However, none of the studies reported this information. We downgraded one level for indirectness. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF in lymph node aspirate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012768-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF for rifampicin resistance</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants:</b> people with tuberculosis detected by Xpert Ultra or Xpert MTB/RIF </p> <p><b>Role:</b> initial test<b>,</b> replacement test for standard practice, which includes culture‐based drug susceptibility testing or line probe assay </p> <p><b>Settings:</b> primarily tertiary care centres, the index test was often run in central (reference laboratories), where drug susceptibility testing for the reference standard could be performed </p> <p><b>Index tests:</b> Xpert Ultra and Xpert MTB/RIF </p> <p><b>Reference standard:</b> culture‐based drug susceptibility testing using solid or liquid media or line probe assay </p> <p><b>Studies:</b> cross‐sectional studies </p> <p><b>Xpert Ultra pooled sensitivity (95% CrI): 100.0% (95.1 to 100.0); pooled specificity (95% CrI): 100.0% (99.0 to 100.0)</b> </p> <p><b>Xpert MTB/RIF pooled sensitivity (95% CrI): 96.5% (91.9 to 98.8); pooled specificity (95% CrI): 99.1% (98.0 to 99.7)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert Ultra result</b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for rifampicin resistance using Xpert Ultra (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 15%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients correctly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (19 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (95 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 (143 to 150)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 7)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients correctly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>980 (979 to 980)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 (899 to 900)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>850 (849 to 850)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>105 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 1)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Xpert MTB/RIF result</b> </p> </th> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>1000 people tested for rifampicin resistance using Xpert MTB/RIF (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 2%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 10%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence of 15%</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐positives</b> (patients correctly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (18 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (92 to 99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 (138 to 148)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐negatives</b> (patients incorrectly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0 to 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2 to 12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>True‐negatives</b> (patients correctly classified as rifampicin susceptible) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 (960 to 977)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>892 (882 to 897)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>842 (833 to 847)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>822 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>False‐positives</b> (patients incorrectly classified as rifampicin resistant) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (3 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (3 to 18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (3 to 17)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; TB: tuberculosis.</p> <p>We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of rifampicin resistance in the included studies was 19.2%. For Xpert MTB/RIF, the median prevalence of rifampicin resistance in the included studies was 11.9%. </p> <p><sup>a</sup>All these studies were conducted in China (high TB‐burden country). Applicability to other settings comes with some uncertainty and therefore we downgraded one level for indirectness.<br/><sup>b</sup>There was a low number of participants contributing to this analysis for the observed sensitivity. We downgraded one level for imprecision. </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Xpert Ultra and Xpert MTB/RIF for rifampicin resistance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Forms of extrapulmonary TB</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of extrapulmonary TB</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diagnostic specimens and means of collection</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculous meningitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the meninges affects people of all ages but is most common among children and people with untreated HIV infection. In adults, tuberculous meningitis presents with gradual onset of headache, neck stiffness, malaise, and fever, and if untreated can progress to altered sensorium, focal neurological deficits, coma, and death. Young children may present with poor weight gain, low‐grade fever, and listlessness. Infants may present with fever, cough (related to the primary pulmonary infection that occurs before tuberculous meningitis develops), change of consciousness at presentation, bulging anterior fontanel, and seizures (<a href="./references#CD012768-bbs2-0348" title="ThwaitesGE , Van ToornR , SchoemanJ . Tuberculous meningitis: more questions, still too few answers. Lancet Neurology2013;12(10):999-1010.">Thwaites 2013</a>). Tuberculous meningitis is sometimes associated with a concurrent cerebral tuberculoma, or, more rarely, a tuberculous abscess </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrospinal fluid, acquired by lumbar puncture with or without radiological guidance; biopsy of tuberculoma, acquired surgically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural tuberculosis, also called TB pleurisy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TB infection of the pleura presents with gradual onset of pleuritic chest pain, shortness of breath, fever, night sweats, and weight loss. Chest X‐ray may demonstrate unilateral or occasionally bilateral pleural effusion. The severity of symptoms is highly variable, with many patients experiencing spontaneous resolution of symptoms, while others may develop severe pleural effusions requiring drainage. Pleuro‐pulmonary tuberculosis, in which parenchymal lung involvement is visible on a chest X‐ray, is associated with higher mortality than isolated pleural infection, which appears to be rarely fatal (<a href="./references#CD012768-bbs2-0341" title="ShuCC , WangJT , WangJY , LeeLN , YuCJ . In-hospital outcome of patients with culture-confirmed tuberculous pleurisy: clinical impact of pulmonary involvement. BMC Infectious Diseases2011;11:46. [DOI: 10.1186/1471-2334-11-46]">Shu 2011</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid; pleural biopsy, which may be performed via thoracoscopy or percutaneously with Abram's needle, with or without ultrasound guidance </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node tuberculosis, also called TB lymphadenitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the lymph nodes may affect one node or a group of nodes, or multiple groups within a chain. Lymph node tuberculosis is relatively more common among children than adults. The most common presentation is of a single, firm, non‐tender enlarged node in the neck, although any lymph node group can be affected. This may be accompanied by fever, weight loss, and night sweats, particularly in people with HIV. Patients with tuberculosis in deep lymph nodes, such as the mediastinal or mesenteric lymph nodes, may present with fever, night sweats, and weight loss, or, more rarely, with symptoms related to compression of adjacent structures. Over time lymph nodes become fluctuant and may discharge via a sinus to the skin or an adjacent viscus. It should be noted that lymphadenopathy may also be seen in other forms of tuberculosis as part of the immune response, but this is not usually caused by direct infection of the lymph nodes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fine‐needle aspiration of fluid from affected lymph node, with or without radiological guidance; surgical biopsy of superficial lymph nodes; endoscopic biopsy of deep lymph nodes with ultrasound guidance </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone or joint tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of bones or joints or both causes chronic pain, deformity, and disability, and tuberculosis of the cervical spine can be life‐threatening. The usual presenting symptom is pain. Fever and weight loss, with or without signs of spinal cord compression, may be present. Patients with advanced disease may have severe pain, spinal deformity, paraspinal muscle wasting, and neurological deficit. Children may have failure to thrive and difficulty walking </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspiration of joint fluid or periarticular abscesses; percutaneous computed tomography‐guided biopsy of lesions is preferred, but some patients may require open biopsy </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genitourinary tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the genitourinary tract includes renal tuberculosis and tuberculosis of the reproductive system. Renal tuberculosis presents with flank pain, haematuria, and dysuria. Female genital tuberculosis presents with infertility (and may be otherwise asymptomatic), pelvic pain, and vaginal bleeding. Testicular tuberculosis presents with a scrotal mass and infertility </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine; biopsy of affected organs, acquired under radiological guidance or surgically</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pericardial tuberculosis, also called TB pericarditis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the pericardium presents with fever, malaise, night sweats, and weight loss. Chest pain and shortness of breath are also commonly‐experienced symptoms. Pericardial tuberculosis may be associated with pericardial effusion, which can be severe and lead to life‐threatening tamponade. Some patients go on to develop pericardial constriction, which can lead to heart failure and death and may require surgical intervention even after mycobacterial cure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pericardial fluid acquired by pericardiocentesis; pericardial biopsy, acquired under radiological guidance or surgically </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peritoneal tuberculosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tuberculosis of the peritoneum usually presents with pain and abdominal swelling, which may be accompanied by fever, weight loss, and anorexia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ascitic fluid acquired by paracentesis; peritoneal biopsy (<a href="./references#CD012768-bbs2-0273" title="ChowKM , ChowVC , HungLC , WongSM , SzetoCC . Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clinical Infectious Diseases2002;35(4):409-13.">Chow 2002</a>) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disseminated tuberculosis, also called miliary tuberculosis. It has been proposed that the designation ‘miliary TB' be restricted to disseminated TB with miliary shadows on chest radiograph (<a href="./references#CD012768-bbs2-0325" title="ReuterH , WoodR , SchaafHS , DonaldPR . Overview of extrapulmonary tuberculosis in adults and children. In: SchaafHS , ZumlaA , editors(s). Tuberculosis: A Comprehensive Clinical Reference. 1st edition. Amsterdam: Elsevier Science Publishers, 2009:377-90.">Reuter 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disseminated tuberculosis involves two or more distinctly separate sites. Manifestations may be varied, ranging from acute fulminant disease to non‐specific symptoms of fever, weight loss, and weakness. HIV‐positive people are more likely to have disseminated tuberculosis than HIV‐negative people. In a systematic review of the prevalence of tuberculosis in post mortem evaluations of HIV‐positive people, among adults disseminated tuberculosis was found in 88% of tuberculosis cases and was considered the cause of death in 91% of TB cases (<a href="./references#CD012768-bbs2-0290" title="GuptaRK , LucasSB , FieldingKL , LawnSD . Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS2015;29(15):1987-2002.">Gupta 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood; specimens acquired from affected extrapulmonary sites</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: TB: tuberculosis.</p> <p>We adapted the table from <a href="./references#CD012768-bbs2-0339" title="SharmaSK , RyanH , KhapardeS , SachdevaKS , SinghAD , MohanA , et al. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian Journal of Medical Research2017;145(4):448-63.">Sharma 2017b</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Forms of extrapulmonary TB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary accuracy of Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis and rifampicin resistance</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference standard</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number studies (participants)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number (%) with TB or rifampicin resistance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Positive predictive value (95% CrI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Negative predictive value (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (18.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.4% (79.1 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2% (83.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0% (36.6 to 69.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.7% (97.5 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (496)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (32.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.7% (45.7 to 77.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (96.6 to 99.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9% (65.5 to 99.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.0% (94.2 to 97.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1% (62.8 to 79.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9% (95.4 to 98.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8% (62.3 to 80.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8% (95.9 to 97.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (2203)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>862 (39.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.3% (32.1 to 52.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8% (99.3 to 100.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.3% (87.2 to 100.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.0% (93.0 to 95.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ultra, direct comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (18.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.0% (77.9 to 95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.0% (82.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.2% (35.6 to 69.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.7% (97.3 to 99.4)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF, direct comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (18.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2% (43.7 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.8% (93.4 to 98.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.4% (49.0 to 83.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.8% (93.9 to 97.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (398)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 (39.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0% (58.0 to 86.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0% (63.1 to 97.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.8% (17.9 to 79.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9% (94.5 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5% (39.8 to 59.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.9% (97.6 to 99.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.2% (68.9 to 94.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.6% (93.7 to 95.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pleural fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1024)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616 (60.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9%</p> <p>(11.5 to 27.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.3%</p> <p>(98.1 to 99.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.6% (49.2 to 91.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7% (91.0 to 92.5)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9% (82.7 to 93.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2% (78.0 to 92.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.7% (31.4 to 55.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.6% (97.9 to 99.2)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>composite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (679)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (55.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.6%</p> <p>(61.9 to 93.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.4%</p> <p>(91.3 to 98.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0% (51.1 to 86.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9% (95.8 to 99.2)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Lymph node biopsy</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (786)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 (28.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4%</p> <p>(73.5 to 89.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.3%</p> <p>(60.3 to 91.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6% (18.7 to 51.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6% (96.2 to 98.6)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Urine</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (943)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (7.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.9%</p> <p>(71.4 to 94.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.1%</p> <p>(93.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.0% (58.3 to 96.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.4% (96.9 to 99.4)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bone or joint aspirate</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (471)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (23.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9%</p> <p>(93.1 to 99.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.4%</p> <p>(80.2 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.7% (35.4 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8% (99.2 to 100.0)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Peritoneal fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (580)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (16.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1%</p> <p>(42.1 to 76.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6%</p> <p>(95.4 to 98.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.0% (58.2 to 86.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5% (93.8 to 97.4)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pericardial fluid</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>culture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (181)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (31.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4%</p> <p>(32.4 to 82.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.7%</p> <p>(74.9 to 99.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4% (18.3 to 88.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.4% (92.1 to 97.9)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rifampicin resistance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSTor LPA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (129)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (18.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (95.1 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (99.0 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.9% (91.7 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100.0% (99.5 to 100.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rifampicin resistance</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSTor LPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (970)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 (15.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.5% (91.9 to 98.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (98.0 to 99.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.0% (84.3 to 97.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.6% (99.1 to 99.9)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval; CSF: cerebrospinal fluid; LPA: Line probe assay; TB: tuberculosis. </p> <p>Studies included in the table are limited to those that report data for both sensitivity and specificity; thus the number of studies (specimens) may differ slightly from those reported in the main text of the review. For tuberculosis detection, the reference standard was culture and a composite reference standard. For rifampicin resistance detection, the reference standards were culture‐based drug susceptibility testing or line probe assay. Pooled sensitivity and pooled specificity are posterior median estimates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary accuracy of Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis and rifampicin resistance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Latent class meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Form of extrapulmonary tuberculosis, type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Culture‐confirmed tuberculosis (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Positive predictive value (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Negative predictive value (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Accuracy estimates of Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tuberculous meningitis, cerebrospinal fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7% (65.5 to 84.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.5% (99.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5% (89.7 to 96.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.3% (96.3 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pleural tuberculosis, fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.1% (42.8 to 64.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.6% (99.3 to 99.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.7% (89.5 to 96.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.0% (94.0 to 96.2)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lymph node tuberculosis, aspirate</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.5% (85.2 to 95.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.5%</p> <p>(99.1 to 99.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.2% (91.4 to 97.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.1% (98.4 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Accuracy estimates of culture</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tuberculous meningitis, cerebrospinal fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (3395)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571 (16.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8% (72.5 to 88.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.2% (98.7 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (86.9 to 95.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.9% (97.0 to 98.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pleural tuberculosis, fluid</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3065)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>644 (21.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5% (80.5 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.0% (98.2 to 99.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8% (84.2 to 94.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8% (97.9 to 99.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lymph node tuberculosis, aspirate</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (1588)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 (39.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.9% (69.9 to 91.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8% (97.8 to 99.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.7% (80.1 to 94.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.1% (96.7 to 99.1)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> <p>We generally used non‐informative priors in the latent class model.<br/>Accuracy estimates were determined using a bivariate random‐effects approach for comparison. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Latent class meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Accuracy of Xpert Ultra versus Xpert MTB/RIF in cerebrospinal fluid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Detection of tuberculosis in CSF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Test (studies, participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Xpert Ultra (5, 471)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Xpert MTB/RIF (5, 471)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (Xpert Ultra minus Xpert MTB/RIF)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (Xpert Ultra minus Xpert MTB/RIF)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.0% (77.9 to 95.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.2% (43.7 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.2% (9.1 to 44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.997</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.0% (82.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8% (93.4 to 98.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.6% (−12.9 to −0.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.022</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Accuracy of Xpert Ultra versus Xpert MTB/RIF in cerebrospinal fluid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Impact of concentrating cerebrospinal fluid on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Covariate (number of studies, participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Concentration step, Xpert Ultra</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Concentrated specimen (3, 421)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.5% (76.7 to 97.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (84.5 to 96.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Unconcentrated specimen (3, 54)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.4% (67.8 to 97.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (58.4 to 99.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6% (−13.9 to 24.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4% (−9.5 to 32.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probability (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.653</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Concentration step, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Concentrated specimen (14, 2279)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6% (67.2 to 85.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.4% (96.1 to 98.4)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Unconcentrated specimen (17, 1123)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.4% (48.3 to 70.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8% (94.0 to 98.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.4% (2.8 to 32.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6% (−1.7 to 3.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (concentrated minus unconcentrated)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.696</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Impact of concentrating cerebrospinal fluid on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysis, (number of studies, specimens)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled sensitivity (95% CrI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pooled specificity (95% CrI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Cerebrospinal fluid, Xpert Ultra</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Among studies with prevalence ≥ 30% (3, 54)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.3% (68.3 to 97.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0% (64.3 to 97.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Among studies with prevalence &lt; 30% (3, 421)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8% (77.3 to 96.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9% (82.5 to 96.6)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.2% (−23.0 to 13.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.8% (−27.7 to 9.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probability (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.308</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Cerebrospinal fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 30% (6, 610)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.0% (49.0 to 81.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.1% (86.8 to 97.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 30% (24, 2785)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0% (62.4 to 81.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.3% (95.9 to 98.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.8% (−25.5 to 12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.1% (−10.5 to 0.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 30% group minus &lt; 30% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.071</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Cerebrospinal fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 10% (19, 2190)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.7% (58.5 to 78.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1% (92.7 to 96.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 10% (11, 1205)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.2% (57.4 to 86.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.6% (97.5 to 99.3)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 10% group minus &lt; 10% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.5% (‐21.2 to 13.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.5% (‐6.0 to ‐1.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 10% group minus &lt; 10% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Pleural fluid, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 50% (6, 627)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.7% (11.2 to 33.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.6% (97.9 to 99.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 50% (4, 397)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5% (6.5 to 30.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.0% (96.9 to 99.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 50% group minus &lt; 50% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1% (−11.8 to 21.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5% (−1.2 to 2.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 50% group minus &lt; 50% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.759</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Lymph node aspirate, Xpert MTB/RIF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence ≥ 35 (9, 911)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.1% (88.9 to 96.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.2% (69.5 to 92.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Among studies with prevalence &lt; 35% (5, 677)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.2% (64.9 to 87.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.0% (78.3 to 95.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Difference (≥ 35% group minus &lt; 35% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.7% (5.4 to 28.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.4% (−21.3 to 76)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probability (≥ 35% group minus &lt; 35% group)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.158</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> <p>Prevalence refers to the percentage of culture‐confirmed tuberculosis specimens or confirmed rifampicin‐resistant specimens in the study. We selected prevalence levels to approximate the lower bound of the interquartile range or in consideration of the range of prevalences reported in the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses, Xpert Ultra in cerebrospinal fluid</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of specimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of studies (specimens)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Predicted sensitivity (95% Crl)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Predicted specificity (95% Crl)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>All participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.4% (79.1 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2% (83.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0% (36.6 to 69.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.7% (97.5 to 99.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Consecutive participant selection</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (471)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.9% (76.4 to 94.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4% (81.1 to 95.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.0% (65.2 to 96.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.5% (65.5 to 97.7)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reference standard blinding</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5% (74.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.1% (76.9 to 94.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (63.4 to 97.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.2% (61.0 to 97.1)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Single specimen per participant</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.5% (74.7 to 95.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.1% (76.9 to 94.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% (63.4 to 97.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.2% (61.0 to 97.1)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: Crl: credible interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses, Xpert Ultra in cerebrospinal fluid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Systematic reviews of Xpert MTB/RIF and Xpert Ultra for extrapulmonary tuberculosis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Systematic review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Search period</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (total number of extrapulmonary specimens)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Forms of extrapulmonary TB or types of specimens</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Accuracy against culture reference standard</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Tuberculous meningitis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pleural tuberculosis (pleural fluid)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymph node tuberculosis</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0271" title="ChangK , LuW , WangJ , ZhangK , JiaS , LiF , et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection2012;64(6):580-8.">Chang 2012</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 1 October 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1058)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple forms combined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 15</p> <p>October 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (4461)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 81%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 46%; specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 83%; specificity 94%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0307" title="Maynard-SmithL , LarkeN , PetersJA , LawnSD . Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infectious Diseases2014;14:709. [DOI: 10.1186/s12879-014-0709-7]">Maynard‐Smith 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 November 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (6026)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF, other forms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median sensitivity 85% (IQR 75% to 100%); median specificity 100% (IQR 98% to 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 34%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 96%; specificity 93%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0319" title="PenzE , BoffaJ , RobertsDJ , FisherD , CooperR , RonksleyPE , et al. Diagnostic accuracy of the Xpert® MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. International Journal of Tuberculosis and Lung Disease2015;19(3):278-84.">Penz 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 15 August 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (9523)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node, pleural fluid, CSF, other forms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 69%; specificity 97%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 37%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 87%; specificity 92%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0335" title="SehgalIS , DhooriaS , AggarwalAN , BeheraD , AgarwalR . Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: systematic review and meta-analysis. Journal of Clinical Microbiology2016;54(4):1133-6.">Sehgal 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 31 August 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (2486)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 51%;</p> <p>specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0303" title="LiS , LiuB , PengM , ChenM , YinW , TangH , et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLOS One2017;12(7):e0180725. [DOI: 10.1371/journal.pone.0180725]">Li Y 2017</a><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 20 June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple forms combined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0291" title="GuptaR , TalwarP , TalwarP , KhuranaS , KushwahaS , JalanN , et al. Diagnostic accuracy of nucleic acid amplification based assays for tuberculous meningitis: a meta-analysis. Journal of Infection2018;77(4):302-13.">Gupta 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 25 March 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (8977)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 57%; specificity 98%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0322" title="PormohammadA , NasiriMJ , McHughTD , RiahiSM , BahrNC . A systematic review and meta-analysis of the diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis. Journal of Clinical Microbiology2019;57(6):e01113-18.">Pormohammad 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upto 11 Nov 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CSF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 61%; specificity 99%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012768-bbs2-0375" title="YuG , ZhongF , YeB , XuX , ChenD , ShenY . Diagnostic accuracy of the Xpert MTB/RIF assay for lymph node tuberculosis: a systematic review and meta-analysis. BioMed Research International2019;2019:4878240.">Yu 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 6 July 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert MTB/RIF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21(1629)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lymph node</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity 84%; specificity: 91%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012768-bbs2-0376" title="ZhangM , XueM , HeJQ . Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases2020;90:35-45.">Zhang 2020</a><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 20 May 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xpert Ultra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1500)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple specimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; CSF: cerebrospinal fluid: IQR: interquartile range; TB: tuberculosis. </p> <p><sup>a</sup>For all forms of extrapulmonary tuberculosis combined, <a href="./references#CD012768-bbs2-0271" title="ChangK , LuW , WangJ , ZhangK , JiaS , LiF , et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection2012;64(6):580-8.">Chang 2012</a> reported pooled sensitivity and specificity of 80.4% (95% confidence interval (CI) 75.0 to 85.1) and 86.1% (95% CI 83.5 to 88.4), respectively.<br/><sup>b</sup>Using a composite reference standard, <a href="./references#CD012768-bbs2-0277" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal2014;44(2):435-46.">Denkinger 2014</a> found the following pooled sensitivity and specificity estimates: lymph node tuberculosis (aspirate or tissue) 81.2% (95% CI 72.4 to 87.7) and 99.1% (95% CI 94.5 to 99.9); pleural tuberculosis 21.4% (95% CI 8.8 to 33.9) and 100% (95% CI 99.4 to 100); and meningeal TB 62.8% (95% CI 47.7 to 75.8) and 98.8% (95% CI 95.7 to 100), respectively.<br/><sup>c</sup>For both pulmonary and extrapulmonary tuberculosis, review authors included 106 studies involving 52,410 specimens. For all forms of extrapulmonary tuberculosis combined, <a href="./references#CD012768-bbs2-0303" title="LiS , LiuB , PengM , ChenM , YinW , TangH , et al. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis. PLOS One2017;12(7):e0180725. [DOI: 10.1371/journal.pone.0180725]">Li Y 2017</a> reported pooled sensitivity and specificity of 80% (95% CI 69 to 88) and 97% (95% CI 94 to 98), respectively.<br/><sup>d</sup><a href="./references#CD012768-bbs2-0376" title="ZhangM , XueM , HeJQ . Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases2020;90:35-45.">Zhang 2020</a> included 7 studies involving 1500 specimens. For all forms of extrapulmonary tuberculosis combined, pooled sensitivity and specificity were 85.1% (95% CI 76.7 to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), respectively. </p> <p><a href="./references#CD012768-bbs2-0340" title="ShenY , YuG , ZhongF , KongX . Diagnostic accuracy of the Xpert MTB/RIF assay for bone and joint tuberculosis: a meta-analysis. PLOS One2019;14(8):e0221427.">Shen 2019</a> provided pooled estimates for bone or joint tuberculosis. The review included 14 studies with 1884 specimens with a pooled sensitivity of 96% and specificity of 85%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Systematic reviews of Xpert MTB/RIF and Xpert Ultra for extrapulmonary tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/full#CD012768-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012768-tbl-0014"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Prespecified changes for review update 2021</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Protocol section</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Appraisal points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Address here</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Background and research question</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>• Review and update Background section, including supporting references to take account of any changes that may have occurred. This should include updating any new information and current policy debates on the topic </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This review update will describe the burden of extrapulmonary tuberculosis worldwide based on the latest WHO Global Tuberculosis Report. The Background will describe the updated WHO guidelines on molecular methods for diagnosing tuberculosis, including Xpert MTB/RIF and Xpert Ultra. The WHO Meeting to update the guidelines took place 3 ‐ 6 December 2019. This Cochrane Review update will have informed these guidelines </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inclusion criteria</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>• Review current PICO(s) and amend in light of new knowledge.<br/>• Identify any changes in usual‐care standards.<br/>• Check for standardised core outcomes sets, such as those developed in collaboration with the core outcome measures in effectiveness trials (COMET) initiative (<a href="http://www.comet-initiative.org/" target="_blank">www.comet-initiative.org</a>) or by guideline groups since the original review.<br/>• Check for any relevant patient‐reported outcomes to include subsequent to the original review.<br/>• Consider any new studies with less risk of bias that might warrant a stricter study design inclusion criterion (where the older version, when there was a dearth of evidence, included observational or quasi‐randomised comparisons). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is a diagnostic test accuracy review.</p> <p>Participants, index tests, and target condition, will be the same as in <a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a> except as follows: </p> <p>The update will be restricted to adults (15 years and older). The reason for this is that we have a separate Cochrane Review underway that is evaluating the tests for extrapulmonary tuberculosis in children. </p> <p>We will add a composite reference standard, defined as culture or clinical criteria as defined by the primary study authors. The addition of a composite reference standard was specifically requested by the WHO and Guideline members. </p> <p>The primary objectives are to assess the diagnostic accuracy of Xpert Ultra for the diagnosis of extrapulmonary tuberculosis and to assess the diagnostic accuracy of Xpert Ultra for the detection of rifampicin resistance in adults. </p> <p>Secondary objectives are the following.</p> <p>‐ to investigate potential sources of heterogeneity in test accuracy, including volume of CSF for TB meningitis and processing methods for lymph node TB </p> <p>‐ to compare the accuracy of Xpert Ultra and Xpert MTB/RIF in studies that evaluated both tests. </p> <p>Concerning patient outcomes, the Discussion will summarize and refer to key findings in the test‐treatment Cochrane Review by Haraka et al. (currently undergoing peer review). Although the Haraka review relates to pulmonary tuberculosis, it is the only evidence on patient outcomes of which we are aware. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We will use QUADAS‐2 to appraise methodological quality of included studies consistent with <a href="./references#CD012768-bbs2-0378" title="KohliM , SchillerI , DendukuriN , DhedaK , DenkingerCM , SchumacherSG , et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub2]">Kohli 2018</a>. </p> <p>If data are sufficient, we will perform meta‐analyses using a bivariate random‐effects model. The analyses will include: </p> <p>1. Xpert Ultra for different forms of extrapulmonary tuberculosis, culture reference standard </p> <p>2. Xpert Ultra for different forms of extrapulmonary tuberculosis, composite reference standard </p> <p>3. Accuracy of Xpert Ultra versus Xpert MTB/RIF in studies that evaluated both tests</p> <p>4. Xpert Ultra for detecting rifampicin resistance</p> <p>The different forms (and corresponding specimens for diagnosis) of extrapulmonary TB include: tuberculous meningitis, lymph node tuberculosis, pleural tuberculosis, genitourinary tuberculosis, bone or joint tuberculosis. </p> <p>We will create 'Summary of findings' tables for the two primary objectives of the review. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>TB: tuberculosis.</p> <p>This table was approved by the CIDG editorial team on 17 December 2019.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Prespecified changes for review update 2021</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/information#CD012768-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012768-tbl-0013"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 Cerebrospinal fluid, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Cerebrospinal fluid, Xpert Ultra, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 Cerebrospinal fluid, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 Cerebrospinal fluid, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2203</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 Cerebrospinal fluid, Xpert Ultra, HIV positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 Cerebrospinal fluid, Xpert MTB/RIF, HIV positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 Pleural fluid, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 Pleural fluid, Xpert Ultra, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">9 Pleural fluid, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3268</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">10 Pleural fluid, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1024</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">11 Pleural tissue, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">12 Pleural tissue, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">13 Lymph node aspirate, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">14 Lymph node aspirate, Xpert Ultra, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">15 Lymph node aspirate, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">16 Lymph node aspirate, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">17 Lymph node biopsy, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">18 Lymph node biopsy, Xpert Ultra, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">19 Lymph node biopsy, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">20 Lymph node biopsy, Xpert MTB/RIF, composite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">21 Urine, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">22 Urine, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">23 Urine, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">24 Bone or joint aspirate, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">25 Bone or joint aspirate, Xpert Ultra, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">26 Bone or joint aspirate, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">27 Bone or Joint aspirate, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">28 Bone or joint tissue, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">29 Peritoneal fluid, Xpert Ultra, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">30 Peritoneal fluid, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">31 Peritoneal tissue, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">32 Pericardial fluid, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">33 Pericardial fluid, Xpert MTB/RIF, composite reference standard <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">34 Blood, Xpert MTB/RIF, culture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">35 Rifampicin resistance, Xpert Ultra <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">36 Rifampicin resistance, Xpert MTB/RIF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1246</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012768.pub3/references#CD012768-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012768.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012768-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012768-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012768-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012768-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012768-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012768-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012768\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012768\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012768\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012768\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012768\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012768.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012768.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012768.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012768.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012768.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717071069"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012768.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717071073"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012768.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daeef08ee936e',t:'MTc0MDcxNzA3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 